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General introduction and  
outline of this thesis
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Chapter 1
Pompe disease is a metabolic myopathy. Since the first description of the disease 
in 1932 by J.C. Pompe,1 tremendous progress has been made from discovering the 
biochemical and genetic basis of the disease to developing enzyme replacement 
therapy (ERT). 
With this therapy, the management of Pompe disease has moved from supportive 
care alone, to a disease-specific intervention aimed at correcting the underlying 
enzymatic defect. While in the past research mainly concentrated on elucidating 
the biochemical pathways and pathophysiology of Pompe disease, nowadays focus 
has shifted towards documenting the natural history of the disease and studying 
the effect of the new treatment.
A structured follow-up of a large number of patients is difficult in a rare disorder 
like Pompe disease. The establishment of an expert center for Pompe disease at 
the Erasmus MC University Medical Center has helped us to systematically study 
all Pompe patients living in the Netherlands. At present, we follow 149 patients, 
of which 18 patients are diagnosed with classic-infantile Pompe disease; and 20 
children and 111 adults with less progressive forms of the disease. 
The studies in this thesis have focused on children with Pompe disease. Our aim 
was to delineate the first presentation and clinical characteristics of the disease and 
to study the long-term effects of enzyme replacement therapy with recombinant 
human alpha-glucosidase. 
POMPE DISEASE
Pompe disease (OMIM #232300), also called glycogen storage disease type 2 or 
acid maltase deficiency, is a rare lysosomal storage disorder that was named after 
the Dutch pathologist JC Pompe (Figure 1A). In 1932 he presented the case of a 
7-month old infant who allegedly had died of pneumonia but showed a massively 
enlarged heart on post-mortem investigation. Initially the patient was diagnosed 
to have died from idiopathic hypertrophy of the heart and a bronchopneumonia 
but on further examination Dr. Pompe not only found large amounts of vacuolar 
glycogen storage in the heart, he also found glycogen in virtually all tissues he 
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examined. This made him suggest that idiopathic hyperthrophy of the heart was 
part of a systemic disorder of glycogen metabolism rather than the result of a 
diffuse tumor (rhabdomyoma) or water accumulation as was suggested before.1 
Dr. Pompe’s first publication led to his thesis called Cardiomegalia Glycogenica 
which he finished in 1936 (Figure 1B). In 1939 he started working as a pathologist 
in a hospital (currently the Onze Lieve Vrouwe Gasthuis) in Amsterdam where 
he used his laboratory to hide people and station an illegal radio transmitter in 
collaboration with the Dutch resistance movement in World War II. Unfortunately 
the radio transmitter was discovered and Dr. Pompe was arrested. In 1945 he was 
executed as retaliation for the destruction of a railway bridge by the resistance 
near St Pancras.2 Although the name Pompe was given to the disease later defined 
as glycogen storage disease type II, two comparable cases were independently 
described in the same year as Pompe did, by Putschar and Bischoff.3,4
Figure 1. (A) Johannes Cassianus Pompe (1901‒1945). (B) Dr. Pompe’s thesis called 
Cardiomegalia Glycogenica. Both pictures were taken from Onze Lieve Wetenschap 2013; 
1:4-5.
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Several major discoveries confirmed Dr. Pompe’s observations. After Drs. Gerty and 
Carl Cori clarified the normal pathway of glycogen metabolism, they focused on the 
so called ‘glycogen storage disorders’.5 In 1957 Gerty Cori classified ‘Pompe disease’ 
as glycogen storage disease type II, but could not discover a defect in the pathway 
of glycogen degradation as was found for the other glycogen storage disorders. 
Around the same time Christian de Duve and colleagues revealed a new cell 
organelle containing hydrolytic enzymes that were active at acidic pH: the 
lysosome. These membrane-bound organelles appeared to be responsible for the 
intracellular digestion of macrocolecules.6 For this discovery he received the Nobel 
Price in Physiology or Medicine in 1974. Eight years later Dr. Henri G. Hers and 
colleagues demonstrated that the lysosomal enzyme acid alpha-glucosidase was 
deficient in tissues from Pompe patients.7,8 With this observation they officially 
identified the first lysosomal storage disorder, of which to date more than 50 have 
been described.9 
Clinical spectrum 
Pompe disease presents as a continuous spectrum of closely related clinical 
phenotypes in which progressive muscle weakness is the main clinical 
manifestation.10,11 
At the most severe end of the spectrum is the classic-infantile form of the 
disease.1,12,13 Skeletal, cardiac and smooth muscles are severely involved and 
patients show a rapid progression of muscle weakness and usually die within their 
first year of life. At the other end of the spectrum are patients with more slowly 
progressive phenotypes; they present with limb-girdle muscle weakness.14 Age at 
presentation and rate of disease progression vary. Deterioration of the strength of 
the limb-girdle and trunk muscles eventually results in wheelchair dependency, 
respirator need, and shortened life expactancy.10,11,15-22
Classic-infantile Pompe disease
The classic-infantile form is relatively homogeneous in presentation and 
disease course. Patients show their first symptoms at a median age of 1.6 to 2.0 
months.12,13,15,23 Presenting symptoms include feeding difficulties, failure to thrive, 
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respiratory distress, recurrent respiratory infections, cardiac problems, generalized 
hypotonia, or paucity of movements. Physical examination typically shows a patient 
with generalized hypotonia characterized by slipping through, a prominent head lag 
and frog like position of the legs. Other frequent findings are enlargement of the 
tongue, decreased tendon reflexes, hepatomegaly, or heart murmur (45‒90% of 
the patients).12,13,15,23 A severe concentric hypertrophic cardiomyopathy is present 
in all patients with classic-infantile Pompe disease, is rapidly progressive and may 
lead to systolic and diastolic dysfunction.12,13,24-26 Characteristic electrocardiogram 
(ECG) changes are a short PR interval,27 increased QT dispersion, and large QRS 
voltages. Patients are at risk for tachyarrhythmia and sudden death.28-31
Motor development is delayed and motor milestones are not achieved or quickly 
lost. Respiratory infections frequently occur, and cardio-respiratory failure is the 
main cause of death. Patients usually die within the first year of life at a median 
age of 6.0 to 8.7 months.12,13 
Atypical infantile Pompe disease
Closely related to the classic-infantile form of Pompe disease is a group of “atypical” 
infantile patients. These patients have a similar clinical presentation as those with 
classic-infantile Pompe disease, but usually present a few months later (mean age 
at presentation 4.8±2.9 months).23 Their cardiac hypertrophy is less severe, and 
they show a more slowly progressive disease course. They survive well beyond the 
first year of life, as long as they have assisted ventilation and nutritional support 
(ages at time of description ranged from 1.5 to 13 years of age, n=9). Main cause of 
death in these patients is respiratory insufficiency.23,32
Patients with attenuated forms of Pompe disease
Children and adults with later onset and less progressive forms of Pompe disease 
represent the majority of patients under care. They are variably referred to as 
patients with childhood, juvenile, adult or late-onset forms of Pompe disease.33 
The presentation and disease course varies widely between patients10,11,14-22,34 and 
sometimes varies even within families.35 
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Several studies were undertaken to delineate the natural history of these forms of 
Pompe disease10,11,14-22,34 and showed that the clinical spectrum was much broader 
than initially recognized. Onset of symptoms can present at any age, ranging from 
infancy to late adulthood. First symptoms are most often mobility problems caused 
by limb-girdle muscle weakness, such as difficulties in climbing stairs, rising from a 
chair, rising from supine position, walking, running, or playing sports. Fatigue,14,36,37 
myalgia38 and less familiar features such as ptosis,18,39-43 bulbar weakness18,39,44-46 
and scapular winging15,18,46 have also been reported. Respiratory muscle weakness 
has been found in the majority of Pompe patients. Respiratory insufficiency may 
present at any age, even when patients have mild muscular problems18,19,47-52 and 
is the main cause of death.14,15 Some recent publications indicate that glycogen 
accumulation in vascular smooth muscle cells can cause dilatative arteriopathy 
leading to cerebral or thoracic aneuryms that can become another life-threatening 
complication of Pompe disease.14,53-63 
Cardiac hypertrophy or conduction problems are rarely found in adult patients,64,65 
although a post-mortem investigation in such a case did reveal glycogen 
accumulation in cardiomyocytes66 It has been speculated that this glycogen 
accumulation may lead to conduction disorders such as Wolff-Parkinson-White 
syndrome.34,64 
In general, the muscle weakness in patients with non-classic forms of Pompe disease 
progresses slowly and the rate of disease progression varies widely.14,16,18,22,32,51,67 
Hagemans showed that approximately 50% of patients have become wheelchair 
bound or ventilator dependent within 10 to 15 years after diagnosis.32 In her study, 
the median survival after diagnosis was 27 years 68 and the disease severity seemed 
to be related to the disease duration and not to age. Exception to this was a subset 
of patients under the age of 15 years who showed an extremely rapid disease 
course.32 Close follow-up and timely intervention is necessary for these patients.
Pathology
Pompe disease is caused by acid alpha-glucosidase deficiency, an enzyme that 
catalyzes the hydrolysis of the glycogen that is stored within lysosomes. Partial or 
total deficiency leads to the accumulation of lysosomal glycogen in all cells of the 
body, but the pathological changes are most notable in skeletal muscle (Figure 2).11
15
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Figure 2. Longitudinal sections of skeletal muscle were stained with Periodic Acid-Schiff 
(PAS). Panel A shows a muscle biopsy of a patient with Pompe disease which contains 
massive glycogen storage, vacuolar myopathy and myofibrillar loss. Panel B shows a muscle 
biopsy of a healthy control.
Little is known about the exact mechanism through which glycogen accumulation 
in lysosomes leads to muscle weakness and destruction of skeletal muscle. The 
process has been extensively studied in both mice and humans.69-76 It appeared that 
large clusters of enlarged, glycogen-filled, lysosomes obstruct the longitudinal force 
transmission of muscle fibers leading to muscle weakness,75,77 and that additional 
formation of centrally localized autophagic vacuoles contributes substantially to 
the cellular damage.78,79 Continuous accumulation of glycogen may even cause 
rupture of the lysosomal membrane whereby autolytic enzymes are released into 
the cytoplasm.69 
In recent studies in Pompe knock-out (KO) mice, the secondary pathogenic 
mechanism involving the autophagic pathway was demonstrated.78-82 Autophagy 
is a process involving the lysosomal degradation of the cell’s own organelles and 
proteins. Autophagosomes sequester part of the cytoplasm and organelles. They 
fuse with endosomes (the so-called amphisomes) and lysosomes after which their 
content is degraded.83,84 Fukuda et al. described abnormal vesicular trafficking along 
both the endocytic and the authophagic pathways resulting in expansion of the 
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endosomal-autophagosomal compartments and defective lysosomal acidification 
in a Pompe KO mouse model.81
The resulting massive accumulation of autophagic debris not only significantly 
attributes to the muscle damage, but may also pose a serious problem for the 
delivery of exogenous enzymes to lysosomes, the principle mechanism of enzyme 
replacement therapy. 
Two studies performed in patients with Pompe disease showed that the authophagic 
process was equally disturbed as in mice.85,86 But specific involvement of type 2 
fibers, as was seen in KO mice, was less evident.80,85,86 A recent study showed that 
both views on the pathogenesis of muscle damage may apply: in untreated classic-
infantile Pompe disease lysosomal rupture seems to be the predominant cause of 
muscle damage while accumulation of autophagic material seems to be the major 
cause of muscle damage in untreated adults.87 
It is still unknown what triggers the extensive autophagic build-up. Some authors 
have suggested that oxidative stress, hypoglycaemia, or the generation of substrates 
for cellular remodelling during muscle differentiation may induce authophagy 85. As 
for now, these are just hypotheses, but it is obvious that the acid alpha-glucosidase 
deficiency and the ensuing lysosomal glycogen storage are at the beginning of the 
pathological process. 
Genetic heterogeneity
Pompe disease is inherited as an autosomal recessive trait and is caused by 
pathogenic mutations in the gene (OMIM 606800) that codes for lysosomal acid 
alpha-glucosidase (GAA). The gene is localized on chromosome 17q25.2-25.3.88-92 It 
contains 19 coding exons in 20 kb of genomic DNA. At present the Pompe Disease 
Mutation Database, a database that collects all reported nucleotide variations in 
the GAA gene (http://www.pompecenter.nl), is listing 372 published sequence 
variations, of which 248 are proven pathogenic mutations.93 
The type of mutations and the combination of mutant alleles largely explain the 
Pompe disease phenotype. Different mutations in the acid α-glucosidase gene lead 
to different degrees of acid α-glucosidase deficiency, and consequently account for 
different phenotypes. A combination of two mutations that completely eliminate 
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enzyme activity are associated with the severe classic-infantile phenotype.94 This 
phenotype is quite homogeneous. A combination of mutations that encodes 
for residual enzyme activity is usually associated with later onset and slowly 
progressive disease. 
Although there seems to be a tendency of finding lower alpha-glucosidase activities 
in more severely affected patients and higher levels of alpha-glucosidase activities 
in later presenting cases, the correlation between enzyme activity and phenotype 
is not strict in this group of patients.23,94-100 The absence of a genotype-phenotype 
correlation within groups of patients with identical genotypes and even within 
families35,101-103 suggests the involvement of secondary genetic or environmental 
factors that modulate the phenotype.
While most pathogenic mutations are unique, a subset occurs at higher frequency 
in certain ethnic groups. The most common mutation found in Caucasians is 
c.-32-13T>G (also known as IVS1). This mutation was found in more than 70% of 
children and adults with first symptoms at a relatively late age.19,21,34,98,102-104 
Other more frequently found mutations are for example c.525delT, delexon 18 
(c.2481+102_2646+31del) , and c.925G->A among Caucasians;105,106 the c.2560C->T 
(p.R854X) mutation among Africans, African Americans and Brazilians of African 
descent;107 the c.1935 C->A (p.D645E) mutation among Asians;108,109 the c.377G>A 
mutation among Argentineans;110 and the c.1905C->A, the c.-32-3C->A, and the 
c.2560C->T mutations among Brazilians.111
Diagnosis
Due to the rarity of Pompe disease and the fact that many signs and symptoms 
are non-specific and can mimic other musculoskeletal disorders, diagnosing Pompe 
disease can be challenging. Table 1 shows the differential diagnosis for both the 
classic-infantile as well as the other phenotypes (adapted from112). Now that 
Pompe disease has become a treatable condition, timely diagnosis can improve 
patients outcome. Diagnostic delays ranging from 5 to 30 years, as described in the 
literature14,16,34 should therefore be avoided. 
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Table 1. Differential diagnosis of Pompe disease
Classic infantile Pompe disease non-Classic Pompe disease (milder phenotypes)
Spinal Muscular Atrophy type I (Werdnig 
Hoffman disease)
Limb girdle muscular dystrophies (LGMD)
Congenital Muscular dystrophy Duchenne and Becker Muscular Dystrophies
Glycogen storage diseases III (Cori or Forbes 
disease) and IV (Anderson disease)
Spinal Muscular Atrophy type II, III and IV
Mitochondrial/respiratory chain disorders Glycogen storage diseases type V (McArdle 
disease) and VII (Tauri disease)
Deficiencies in lipoprotein metabolism Myasthenia Gravis
Fatty acid oxygenation disorders (e.g. VLCADD) Scapuloperoneal syndromes
Danon disease Mitochondrial myopathies
Idiopathic hypertrophic cardiomyopathy Rigid spine syndrome
Peroxismal disorders Polymyositis/dermatomyositis
Myocarditis Danon disease
Congenital myopathy (e.g. Nemaline myopathy)
Hypothyreoidism
Endocardial fibroelastosis
Overall, patients suspected of having Pompe disease will first undergo a clinical 
evaluation including physical examination, muscle strength tests, pulmonary 
function tests (in sitting and supine position), ECG and echocardiogram, , EMG, and 
chest x-ray and assessment of motor development in infants. Routine laboratory 
measurements such as serum CK, ALT, AST and LDH can be elevated, but they have 
limited diagnostic significance since normal values have been found in patients 
diagnosed with Pompe disease.12,14,18,52,113,114 A muscle biopsy, often performed 
early in the diagnostic work-up of patients with suspected myopathy, may show 
characteristic vacuoles that contain glycogen and stain positive for PAS and acid 
phosphatase.11
In classic-infantile Pompe disease, marked vacuolization is found in nearly all muscle 
fibers. In patients with milder phenotypes, on average only 10‒50% of the muscle 
fibers reveal vacuolization.86 A study performed in 225 child and adult patients with 
less progressive forms of Pompe disease showed that 20% of them had normal 
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muscle glycogen content, and that 3% of the muscle biopsies showed no pathology 
at all.14 To avoid false-negative results, Pompe disease should be diagnosed by 
demonstrating partial or complete deficiency of the lysosomal enzyme acid alpha-
glucosidase or by mutation analysis.115,116 
Measurement of alpha-glucosidase activity can be performed in muscle, fibroblasts, 
leukocytes, lymphocytes, amniotic cells, chorion villi or dried bloodspots. The assay 
in cultured skin fibroblasts has long been and still is the gold standard.117 Using the 
artificial substrate 4-methylumbelliferyl-alpha-D-glucopyranoside (4-MUGluc), the 
assay is very sensitive at detecting low levels (2% of average normal) of alpha-
glucosidase activity and is able to distinguish classic-infantile patients from patients 
with milder forms of the disease.11,97 Performing a skin biopsy, on the other hand, 
is by some clinicians considered invasive and the assay takes several weeks, which 
significantly delays diagnosis. This is one of the reasons why the focus has shifted 
towards using blood samples for diagnosing the disease. While the measurement 
of acid alpha-glucosidase in leukocytes or lymphocytes used to be unreliable,118,119 
Pompe disease can nowadays be diagnosed in whole-blood samples, given that 
acarbose is added to the assay to inhibit the activity of interfering neutral alpha-
glucosidases. The use of glycogen over 4-MUGluc as substrate is preferred since it 
provides a more precise discrimination between patients and healthy subjects.120 
Recently, techniques have been developed that can measure alpha-glucosidase 
activity in dried blood spots using tandem mass spectrometry or fluorimetric 
procedures. The advantage of dried blood spots is that they can easily be collected 
and are therefore not only suitable for newborn screening but also provide a 
rapid first-line test to diagnose Pompe disease.121-125 It is generally agreed that the 
outcome of a dried blood spot test needs to be confirmed by more conventional 
types of testing.115,126 
Epidemiology
Pompe disease is a rare condition with an estimated frequency of one per 
14.000 to one per 300.000 newborns depending on the geographic region that is 
studied.17,127-130 The prevalence of Pompe disease varies between different clinical 
forms and between ethnic groups. 
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In the Netherlands, Pompe disease is the most common single lysosomal storage 
disorder with a birth prevalence of 2‒3 per 100.000 live births.131,132 This is different 
than in other countries. For example, Gaucher disease is the most common single 
lysosomal storage disorder in Australia (1.8 per 100,000 births),130 whereas GM2 
Gangliosidosis variant B is the most prevalent lysosmal storage disorder in Portugal 
(3.1 per 100,000 births).133 
Although prevalence rates of individual LSDs show these diseases to be rare, taken 
as a group they are quite common with a birth prevalence ranging from one per 
4000 to one per 9000 live births.130,132,133
TREATMEnT OF PATIEnTS WITH POMPE DISEASE
In 2006 both the European Medicines Agency (EMA) and the U.S. Food and 
Drug Administration (FDA) granted marketing approval for the drug Myozyme 
(alglucosidase alfa).134,135 With this approval a major milestone was reached and 
alglucosidase alfa became the first treatment ever for Pompe disease. In fact, it is 
the first therapy ever approved for an inherited muscle disorder.136 
In healthy human beings, endogenous alpha-glucosidase is synthesized in the 
rough endoplasmic reticulum (RER) and, after passing through the RER, enters the 
Golgi complex at the cis-side, binds to the mannose-6-phosphate (M6P) receptor 
at the trans-side and continues its way to the lysosomes.137,138 The M6P receptors 
deliver the enzyme to the late endosomes after which the enzyme ends up in 
the lysosomes. The M6P receptor recycles back to the trans-Golgi network.139 
Approximately 90% of the M6P receptors are located in the Golgi apparatus or 
in the endosomal system.140 The remaining percentage is present at the plasma 
membrane, where they can bind extracellular enzymes and mediate their transport 
to the lysosomes. Endocytosis of extracellular enzyme at the plasma membrane is 
the rationale behind enzyme replacement therapy with alglucosidase alfa.141 
In 1964, Christian de Duve suggested that lysosomal storage disorders could be 
treated by replacing the defective enzyme: “In our pathogenic speculations and 
in our therapeutic attempts, it may be well to keep in mind that any substance 
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which is taken up intracellularly in an endocytotic process is likely to end up within 
lysosomes. This obviously opens up many possibilities for interaction, including 
replacement therapy”.142 The first attempts with exogenous enzymes derived from 
Aspergillis Niger,143-145 followed by enzyme preparations from human placenta146 
were unsuccessful. It was not until Fratantoni and Neufeld147 succeeded in 
correcting the enzyme defect of cultured fibroblasts from Mucopolysaccharidosis 
patients via cross-correction that the importance of receptor mediated endocytosis 
via the M6P receptor was discovered by Sly and colleagues.148,149 
These findings led to the initial studies in which M6P-containing acid alpha-
glucosidase was administered to cultured fibroblasts and skeletal muscle from 
Pompe patients and knock out mice with Pompe disease.150-153 After positive 
results, two methods to produce recombinant acid alpha-glucosidase for the 
treatment of Pompe disease were almost simultaneously developed. One involved 
the production of enzyme in the milk of transgenic rabbits, in which genomic DNA 
constructs were used;154-156 the other involved Chinese hamster ovary cell lines 
expressing high levels of recombinant enzyme, in which cDNA constructs were 
used.157,158 Both enzyme preparations were tested in patients with Pompe disease. 
After the initial studies the production of recombinant human alpha-glucosidase 
from rabbit milk was discontinued as large-scale production appeared to be easier 
in CHO cells.159 
Enzyme replacement therapy: outcome in classic-infantile Pompe disease
The first clinical trials studying the effect of enzyme replacement therapy started 
in 1999.160-164 The initial studies mainly focused on the classic-infantile phenotype, 
while only very few patients with less severe phenotypes participated in trials. 
The experiences gathered in these initial studies are described in the following 
paragraphs. 
Nine infants with Pompe disease were included in the first three pilot studies. One 
of these eight patients did not have classic-infantile Pompe disease but a variant 
phenotype.161 They received recombinant alpha-glucosidase derived from the milk 
of transgenic rabbits in a weekly dose of 20‒40 mg/kg (159161-163,165 or CHO-cell 
derived recombinant human alpha-glucosidase initially 5 mg/kg twice weekly, later 
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10 mg/kg 2‒5 times a week.166-168 The children varied in age from 2.5 to 8 months at 
start of treatment. Study duration varied between 1.4 to 3 years. All eight patients 
with classic-infantile Pompe disease survived beyond the first year of life although 
five with ventilator support. One patient died at the age of four years. A significant 
improvement in cardiac dimension and function, obtained in all patients, almost 
certainly contributed to their prolonged survival. Muscle strength and motor 
function showed a more variable response to treatment; 2/8 patients learned to 
walk, and 2/8 patients were able to sit without support. The other patients (4/8) 
showed minor or no motor gains. The most impressive improvements were found 
in those patients that were least affected at baseline. 
It was not until 2006 and 2007 that the results of two open label, multicenter, 
multinational studies were published.169,170 The first study included eight infants 
with Pompe disease. Some of them had classic-infantile Pompe disease and others 
were atypical variants. The second study included 18 patients and all of them 
had the classic-infantile phenotype. Their age at baseline ranged from 1 to 14.6 
months. Patients received weekly infusions of 10 mg/kg to 20 mg/kg or 40 mg/kg 
recombinant human alpha-glucosidase from CHO cells. The results of these studies 
corroborated the initial results. All but one patient showed improvements in 
cardiac size. Although most patients survived beyond the first year of life, 12 of 26 
patients died at a median age of 31 months (range 14.7 to 44 months), the main 
cause of death being respiratory insufficiency caused by severe respiratory tract 
infections. Almost 60% of the patients was ventilator-free at study end, while 62% 
of the patients could sit or even walk. 
Infusion associated reactions (IARs) occurred in all clinical trials. Most frequently 
reported IARs were rashes, urticaria, fever, tachycardia, malaise, blood pressure 
changes, or bronchospasm. In general, IARs were well managed by slowing 
or temporarily stopping the infusions, or by administering antihistaminica 
or corticosteroids. None of the patients discontinued treatment because of 
unmanageable IARs.
Although these studies showed significant improvements in survival and cardiac 
size and function, respiratory and motor results were more variable. At present, 
the causes of variable response remain largely unknown. Possible factors suggested 
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are patients’ condition at baseline, extent of disease-related muscle pathology, and 
inhibitory antibody formation which may hamper the uptake of the administered 
enzyme into the muscle cells. 
Enzyme replacement therapy: outcome in children and adults
At the time that the studies presented in this thesis started, very little was known 
about the effect of ERT in children and adults. One pilot study in two juvenile 
patients (11 and 16 years old at baseline, respectively) and one adult patient (32 
years old at baseline), who had received therapy with enzyme from rabbit milk 
for three years (initially 10 mg/kg/week and after 12 weeks 20 mg/kg/week), 
had demonstrated positive results.164 All three patients were wheelchair bound 
at baseline. The youngest patient had normal respiratory function, but the older 
two were invasively ventilated. The oldest patient was severely affected. He was 
bedridden for most of the day. After three years of treatment, the pulmonary 
function had stabilized in all patients. The patients were less fatigued, which enabled 
the oldest patient to sit in a wheelchair for most of the day and to participate in 
family activities. The youngest patient showed the most impressive response. He 
gained sufficient muscle strength to abandon his wheelchair and to walk after 72 
weeks of treatment. 
An observational study in three patients, who started enzyme replacement therapy 
between the ages of 2.8 and 19.9 years,171 and two case studies, reporting about 
five adult patients (age at baseline 39‒68 years),172,173 supported these results and 
showed that ERT can lead to improvements of motor and respiratory functions, 
especially when treatment is started before significant muscle damage has 
occurred.171
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SCOPE AnD AIMS OF THIS THESIS
The pilot studies probing the effect of enzyme replacement therapy in classic-
infantile Pompe disease had provided a first insight in the possible benefits of 
this type of treatment. Although more than a decade has passed since those first 
studies were started, long-term treatment effects are still largely unknown. Now 
that these patients survive far beyond their first year of life, the most important 
question is whether the striking regression of cardiac hypertrophy, closely related 
to decreased morbidity and mortality, sustains. New aspects of the disease may 
emerge as children survive and grow older. 
Most information on presenting symptoms and disease progression in patients 
with Pompe disease comes from studies that were predominantly performed in 
adult patients. In retrospect approximately 58% of these adult patients remember 
that they already had mild muscular problems during childhood,16 but specific 
information on disease presentation in children with milder forms of the disease 
is scarce. In addition, long-term effects of ERT in this group of patients are largely 
unknown. 
The studies described in this thesis had the following objectives: 1) delineate 
the clinical spectrum of Pompe disease in children with more slowly progressive 
phenotypes of Pompe disease; 2) evaluate the effect of enzyme-replacement 
therapy in these children; 3) investigate the long-term outcome of patients with 
classic-infantile Pompe disease treated with ERT and compare it with the clinical 
phenotype found in children with less progressive forms; 4) compose a new 
measurement scale to better assess the motor function of children with Pompe 
disease. 
Most patients described in this thesis participated in a nationwide prospective 
observational study evaluating the safety and efficacy of ERT in children and adults 
with Pompe disease. All patients were monitored at regular intervals at the Center 
for Lysosomal and Metabolic Diseases at the Erasmus MC University Medical 
Center.
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General introduction
Part I of this thesis focuses on the clinical characteristics and natural course of 
children with more slowly progressive phenotypes of Pompe disease. Chapter 
2 provides clinical and genetic characteristics of children with more slowly 
progressive phenotypes of Pompe disease. Chapter 3 describes the severity of 
pulmonary involvement and the rate of its progression in children and adults with 
Pompe disease. The presence and extent of cardiac involvement in children and 
adults with the common c.-32-13T>G genotype is described in Chapter 4.
Part II focuses on the effect of ERT in children and adults with Pompe disease and 
includes the results of eight years of treatment in two children and one adult with 
Pompe disease (Chapter 5) followed by the results of a three year open-label study 
investigating the effect of treatment with alpha-glucosidase in five juvenile patients 
(Chapter 6). Chapter 7 describes the results of the “LOTS” study: a randomized, 
placebo-controlled multi-center trial in patients with late-onset forms of Pompe 
disease including 90 patients aged 8 years and older.
Part III focuses on classic-infantile Pompe disease. Chapter 8 is a case-report of 
one of the first treated and one of the longest survivors of classic-infantile Pompe 
disease. This patient is currently 15 years old and developed massive gingival 
overgrowth at the age of 3 years. The results of long-term ERT on facial muscle 
function, speech and swallowing are described in Chapter 9. The effect of ERT on 
hearing in chapter 10, and on cardiac dimension and function in Chapter 11. 
In part IV, which contains Chapter 12, the construction and validation of the 
quick motor function test (QMFT) is reported: a functional motor scale specifically 
designed for Pompe disease and used in clinical practice for monitoring disease 
progression and evaluating therapeutic efficacy.
At the end, the results of the studies presented in this thesis are discussed in 
Chapter 13 and future perspectives are given. 
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ABSTRACT
Introduction
Pompe disease is a lysosomal storage disorder that presents as a progressive 
myopathy. The aim of the present study was to gain knowledge on the presentation 
of Pompe disease in children with a non-classic presentation of the disease and to 
describe their specific clinical characteristics and genotypes.
Methods
We conducted a single-center, cross-sectional study. All patients younger than 18 
years of age that were referred to our clinic between 1975-2012 were included in 
this study. Patients were excluded if they were diagnosed with the classic-infantile 
form of Pompe disease. Information considering first symptoms, diagnosis and 
the use of a wheelchair or respirator was collected. Muscle strength, pulmonary 
function, and cardiac function were assessed and mutation analyses and blood 
tests including CK, LDH, and transaminases, were performed.
Results
31 juvenile Pompe patients participated in this cross sectional study. First symptoms 
presented at a median age of 2.3 years and diagnosis was made at a median age of 
4 years. Most common first problems were related to delayed motor development 
and limb-girdle weakness. Most prominent muscle weakness was found in the 
neck flexors, neck extensors and flexors of the hip. Muscle strength, measured 
by HHD, ranged from 0.3% to 91% of normal. Pulmonary function was decreased 
in 50% of the patients in a sitting position and in 59% of the patients in supine 
position. 68% of the patients carried the c.-32-13T>G mutation. These patients 
were predominantly male. 
Conclusion
Our study demonstrates that disease severity varies in childhood but that a 
substantial part of patients is already severely affected at young age. Disease 
presentation, distribution of muscle weakness and occurrence of specific symptoms 
like ptosis can be different from adult patients. Patients with other mutations than 
the c.32-13T>G mutation were in general more severely affected. Patients with the 
c.-32-13T>G mutation/null genotype were predominantly male.
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InTRODuCTIOn
Pompe disease, also known as acid maltase deficiency or glycogen storage disease 
type 2 (OMIM 232300), is a lysosomal storage disorder that presents as a progressive 
myopathy. Deficiency of the enzyme acid α-glucosidase (EC 3.2.1.20) causes 
glycogen to accumulate in lysosomes, and ultimately leads to cell destruction.1-3 
In 1932, J.C. Pompe first described the classic-infantile form of the disease.4 These 
patients present with generalized and severe muscle weakness, hypertrophic 
cardiomyopathy, and usually die within their first year of life.5,6 Later, other forms 
were reported and Pompe disease appeared to be a continuous spectrum with the 
severe classic-infantile form at one end, and milder presentations, also referred 
to as childhood, juvenile, adult, and late-onset phenotypes, at the other end. The 
latter patients usually do not have hypertrophic cardiomyopathy and present with 
a more slowly progressive limb-girdle muscle weakness, which eventually results in 
wheelchair dependency, respirator need, and shortened life expectance.2,7-17
Numerous publications can be found in literature describing the natural history of 
the disease in classic-infantile and adult Pompe patients.5,6,10-12,16 But information 
on the disease presentation of children not fulfilling the criteria of classic-infantile 
Pompe disease is scarce.18 
The aim of the present study was to gain knowledge on the presentation of Pompe 
disease in children and to describe their specific clinical characteristics. For this 
purpose we collected information on disease symptoms, distribution and severity 
of muscle weakness, involvement of respiratory function, cardiac structure and 
function, physical limitations, and genotypes of 31 children diagnosed with a 
non-classic presentation of Pompe disease. We compared our findings to Pompe 
patients presenting at adult age.
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METHODS
Subjects
All patients younger than 18 years of age that were diagnosed or referred to our 
center between 1975 and 2010, either coming from the Netherlands or abroad, 
were included in this observational study. Patients were diagnosed by measurement 
of α-glucosidase activity in cultured fibroblasts, leukocytes or muscle biopsy 
specimens, and mutation analysis. Patients were excluded if they were diagnosed 
with classic-infantile Pompe disease. 
Thirty-one patients participated in this cross-sectional study. Patients were 
evaluated as part of an Institutional Review Board approved study (n=28) or as part 
of routine clinical evaluation (n=3). The study was approved by the Institutional 
review Board. A medical history was obtained at first visit. For each patient, 
the following data were collected: gender, current age, geographic origin, first 
symptoms, age at first symptoms, age at diagnosis, wheelchair use, respiratory 
support, specific clinical findings (e.g. facial muscle weakness, bulbar muscle 
weakness, scoliosis, contractures, muscle atrophy), functional impairments, and 
weight and height. Low body weight was defined as weight corrected for height 
that was below -2SD for peers. Blood tests included measurement of creatine 
kinase (CK), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
and lactate dehydrogenase (LDH). All patients underwent clinical and neurological 
examination, performed by a paediatrician, and child neurologist. 
Muscle strength testing
Muscle strength was assessed by both manual muscle strength testing (MMT) 
(n=24) and hand held dynamometry (HHD) (n=24).19,20 The following muscle groups 
were tested with HHD: neck flexors, shoulder abductors, elbow flexors, wrist 
extensors, hip flexors, hip abductors, knee extensors, knee flexors, foot dorsal 
flexors. HHD scores (Newton) were expressed as percentages of the reference 
values (50th percentile) for healthy peers.20 All percentages were cumulated and 
divided by 9 to obtain a total HHD sum score expressed in percentage of normal 
(ranging from 0 to 100%). 
43
Childhood Pompe disease: clinical spectrum and genotype
2
MMT was performed according to the Medical Research Council guidelines21 for 
the following muscle groups: neck flexors, neck extensors, deltoid muscles, biceps, 
triceps, wrist extensors, hip flexors, hip extensors, hip abductors, hip adductors, 
knee flexors, knee extensors, and foot dorsal and plantar flexors.
Pulmonary function testing
Pulmonary function testing was performed by spirometry in both upright 
seated (n=28), and supine position (n=23) according to ATS/ERS standards.22 The 
maximum value of three reproducible tests was used for the analysis. The results 
were expressed as percentage predicted values.23 Three patients were too young 
to reliably perform spirometry. Pulmonary function of five other patients was 
compromised to the extent that they were unable to endure pulmonary function 
testing in supine position. 
Cardiac assessment
Conventional Doppler, and 2D M-mode tracings were performed in all patients 
according to the recommendations of the American Society of Echocardiography 
by an experienced sonographer (JP) (Sonos 5500 ultrasound system, Philips, Best, 
the Netherlands). In addition, standard 12 lead electrocardiograms were made and 
analyzed by a paediatric cardiologist.
Enzymatic and molecular assays
The acid α-glucosidase activity was measured in leukocytes24 and cultured skin 
fibroblasts15 according to standard procedures, and was expressed in nmol/hr/mg 
protein. The protein concentrations of cell homogenates was measured as previously 
described.25
Genomic DNA was isolated from blood or cultured fibroblasts and mutation 
analysis was performed according to standard procedures.15,26 The mutations were 
rated by severity using the format of Kroos et al.27 To determine the severity of the 
various mutations, this format takes into account both the quantity and quality 
of acid α-glucosidase (GAA) expression, and the functional effect of the mutation 
on enzyme activity.26 For splice-site mutations, the effect of the mutations was 
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examined by real-time PCR, to determine the quality and efficiency of mutant GAA-
mRNA.27
Statistics
Demographic and clinical data were summarized using descriptive statistics 
including mean, SD, median, ranges, and percentages. Differences between groups 
were analyzed using a Mann-Whitney test because the data were not normally 
distributed. P-values <0.05 were considered statistically significant. All statistical 
analyses were performed using SPSS for Windows version 17.0.
RESuLTS
Symptom onset and diagnosis
Thirty-one children participated in this cross-sectional study. Table 1 shows the 
patient characteristics and genotype. Twenty-two patients were male, nine were 
female. Seventeen patients were from the Netherlands, 4 from Belgium, 5 from 
Germany, 3 from Greece, 1 from Great Britain, and 1 from the United States. 
The median age at which patients experienced their first symptom was 2.3 years. 
Median age of the patients at time of diagnosis was 4.0 years. The most common 
presenting symptoms were delayed motor development (nine patients), and 
symptoms related to limb-girdle weakness like frequent falling, difficulty climbing 
stairs, and problems with running and performing sports. Fatigue, persistent 
diarrhoea and problems in raising the head in supine position were other first 
complaints. Median time span between symptom onset and diagnosis was 1.0 year 
(range 0 to 5.8 years).
Ten patients were diagnosed presymptomatically. In six of them the diagnosis 
was made after elevated CK and transaminase serum levels were found during a 
hospital admission for unrelated matters. The other four patients were diagnosed 
because they had a sibling with Pompe disease. Five of these ten patients developed 
symptoms between diagnosis and first examination in our hospital (see for details 
Table 1). 
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Clinical findings
All 31 patients were evaluated in our hospital. The age at time of examination 
ranged from 0.1 to 17.3 years. Table 2 shows the findings on clinical examination. 
Low or absent reflexes, a myopathic face, and scoliosis were found in over 50 
percent of the 31 patients. Facial muscle weakness was generally mild and did not 
lead to speech difficulties or dysphagia. One exception was a patient (patient 23 in 
Table 1) who was fed by percutaneous endoscopic gastrostomy catheter and had 
severe dysarthria. This patient was wheelchair bound and ventilator dependent 
since the age of 6 years. 
Flexion contractures were present in 19% of the patients and were most frequently 
found in the ankles. Three patients also had contractures of the hips and knees. 
Several patients underwent corrective surgery for either contractures (n=4, 
patients 1, 6, 10, 29 in Table 1), or scoliosis (n=4, patients 7, 14, 23, 30 in Table 1).
Noteworthy, thirty percent of the patients were underweight; their weight 
corrected for height was: -4.3 to -2.0 standard deviations below healthy peers. 
In all patients, a standardized neurological examination was performed. This 
examination revealed physical limitations in 70% of the patients. In more than 50% 
of the children difficulties were observed with standing up from supine position 
and flexing the neck in supine position (Table 2). Other important limitations were 
problems with standing up from sitting on heels, climbing stairs, and rising from a 
chair. 
Distribution of muscle weakness
Figure 1 shows the severity of muscle weakness and the frequency in which the 
various muscle groups were affected. The most prominent weakness was found 
in the neck flexors, which were affected in 75% of the patients. Other muscles 
that were frequently affected were the gluteus maximus (extension of the hip), the 
ileopsoas (flexion of the hip), and the deltoid muscle. The triceps, wrist extensors, 
and foot plantar flexors were relatively spared. In patients with far advanced 
disease, all muscles were affected.
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Figure 1. (A) the frequency in which the various muscles were affected. (B) the severity of 
involvement of the separate muscle groups. 
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All patients, including those who had no symptoms at the time of examination had 
a lower total HHD sum score than age related peers. Total muscle strength ranged 
from 0.3‒91 % of normal (median 55.4%). Four patients were wheelchair bound at 
the time of investigation; four others became wheelchair dependent in the period 
thereafter. At the moment these eight patients became wheelchair dependent 
their age ranged from 4 to 22 years (n=8, median 7.5 years). The median time 
period between first symptoms and loss of ambulation was 4.5 years (range 3 to 
15 years, n=8).
Table 2. Results of clinical and neurological examination. Deep tendon reflexes that were 
tested were the biceps reflex, the triceps reflex, the knee jerk reflex, and the ankle jerk reflex
number of patients (Total 31)
Clinical findings
Low/absent reflexes 22 (71%)
Weakness facial muscles 16 (52%)
Scoliosis 16 (52%)
Muscle tone decreased 13 (42%)
Scapular winging 12 (39%)
Muscle atrophy 11 (35%)
Scapular winging 11 (35%)
Contractures 9 (29%)
Low body weight 9 (29%)
Ptosis 0   (0%)
Physical limitations
Standing up from supine position 18 (58%)
Flexing the neck in supine position 17 (55%) 
Standing up from sitting on heels 13 (42%)
Climbing stairs 13 (42%) 
Rising from a chair 10 (32%)
Erecting back in prone position 8 (26%)
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Pulmonary function testing
In sitting position, 14 of the 29 patients (50%) had a decreased pulmonary function 
(<80% according to the ATS guidelines). Seventeen of the 29 patients (59%) 
had a decreased Forced Vital Capacity (FVC) in supine position; in five of these 
patients pulmonary function was too compromised to obtain a reliable value. 
FEV1/VC measurements were normal in all patients, indicating a restrictive pattern 
of pulmonary dysfunction. 
The median difference in FVC between sitting and supine position (postural drop) 
was -6.0% (range 0 to -20%). Eight patients had a postural drop between -10 and 
-20%. Five patients were ventilator dependent at the time of first evaluation, and 
one patient became ventilator dependent during follow-up (see Table 1 for details); 
Two additional patients died from respiratory failure at the ages of 6 and 10 years, 
when it was decided not to start respiratory support. The median time period from 
first symptoms to any kind of ventilation or death by respiratory insufficiency was 
5.5 years (range 2 to 11 years, n=8). The median age at start of ventilation or death 
was 9 years (range 5 to 16 years, n=8).
Cardiac evaluation
Six patients showed abnormalities on cardiac evaluation. In three patients the 
findings were considered to be related to Pompe disease. Two patients had a 
hypertrophic cardiomyopathy without outflow tract obstruction (patients 22, 23 in 
Table 1) In one patient, this was first noticed at the age of one year, and in the other 
patient at the age of two years. Their ECGs showed high amplitude QRS complexes 
and repolarisation disturbances consistent with their hypertrophic cardiomyopathy. 
In addition, their ECGs and that of a third patient (patient 3 in Table 1) showed a 
short PR interval and a delta wave suggestive for Wolff-Parkinson-White syndrome. 
Minor abnormalities of the cardiac valves were noted in three patients. The 
abnormalities included a quadricuspid aortic valve, a minor deformity of the 
tricuspid valve leading to minimal tricuspid regurgitation, and minimal insufficiency 
of both atrioventricular valves. These abnormalities were all considered to be 
accidental findings and not related to Pompe disease. 
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Enzymatic and molecular diagnosis
Table 1 shows the genotype of the patients and the severity of their mutations. 
All mutations were previously described in the literature (www.pompecenter.nl). 
Twenty-three patients (74%) carried a potentially mild mutation on one GAA allele 
and a severe mutation on the other. Twenty-one of these patients (68%) carried 
the common c.-32-13T>G splice site mutation. Since none of the mutations in the 
other 8 patients was considered potentially mild, the genotype of these patients 
was considered more severe.
Laboratory parameters
At first visit 29 of 31 patients had elevated CK levels (median 979 U/l, range 358 
to 3078 U/l; normal values below 230 U/l)). Both patients, who had normal CK 
levels, were symptom free at the time of investigation. One of them was diagnosed 
because of an accidental finding of elevated transaminase levels during admission 
for a gastroenteritis; the other was diagnosed because of a sibling with Pompe 
disease. 
Noteworthy, in all patients, including the symptom free patients, the transaminase 
levels were elevated; AST ranged from 82 to 972 U/l (normal values below 51 E/l), 
ALT from 71-487 U/l (normal values below 39 U/l). LDH levels were elevated in 22 
of 30 patients and ranged from 797 to 2828 U/l (normal values below 765 U/l). 
Comparison of patients with the c.-32-13T>G/null genotype (IVS1)and those with 
other genotypes (non-IVS1)
Comparison of the twenty-one patients with the c.-32-13T>G/null genotype to the 
ten patients with other mutations showed no significant differences in age at first 
symptoms and age at diagnosis (Table 3). The median age of the patients at the time 
they were examined was similar. It was noted that patients in the non-IVS1 group 
had lower muscle strength and pulmonary function in sitting and supine position 
than those in the IVS1 group. This was in line with the observation that more 
non-IVS1 than IVS1 patients became wheelchair bound and ventilator dependent 
at a relatively young age. In addition, the two patients with a hypertrophic 
cardiomyopathy belonged to the non-IVS1 group. Another interesting observation 
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was that eighteen of the twenty-one (86%) patients with the c.-32-13T>G/null 
genotype were male, while this was 40% in the non-IVS1 group.
Table 3. Comparison of the patients with the c.-32-13T>G and patients with other mutations 
at the time of examination. 
All c.-32-13T>G other mutations P-value
Patients 31 21 10 –
M/F 22/9 18/3 4/6 –
Age first symptom (median) 2.5 (0.5–13) 1.3 (0.5–13) 4.0 (0.5–10) 0.4
Age diagnosis (median) 4.0 (0–16) 3.0  (0–16) 4.5 (1–15) 0.3
Age at examination (median) 10.2 (0.1–17) 10.8 (0.1–17.3 9.6 (1.3–16.3) 0.3
Disease duration1 (median) 3.9 (0–12.7) 3.2 (0–12.7) 4.0 (0.8–11.5) 0.7
Diagnosed pre-symptom 10 9 1 –
Still symptom free 5 4 1 –
HHD sumscore 52 58.3 34.1 0.004
FVC pred sitting (%) 78 86.8 61.4 0.08
FVC pred supine (%) 72 80.6 57.5 0.04
1 Disease duration is calculated as time between the presentation of first symptoms and first examination 
in our hospital.
DISCuSSIOn
Information on the clinical presentation of children with non-classic forms of Pompe 
disease is scarce. In the present study we evaluated the clinical and molecular 
characteristics of 31 children. The results emphasize that the disease may already 
cause a significant burden of disease in childhood and add to the understanding 
that Pompe disease presents as a broad spectrum of clinical phenotypes. 
The presentation of Pompe disease can be variable. In our patient population, 
children typically presented with weakness of the limb-girdle muscles and/or 
delayed motor development; in all symptomatic patients CK levels were elevated, 
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approximately half of the children had a compromised pulmonary function, and 
two patients with a very rapid deterioration of muscle function had a hypertrophic 
cardiomyopathy. Nevertheless, Pompe disease should also be considered in 
children with less familiar findings such as disproportional weakness of the neck 
flexors, unexplained fatigue, persistent diarrhoea, and an (isolated) elevation 
of transaminase levels. An elevation of ALT and AST was found in all patients 
participating in the present study, whether they showed symptoms of the disease 
or not. 
Although respiratory problems did not precede proximal muscle weakness in any 
of the patients, pulmonary function was already significantly reduced in more 
than half. In 33% of the patients respiratory insufficiency led to the requirement 
of ventilator support or death during childhood. This confirms that pulmonary 
function should be closely monitored in children, as was previously reported for 
adult patients.14,28 The fact that eight patients had postural drops suggestive for 
diaphragm weakness, a well-known feature in Pompe disease and the main cause of 
nightly hypoventilation,28,29 stresses the importance to perform pulmonary function 
tests in both sitting and supine position. Following a recent study in children with 
neuromuscular disorders that found a poor correlation between daytime lung 
function and nocturnal hypoxemia, we suggest the use of systematic sleep studies 
as an additional tool to identify children at risk for nocturnal hypoventilation.30 
Seventy-one percent of the 31 patients that we investigated were male, which 
interestingly included 18 of the 21 patients (86%) with the common c.-32-13T>G/
null genotype compared to only 4 of the 10 patients (40%) with other mutations. 
Two studies that focused on disease variation among children and adult patients 
with the c.-32-13T>G/null genotype, found an equal male to female distribution 
(55% and 58% males respectively). In both studies, however, no attention was given 
to a potential difference in age of onset between male and female patients.15,16 Our 
study shows that such a gender difference exists. Earlier we also found a male 
predominance (67%) in patients under 18 years when we analysed 225 published 
case reports about children and adults with Pompe disease.17 Earlier studies also 
showed that pulmonary function was more affected in men,14 and that more men 
than women had bulbar involvement and shoulder-girdle muscle weakness.14 A 
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study comparing phenotypes in siblings with Pompe disease also confirmed that 
males were more severely affected than females.31 
Since Pompe disease inherits as an autosomal recessive trait, there is no good 
explanation why males with the same genotype would present at an earlier age 
than females other than that secondary gender related factors might play a role in 
the clinical expression of this autosomal recessive disease. Gender differences have 
also been reported for other neuromuscular disorders like fascioscapulohumeral 
muscular dystrophy and some subtypes of limb-girdle muscular dystrophy.32-34 
The only difference between men and women found so far was a better capacity 
in muscle fiber atrophy regeneration in women.34 This may also apply for Pompe 
disease. Although other causes, like differences in genetic and epigenetic factors 
have been suggested, the exact mechanism remains elusive.
Our findings are fully in line with the broad spectrum of clinical phenotypes 
associated with the c.-32-13T>G/null genotype.15,16 Comparison of these patients 
with patients carrying other mutations showed a similar age of disease onset, age 
at diagnosis and actual age. In both groups several patients became wheelchair 
bound and/or ventilator dependent during childhood. Hence, it can be concluded 
that significant morbidity at an early age can occur in patients carrying other 
genotypes as well as in patients carrying the c.-32-13T>G/null genotype. 
On a group level, patients in the non-IVS1 group seemed to be more severely 
affected. This is illustrated by specific cases. Two patients in the non IVS1 group 
had a hypertrophic cardiomyopathy. They became fully wheelchair bound at 4 
and 6 years of age respectively. One died from respiratory failure at the age of 
10 years, and the other patient became completely ventilator dependent when 
she was 6 years old. These two patients express a phenotype that was earlier 
called the “atypical infantile form” of Pompe disease by Slonim et al.18 Overall, 
mutations identified in the non- IVS1 group were more severe (see Table 1 and 
www.pompecenter.nl). Some of the genotypes have been described in literature. 
For example patient 30 (Table 1) had genotype c.-32-3C>A in combination with 
c.877G>A+c.271G>A. This genotype has been described before by Oba-Shinjo et al. 
The patient in our study presented with first symptoms at the age of 10 years and 
showed respiratory insufficiency leading to night-time ventilation at the age of 12 
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year, while the patient from literature presented at the age of 7 years and died of 
respiratory failure at the age of 15 years.35 Two case reports considering genotype 
c.1634C>T in combination with c.2481+102_2646+31del as found in patient 
25 were described before.12 One patient presented at the age of one, became 
dependent on respiratory support at the age of 20 years, and wheelchair bound at 
the age of 23 years. The other patient was diagnosed at the age of 16 years, began 
to use a walking stick at the age of 19 years. Pulmonary function worsened severely 
from age 17–19 years on and dropped to 26% of normal at the age of.36 These case 
reports show substantial similarities and both point to the fact that our patient, 
who was only six years old at time of examination, awaits severe respiratory and 
mobility problems at young age. This kind of information may become relevant 
when it comes to decision making on when to start enzyme replacement therapy.
Comparing our results in children with those in adults, we find both similarities 
as well as differences. The wide variation in disease presentation and disease 
progression, as well as the involvement of both respiratory and proximal skeletal 
muscles are similar in children and adults.8-12,15,16 The distribution of muscle 
weakness also shows a limb-girdle pattern in both cases, but there are differences. 
While the neck flexors are by far the most severely affected muscle group in 
children this does not seem to be the case in adults.9,12 Although neck flexors were 
shown to be affected in the majority (50‒80%) of adult patients (n=94) t, muscle 
strength of the neck flexors was only mildly reduced.37 Relative mild involvement 
was also shown by a recent MRI study performed in 20 adult patients by Carlier et 
al.38 Another difference is the relative sparing of the quadriceps muscle in adult 
patients.37,38 In the current population of 31 children with Pompe disease, the 
muscles of the thigh were more heterogeneously affected, and the quadriceps 
muscle were not spared. Additionally, we did not find ptosis in any of our patients, 
while this has recently been described to be present in 14.7 to 23% of adult Pompe 
patients.37,39,40 It should be noted that ptosis was often found in an early stage of 
the disease, even as a presenting symptom in adult Pompe patients. While van 
der Beek et al found difficulties with speech, chewing or swallowing, suggestive 
for bulbar weakness in 28% of patients, we found bulbar weakness in only one 
patient. On the contrary, scoliosis was present in 52% of our patients, compared 
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to only 21 to 23% of adult Pompe patients.17,37 In several children the scoliosis was 
so severe that it interfered with mobility or influenced respiratory function, four 
patients needed surgical correction. A cross-sectional analysis of data from the 
Pompe Registry, a large multinational observational program, found scoliosis to be 
present in 57% of patients with disease onset in childhood.41 
Some limitations of our study should be mentioned. A selection bias can be present 
since our centre serves as an (inter)national referral centre for Pompe disease. This 
probably has caused the referral of more severely affected patients. Nevertheless, 
ten of the thirty-one patients were diagnosed pre-symptomatically, of which five are 
still symptom-free. A second limitation was that the study was cross-sectional. The 
approval of enzyme replacement therapy in 2006 interfered with the collection of 
longitudinal follow-up data since all children that manifested significant symptoms 
of the disease started to receive enzyme replacement therapy at some time during 
follow-up.
In conclusion, several studies among adult Pompe patients reported the occurrence 
of mild symptoms during childhood.8,99,11 Our study, on the contrary, demonstrates 
that although the course of childhood Pompe disease varies widely, a substantial 
proportion of patients manifests serious problems during their youth. We stress 
that Pompe disease should also be considered in the differential diagnosis of 
patients with less familiar signs such as disproportional weakness of the neck 
flexors, unexplained fatigue, persistent diarrhoea, and an isolated elevation of 
transaminase levels. Disease presentation, distribution of muscle weakness, and 
the occurrence of specific symptoms such as bulbar muscle weakness or ptosis, 
appear to be different from adult patients. Patients with other mutations than the 
c.-32-13T>G mutation were in general more severely affected, which is in line with 
more severe genotypes present in these patients. Children with a c.-32-13T>G/null 
genotype presenting in childhood appeared to be predominantly males. 
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ABSTRACT
Respiratory insufficiency is a serious threat to patients with Pompe disease, a 
neuromuscular disorder caused by lysosomal acid alpha-glucosidase deficiency. 
Innovative therapeutic options which may stabilize pulmonary function have 
recently become available. We therefore determined proportion and severity of 
pulmonary involvement in patients with Pompe disease, the rate of progression of 
pulmonary dysfunction, and predictive factors for poor respiratory outcome.
In a single-center, prospective, cohort study, we measured vital capacity (VC) in 
sitting and supine positions, as well as maximum inspiratory (MIP) and expiratory 
(MEP) mouth pressures, and end expiratory CO
2
 in 17 children and 75 adults with 
Pompe disease (mean age 42.7 years, range 5‒76 years).
Seventy-four percent of all patients, including 53% of the children, had some 
degree of respiratory dysfunction. Thirty-eight percent had obvious diaphragmatic 
weakness. Males appeared to have more severe pulmonary involvement than 
females: at a group level, their mean VC was significantly lower than that of females 
(p<0.001), they used mechanical ventilation more often than females (p=0.042) 
and the decline over the course of the disease was significantly different between 
males and females (p=0.003). Apart from male gender, severe skeletal muscle 
weakness and long disease duration were the most important predictors of poor 
respiratory status. During follow-up (average 1.6 years, range 0.5–4.2 years), three 
patients became ventilator dependent. Annually, there were average decreases in 
VC in upright position of 0.9% points (p=0.09), VC in supine position of 1.2% points 
(p=0.049), MIP of 3.2% points (p=0.018) and MEP of 3.8% points (p<0.01).
We conclude that pulmonary dysfunction in Pompe disease is much more common 
than generally thought. Males, patients with severe muscle weakness, and those 
with longer disease duration seem most at risk.
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InTRODuCTIOn
Pompe disease is a rare inherited metabolic disorder1-4 caused by deficiency of the 
lysosomal enzyme acid α-glucosidase. The spectrum of phenotypes is continuous, 
but in clinical practice two subtypes can be recognized: 1) the classic infantile 
phenotype, in which the disease manifests shortly after birth, leading to generalized 
muscle weakness, cardiorespiratory failure and death within the first year of life;5,6 
and 2) a more slowly progressive phenotype predominantly affecting skeletal and 
respiratory muscles, in which cardiac involvement is only sporadically present.7,8 
Symptoms in this latter group of patients can become manifest at any age, from 
as early as the first year of life to as late as the sixth decade.9-12 The course of the 
disease can vary substantially between patients,13 and the severity of respiratory 
involvement is not always related to the degree of skeletal-muscle weakness.14,15
Due to the disproportionate involvement of the diaphragm, respiratory 
insufficiency is a serious threat to patients with Pompe disease;16,17 this is also seen 
in several other neuromuscular disorders such as Duchenne muscular dystrophy 
or facioscapulohumeral dystrophy. As the disease progresses, many patients 
ultimately become dependent on mechanical ventilatory support, and respiratory 
failure is a major cause of death.7,12 However, most studies have investigated only 
a small number of patients, or only a selected group; the actual percentage of 
patients with respiratory dysfunction, who are thus at risk for developing respiratory 
failure, is therefore not exactly known.11,14,15,17 Neither is it known which factors are 
associated with poor pulmonary outcome.
In April 2010, a placebo controlled trial showed that pulmonary function in patients 
older than eight years may be stabilized by treatment with recombinant human 
α-glucosidase. Early identification of respiratory problems may thus be important 
for the timely initiation not only of mechanical ventilation, but also of enzyme 
therapy.18,19
To establish the proportion of patients with pulmonary involvement, and also the 
severity of pulmonary dysfunction and the rate of deterioration, we conducted a 
prospective cohort study in 92 untreated children and adults with Pompe disease. 
We also aimed to identify predictive factors for poor respiratory outcome.
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MATERIALS AnD METHODS
Study population and study design
Ninety-two patients (17 children and 75 adults) were included in an ongoing 
prospective cohort study on the natural course of Pompe disease. Participation 
was open to all patients who did not have the classic infantile type of Pompe 
disease. Diagnosis in all patients was confirmed through mutation analysis and by 
measuring acid α-glucosidase deficiency in leukocytes, muscle tissue or fibroblasts.
All patients were examined at Erasmus MC University Medical Center between 
August 2003 and August 2009. They were recruited either through neuromuscular 
centers in the Netherlands and Belgium, or through the Dutch neuromuscular 
patient organization, or were referred to our center of expertise by their 
treating physicians. Throughout the study, none of the patients received enzyme 
replacement therapy. The research protocol was approved by the Central 
Committee on Research Involving Human Subjects in the Netherlands (CCMO). All 
patients or their parents provided written informed consent.
Pulmonary function tests
Vital capacity (VC) and forced expiratory volume in one second (FEV
1
) were 
measured using a Lilly type pneumograph (Viasys Healthcare, Würzburg, Germany) 
according to ATS/ERS standards.20 Patients were tested in upright seated or supine 
position while wearing a nose clip. Three repeated flow volume curves were made; 
in case of a non-characteristic curve, an extra measurement was performed. The 
best effort, determined as the measurement with the highest sum of VC and FEV
1
, 
was used in further analyses. Values were expressed as percentage of predicted 
normal values (based on able-bodied persons of the same age, gender, and height) 
or as z-scores, calculated as the difference between the observed and predicted 
value divided by the standard deviation from the reference value. Z-scores <-1.64 
(5th percentile of the reference population) were considered abnormally low. 
Reference values were derived from published data.21,22 For vital capacity a further 
subdivision was made to categorize the severity of lung function impairment: mild 
(z-score -3 to -1.64), moderate (z-score -4 to -3) and severe (z-score <-4). A drop 
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in percentage predicted VC upon changing posture from the upright to the supine 
position of more than 25% was considered as diaphragmatic weakness.23-25
Maximum static inspiratory (MIP) and expiratory (MEP) pressures were recorded 
using a differential pressure transducer (Viasys Healthcare, Würzburg, Germany) 
according to ATS/ERS standards.23 Patients were comfortably seated, wearing a 
nose clip. Pressures were measured against an obstructed mouthpiece with a small 
leak to prevent glottic closure during the MIP maneuver and to reduce the use of 
buccal muscles during the MEP maneuver. In addition, the patient held the cheeks 
during the MEP maneuver. MIP was measured at residual volume after maximal 
expiration and MEP at total lung capacity after maximal inspiration. Pressures had 
to be maintained for at least one second. Maneuvers were repeated until three 
reproducible measurements were recorded. At least 1 min was taken between 
consecutive measurements. The highest value obtained was taken for analysis. 
Reference values were taken from published data.26 MIP below the lower limit of 
the normal predicted value was interpreted as diaphragmatic weakness.
The carbon dioxide fraction in the expired gas was measured with a capnograph 
(ms-capno, Viasys Healthcare, Würzburg, Germany) at maximum expiration (P
EE,CO2
). 
In the absence of ventilation irregularities, the P
EE,CO2 
approximates the arterial 
carbon dioxide pressure (P
a,CO2
). A daytime P
EE, CO2 
over 6,0 kPa suggests hypercapnia 
and chronic alveolar hypoventilation.27
Additional clinical information
Information was gathered on the following: 1) age at symptom onset, 2) age at 
diagnosis, 3) disease duration since first symptoms, 4) height, 5) weight, 6) gender, 
7) use of wheelchair or walking aids, 8) muscle strength, 9) use of ventilatory 
support, 10) number of hours of ventilatory support per day, 11) presence of 
sleep disorders, 12) presence of scoliosis and scoliosis surgery, 13) smoking habit, 
14) concomitant diseases such as chronic obstructive pulmonary disease or asthma, 
and 15) family history of pulmonary disease.
Muscle strength was graded through manual muscle testing using the Medical 
Research Council (MRC) grading scale28 (range 0–5; all patients were assessed by 
the same examiner (NvdB) without having access to the pulmonary function data). 
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A muscle sumscore was calculated for the following muscle groups: neck extensors, 
neck flexors and bilateral shoulder abductors, elbow flexors, elbow extensors, hip 
flexors, hip abductors, knee flexors and knee extensors. This sumscore ranges from 
0 (“total paralysis”) to 80 (“normal strength”).
Statistical analyses
Continuous variables are presented using median and range. For categorical 
variables, percentages or frequencies are given. Pulmonary function testing 
could not be performed in six patients who were ventilated 24 h a day through a 
tracheostomy tube. In the statistical analyses these patients were considered to 
have the most severely affected pulmonary function, and were artificially given a 
VC of -8.5SD (just below the least observed value), since their omission might have 
led to biased results.
Baseline differences between males and females were assessed using Χ2 tests 
(wheelchair use and ventilator use) or Mann-Whitney tests (age, disease duration, 
mobility, age at first symptoms, age at diagnosis and MRC sumscore).
The relationships between disease duration, MRC sumscore, mobility, gender, 
MIP, MEP and vital capacity were calculated using the Spearman’s rank correlation 
coefficients (ρ).
Multiple linear regression analysis was used to further explore the relationship of 
VC versus gender and disease duration, with adjustment for age, MRC sumscore 
and mobility.
Longitudinal analysis of pulmonary function was performed using random 
coefficient models for repeated measurements, allowing for irregularly measured 
data. For subgroup analyses, patients were divided into groups on the basis of 
disease duration (<5, 5 to 10, 10 to 15, or ≥15 years); mobility (no walking aids, 
walking aids, partial wheelchair use, fully wheelchair dependent); vital capacity at 
study entry (normal, mild to moderately reduced, severely reduced); and muscle 
strength at baseline (severely affected, moderately affected, mildly affected).
All analyses were performed with SPSS for Windows (version 15, SPSS Inc., 
Chicago, IL) or SAS (version 9.1, SAS Institute Inc., Cary, NC). A p-value of ≤0.05 was 
considered statistically significant.
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RESuLTS
Baseline measurements
Clinical characteristics
The study population comprised 92 patients with Pompe disease: 17 children aged 
between 5 and 17 years, and 75 adults. Fifty-four percent of the patients were 
male. Disease duration at the time of the initial investigation ranged from 0 to 
47 years. The median age at which patients had experienced their first symptoms 
was 30 years (range 1 to 62 years). Seven patients (six children and one adult) had 
been diagnosed within the first two years of life. None of these patients had a 
hypertrophic cardiomyopathy, a typical feature of the classic infantile phenotype. 
Sixty-nine adults and 10 children (86% of all patients) expressed the common 
c.-32-13T>G (IVS1-13T>G) mutation combined with a second pathogenic mutation 
on the other allele.
Twenty-one of the 75 adults (28%) and eight of the 17 children (47%) had a mild 
scoliosis. One child had a severe scoliosis requiring surgery. Twenty-four of the 75 
adults (32%) used mechanical ventilation either non-invasively (n=18) or invasively 
(n=6; all males). Two of the 17 children (12%) used nocturnal non-invasive 
ventilation (one boy, age 13 years, age at start of ventilation 13 years; one girl, age 
9 years, age at start of ventilation 8 years). In one patient, respiratory insufficiency 
had been the first symptom of Pompe disease. Six patients (four adults and two 
children) who used ventilatory support were able to walk without needing walking 
devices. Table 1 shows the clinical characteristics of the patient group.
Pulmonary function tests
Spirometry
In upright seated position, 45 of the 75 adults (60%) had a decreased VC. VC was 
mildly decreased in 15, moderately decreased in 11 and severely decreased in 19 
(including the six patients being ventilated through a tracheostomy tube). The 
FEV
1
/VC ratio was >80% in all but one patient, indicating a restrictive nature of the 
compromised pulmonary function. Of the 17 children, eight (47%) had a decreased 
VC in sitting position. Vital capacity was mildly decreased in three, moderately 
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decreased in one and severely decreased in four. The FEV
1
/VC ratio was >80% in 
all children. The youngest patient in whom a diminished pulmonary function was 
measured was seven years old. At a group level, mean VC was significantly lower 
in the patients who had a scoliosis compared to those without a scoliosis (mean 
z-score -3.1 (65.3% predicted) against mean z-score -1.7 (85.1% predicted), p=0.02). 
Of the group of 92 patients, three had COPD (all adults), four had asthma (three 
adults, one child), and none had first-degree relatives with pulmonary disease. 
Twelve adult patients were current smokers, while 27 had smoked in the past. 
Comparing distributions of VC between these subgroups of patients, no significant 
differences were found.
Measured in supine position, VC was diminished in 59 adult patients (79%) and 
in 10 children (59%). When patients moved from a sitting to supine position, VC 
fell in 18 (20%) by more than 25% (so called “postural drop”), indicating possible 
diaphragmatic weakness. Testing in the supine position was not attempted in 
11 patients whose pulmonary function was already severely restricted in seated 
position. Two patients whose VC was normal or mildly reduced when they were 
seated nonetheless required ventilatory support when supine. Figure 1 shows 
a) the VC in sitting and supine positions expressed as percentage of the predicted 
value, and b) the magnitude of the difference when the patient changed position. 
This is indicated as “postural drop”.
Twenty of the 66 patients who received no ventilatory support complained of 
frequent dyspnoea while at rest or in supine position, or of morning headache, 
sleep disturbances or difficulty concentrating. Pulmonary function was severely 
impaired in ten of these patients (<-4SD or <50% of the predicted normal value), 
only two of whom had already been monitored for nightly hypoventilation by a 
center for home ventilation; the other eight were referred by us. In three, nocturnal 
ventilation had to be initiated. In addition, seven patients who did not have any 
respiratory complaints were found to have a severely reduced pulmonary function 
in the supine position. Evaluation of their respiration during sleep did not lead to 
installation of mechanical ventilation so far. It is noteworthy that VC had never 
previously been measured in 13 of these 17 patients whose pulmonary function 
appeared to be severely reduced, or at least not in supine position.
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Figure 1. (A) Vital capacity in upright seated position compared to vital capacity in supine 
position in 17 children and 69 adults with Pompe disease. The light gray represents vital 
capacity in upright position; the dark gray represents vital capacity in supine position. 
Asterisks identify patients using ventilatory support. The six adult patients who are 
ventilated invasively 24 hours a day are not included in the graph. (B) Difference between 
vital capacity in sitting and supine positions, expressed in percentage (i.e. “postural drop”). 
The dotted line represents a difference between vital capacity in sitting and supine positions 
of 25%, defined as diaphragmatic weakness. # identifies patients whose pulmonary function 
was already so severely restricted when seated, that they could not perform the test when 
supine. For patients 3, 5, 12, 14, 65 and 80, vital capacity was identical in sitting and supine 
positions.
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The severity of pulmonary dysfunction was significantly but moderately associated 
with the degree of skeletal muscle weakness measured by MRC sumscore (ρ=0.55, 
p<0.001, Figure 2), mobility (ρ=0.50, p<0.001) and disease duration (ρ=-0.46, 
p<0.001). 
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Figure 2. Relationship between vital capacity and MRC sumscore in 88 patients with Pompe 
disease. This muscle sumscore was composed by adding the grades (0–5) for the following 
muscle groups: neck extension, neck flexion and bilateral shoulder abduction, elbow flexion, 
elbow extension, hip flexion, hip abduction, knee flexion and knee extension (range 0–80). 
Circles represent females, squares represent males. MRC sumscore did not differ significantly 
between males and females (p=0.64).
An important finding was that there appeared to be a difference in the degree 
of pulmonary dysfunction between males and females. Firstly, at a group level, 
VC in male patients was significantly lower than in females (mean z-score -3.6 
(69.6% predicted) against mean z-score -1.3 (82.8% predicted), p<0.001). Secondly, 
more males than females used ventilatory support (p=0.042, Table 1). Thirdly, all 
patients who were ventilated 24 h a day, whether invasively or otherwise, were 
male. Regression analyses showed that the difference in severity of pulmonary 
involvement between males and females increased with disease duration. In 
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females, z-score decreased by 1.5 points (p=0.15) from the category with a disease 
duration less than 5 years compared to the category with a disease duration of 
more than 15 years, while in males the corresponding decrease was 6.9 points 
(p<0.001; Figure 3). This difference in decline of vital capacity between males and 
females over the course of the disease was significant (p=0.001) and remained 
significant after adjustment for age, MRC sumscore and mobility (p=0.003). For the 
latter factors, it was found that older age, a higher MRC sumscore, and a better 
mobility score were associated with a higher VC (all p≤0.01).
Table 1. Clinical characteristics of the study population (n=92)
Males (n=50) Females (n=42)
Age at first study visit, y 45 (5–76) 47 (8–71)
Age first complaints, y 30 (1–61) 33 (1–62)
Age at diagnosis, y 36 (1–67) 36 (1–63)
Disease duration, y 12 (0–48) 10 (0–41)
Use of walking aids, n 6 (12) 5 (12)
Wheelchair use, n 16 (32) 11 (26)
Age at start of wheelchair use, y 49 (3–76) 50 (35–67)
Disease duration at start of wheelchair use, y 21 (2–46) 16 (5–26)
Use of ventilatory support, n 19 (38)a 7 (17)
Non-invasive (nose hood or face mask) 13 7
Invasive (tracheostomy tube) 6 –
Number of hours ventilatory support per day 12 (8–24) 9 (8–14)
Age at start of ventilatory support, y 45 (13–66) 46 (8–68)
Disease duration at start of ventilatory support, y 6 (0–36) 15 (1–28)
Continuous variables are presented as median (range); categorical data are presented as number (%). 
a Ventilatory support was used more frequently by male patients (Χ2 4.13; p=0.042).
Respiratory muscle strength
Respiratory muscle strength was assessed in 62 adults. MIP was reduced in 
24 patients (39%; mean value 66.0±29.6% predicted, range 15–155% predicted) 
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and MEP in 38 patients (61%; mean value 64.7±30.9% predicted, range 13–141% 
predicted). Inspiratory and expiratory muscle strength were both affected in 
24 patients. One patient had isolated inspiratory muscle weakness, and 14 patients 
had isolated expiratory muscle weakness.
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Figure 3. Relationship between disease duration, gender and vital capacity in 92 patients 
with Pompe disease. The observed values and median value for each category are presented. 
The dotted line represents the fifth percentile of the predicted vital capacity.
Overall, VC was strongly correlated with MIP and MEP (ρ=0.75 (MIP) and ρ=0.79 
(MEP), both p<0.001; Figure 4). Despite this, inspiratory and/or expiratory 
respiratory muscle strength were reduced in four patients, while VC measured in 
upright and supine positions was completely normal.
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Figure 4. Relationship between vital capacity and maximum inspiratory pressure (A, 
n=60) and maximum expiratory pressure (B, n=62) in patients with Pompe disease. Circles 
represent females, squares represent males.
Capnography
Capnography was performed in 65 adult patients, ten of whom had P
EE,CO2 
values of 
more than 6.0 kPa (patient range 6.06 to 7.41 kPa). Five of these patients, who also 
had clinical symptoms of hypercapnia, were already being mechanically ventilated 
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at night and during part of the day. They were referred to their center for home 
ventilation to see whether adjustments had to be made to their ventilation settings.
Three of the other five patients had a combination of severely reduced VC in supine 
position, impaired respiratory muscle strength and complaints such as morning 
headache, falling asleep in the daytime, or difficulty concentrating. They belonged 
to the group of patients that had been referred to a center for home ventilation. 
Subsequently, mechanical ventilatory support was started in one. 
The last two patients had normal or only mildly reduced VC without signs of 
respiratory muscle weakness, P
EE,CO2
 being only marginally elevated in one (PEE,CO2 
6.06 kPa). These two patients had no respiratory complaints.
Prospective longitudinal follow-up
General aspects
Prospective follow-up data were available for 53 adult patients (21 males, 
32 females). Duration of follow-up ranged from 0.5 to 4.2 years (median 1.6 years). 
Within this period, mechanical ventilation was started in three patients. Five 
patients increased the number of hours of ventilation per day. One patient, who 
was severely affected and dependent on wheelchair use and ventilatory support, 
died of respiratory failure at the age of 55.
Pulmonary function during longitudinal follow-up
At a group level, VC in upright seated position, expressed as percentage of the 
predicted value, deteriorated by 0.9% points per year (p=0.094). The average rate 
of decline in VC measured in supine position was 1.2% points per year (p=0.049). 
MIP deteriorated by 3.2% points per year (p=0.018), and MEP by 3.8% points per 
year (p<0.01) (Figure 5).
In five individual patients, the disease progressed very rapidly, with pulmonary 
function in seated position declining by more than 10 percentage points per year. 
We did not find any significant differences in characteristics (age at first symptoms, 
gender, mobility, MRC sumscore, wheelchair use, use of ventilation), between these 
patients and the larger group of patients whose disease progressed less rapidly.
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Although we noted during the prospective follow-up phase of the study that some 
of the specified subgroups (gender, mobility, current age and disease duration) 
seemed to influence the estimated rate of decline in pulmonary function, the 
differences in rate of progression between subgroups were not consistent 
throughout.
DISCuSSIOn 
The purposes of our study were to determine the proportion and severity of 
pulmonary involvement in patients with Pompe disease, the rate of deterioration 
of pulmonary function, and to identify predictive factors for poor respiratory 
outcome.
With regard to the proportion of patients with pulmonary involvement, we found 
that 79% of the adults and 59% of the children, had some degree of pulmonary 
dysfunction.
With regard to severity, 42 patients, 26 of whom used mechanical ventilation, had 
a severely reduced pulmonary function in sitting or supine position (<-4SD or <50% 
of the predicted normal value). Pulmonary function was already moderately to 
severely decreased in seven of the children, three of whom were under the age of 
ten. Two of these seven children required ventilatory support from a young age (8 
and 13 years). This indicates that the disease progresses more rapidly in a subset 
of children, and supports the findings by an international patient-oriented survey 
that our group has reported earlier.12
Thirty-five of the 92 patients (38%) in our study cohort had signs of diaphragmatic 
weakness, manifested by an inability to endure testing in supine position, a large 
drop in VC upon changing posture, or decreased MIP. Two patients required night-
time ventilation due to respiratory insufficiency when supine, despite having 
normal or only slightly reduced VC when upright. As this group of patients may 
progress insidiously to respiratory failure when pulmonary function is measured 
only in upright seated position, they are in particular need of specific attention.
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In 36 patients, VC had never been tested before, or at least not when they were 
supine. Of these, 13 (20% of all patients who were not ventilated) appeared to 
have a severely reduced pulmonary function in supine position. Three of these 
patients required the initiation of nocturnal mechanical ventilation. As only half of 
them had clinical signs indicating potential pulmonary dysfunction, it is clear that 
clinical respiratory complaints do not always predict the presence or severity of 
pulmonary dysfunction, and should not be relied on when selecting patients for 
pulmonary function testing. 
Despite the fact that vital capacity was strongly correlated to MIP and MEP, a 
small number of patients whose VC was normal had evident respiratory muscle 
weakness. Future follow-up will show whether this might be a first indication of 
respiratory insufficiency.
Ten patients had abnormal end expiratory CO
2
 values, two of whom had normal or 
only mildly reduced VC without signs of respiratory muscle weakness. Further follow-
up will show whether their hypercapnia precedes decline in pulmonary function. 
It has been reported that the severity of hypercapnia may be disproportionate to 
that of respiratory muscle weakness in patients with neuromuscular disorders. One 
possible explanation is that pulmonary microatelectasis or rib cage abnormalities 
(such as scoliosis) increase elastic load.29-31 Since nearly all patients with pulmonary 
dysfunction were identified by measurement of VC in sitting and supine positions 
and measurement of respiratory pressures, it is unclear if standard measurement 
of end expiratory CO
2
 adds to the regular assessment of Pompe patients, other than 
in evaluating ventilatory settings in patients already using mechanical ventilation.
We identified three factors that were associated with more severe pulmonary 
involvement.
First, pulmonary function seems to decline faster in men than in women. This could 
not be explained by differences in age or disease duration; neither could it be 
explained by the severity of skeletal muscle weakness or the presence of scoliosis. 
This is the first time a possible gender difference has been found. We have no 
clear explanation for it: smoking habit and body mass index were not significantly 
different, nor had any of the patients experienced environmental exposures known 
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to be associated with reduced pulmonary function. In sleep disorders, gender 
differences have also been reported in which males are affected more severely 
than females. Two hypotheses have been put forward to explain these differences: 
1) higher upper airway resistance caused by different body-fat distributions, and 
2) differences in central ventilatory control induced by sex hormones.32,33 Similar 
explanations may apply to patients with Pompe disease. For the time being, the 
mechanisms underlying these gender differences are uncertain and our findings 
need further investigation.
The second factor associated with poor pulmonary outcome was the severity of 
skeletal muscle weakness measured by MRC sumscore and mobility. In fact, these 
factors showed the best correlation with pulmonary involvement, though still 
moderate. This is in line with what was reported previously in smaller or selected 
groups of patients.14,15 There nonetheless remains a subgroup of patients in whom 
either pulmonary function or skeletal muscle strength is substantially more severely 
affected than the other.
The third factor associated with poor pulmonary outcome has also been observed 
by other authors: that longer disease duration leads to more advanced pulmonary 
involvement.12,17
Regarding the rate of progression, we found a significant decline in vital capacity 
measured in the supine position, and also in maximum inspiratory pressure and 
maximum expiratory pressure during the prospective follow-up phase of this study; 
the decline in vital capacity measured when seated upright was not significant. 
Relative to that found in other recent studies,13,17,34 the annual rate of decline we 
report seems rather small. We can think of two possible explanations which may 
have led us to slightly underestimate the actual rate of decline. 
First, the introduction of enzyme-replacement therapy for patients with Pompe 
disease in 2006 provided a therapeutic option for this previously untreatable 
disease. At our center, we decided first to treat children and severely affected 
adults, while less affected patients started to receive ERT at a later stage. As a 
result, prospective follow-up data on the natural course are therefore available for 
only 53 adult patients from our study cohort, and the patients who were affected 
relatively mildly were followed for longer.
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A second, related, issue is the fact that the follow-up cohort comprised fewer 
males than females, and only those males who were affected relatively mildly. This 
may also explain the fact that although we found a difference in the severity of 
pulmonary involvement between males and females when studying the baseline 
cohort, our prospective analyses did not show any differences in the rate of 
progression between the two sexes.
In conclusion, even though awareness of Pompe disease is high in the Netherlands, 
pulmonary function testing was not routinely performed upon diagnosis, and 
even cases of severely reduced pulmonary function were sometimes overlooked. 
Because it was possible to identify pulmonary dysfunction in nearly all patients 
by measuring VC in the upright and supine positions, we believe that the regular 
assessment of all patients with Pompe disease should at least include these 
measurements. 
With regard to poor respiratory outcome, male sex, severe skeletal muscle 
weakness, and advanced disease duration were the most important predictors. 
These findings may help to identify patients at risk for developing respiratory 
failure, so that supportive measures such as night-time ventilation can be initiated 
as soon as they are needed.
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ABSTRACT
Background and objective
Pompe disease is an inherited metabolic disorder caused by deficiency of acid 
α-glucosidase. All affected neonates have a severe hypertrophic cardiomyopathy, 
leading to cardiac failure and death within the first year of life. We investigated 
the presence and extent of cardiac involvement in children and adults with Pompe 
disease with the common c.-32-13T>G genotype to determine the usefulness of 
cardiac screening in these patients with relatively ‘milder’ phenotypes.
Methods 
Cardiac dimensions and function were evaluated through echocardiography, 
electrocardiography and Holter monitoring. The total group comprised 68 patients 
with Pompe disease, of whom 22 patients had disease onset before the age of 18.
Results 
Two patients (3%) had cardiac abnormalities possibly related to Pompe disease: 
Electrocardiography showed a Wolff-Parkinson-White pattern in an 8-year-old girl, 
and one severely affected adult patient had a mild hypertrophic cardiomyopathy. 
This hypertrophy did not change during treatment with recombinant human 
α-glucosidase. In addition, four adult patients showed minor cardiac abnormalities 
which did not exceed the prevalence in the general population and were attributed 
to advanced age, hypertension or pre-existing cardiac pathology unrelated to 
Pompe disease.
Conclusions
Cardiac involvement is rare in Pompe patients with the common c.-32-13T>G 
genotype. The younger patients were not more frequently affected than the adults. 
Electrocardiographic evaluation appears to be appropriate as initial screening 
tool. Extensive cardiac screening seems indicated only if the electrocardiogram is 
abnormal or the patient has a history of cardiac disease.
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InTRODuCTIOn
Pompe disease (glycogen storage disease type II or acid maltase deficiency) 
is a progressive metabolic myopathy with an estimated frequency of 1 in 
40,000 births.1,2 Deficiency of the lysosomal enzyme acid α-glucosidase leads to 
accumulation of glycogen in a variety of tissues.3 The clinical spectrum is broad, 
ranging from a rapidly progressive phenotype characterized by generalized muscle 
weakness, hypertrophic cardiomyopathy and death usually within the first year of 
life in infants,4,5 to a more slowly progressive proximal myopathy with or without 
respiratory involvement in older children, adolescents and adults.6,7
In infants with the classic infantile phenotype, severe cardiac involvement is present 
in all cases. The electrocardiogram often shows a shortened PR-interval and high 
voltage QRS-complexes. Echocardiography reveals hypertrophy of both ventricles 
and an increased left ventricular (LV) mass index. Ultimately, hypertrophy may 
lead to reduction of the ventricular lumen and LV outflow obstruction, resulting in 
cardiorespiratory failure.5,8
It is well known that cardiac involvement can be an important feature in patients 
with other neuromuscular disorders like myotonic dystrophy and Duchenne 
and Becker muscular dystrophy.9 It is also a feature in other lysosomal storage 
disorders such as Fabry disease10 and mucopolysaccharidoses.11 Furthermore, 
glycogen storage disorders are frequently mentioned in the differential diagnosis 
of hypertrophic cardiomyopathy.12
In contrast to the severe cardiomyopathy in infants, we recently found that cardiac 
involvement is rare in adults with the c.-32-13T>G genotype,13 which is present 
in the majority of all patients with milder phenotypes.14 However, a recent study 
indicated that a more severe phenotype may exist in a subgroup of patients under 
15 years of age.15 The aim of the current study was to compare the occurrence and 
severity of cardiac abnormalities in children and adults with Pompe disease sharing 
the common c.-32-13T>G genotype.
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PATIEnTS AnD METHODS
This study is part of an ongoing research project on the natural course of late-onset 
Pompe disease. Sixty-eight patients were evaluated in our hospital between April 
1998 and April 2008. Patients were recruited through the neuromuscular centres 
within the Netherlands and Belgium and via the Dutch neuromuscular patient 
organisation (Vereniging Spierziekten Nederland) or referred to our hospital by 
their treating physicians. The clinical diagnosis was confirmed in all patients through 
mutation analysis and measurement of decreased acid α-glucosidase activity 
in leukocytes or fibroblasts. The research protocol was approved by the Central 
Committee on Research Involving Human Subjects in the Netherlands (CCMO) and 
written informed consent was obtained from all patients or their parents.
Part of the data found in the adult patients was recently described.13
Information was gathered on gender, current age, age at first complaints, age at 
diagnosis, use of wheelchair or walking aids, pulmonary function, use of respiratory 
support and cardiac risk factors. Disease duration was calculated as the time 
between diagnosis and date of investigation.
GAA genotype
All patients were compound heterozygote and had the common c.-32-13T>G 
(IVS1-13T>G) mutation on one allele. The mutations found on the second 
allele were: c.525delT (n=26), c.2481+102_2646+31del (n=11; also known as 
delexon 18), c.925G>A (n=4), c.1548G>A (n=4), c.379_380del (n=3), c.307T>G 
(n=3), c.1799G>A (n=3), c.2135T>C (n=2), c.461_469del, c.896T>C, c.923A>C, 
c.2331+2T>A, c.2314T>C, c.1933G>A, c.172C>T, c.1441T>C, c.1396G>T, c.1115A>T 
(all n=1). Of these second mutations only c.461_469del does not entirely abolish 
the acid α-glucosidase activity. All other second mutations are fully deleterious. In 
two patients the second mutation could not be found.
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Electrocardiography
Standard 12-lead electrocardiography recordings were examined for LV pre-
excitation, increased LV voltage and rhythm or conduction disturbances. In a subset 
of 21 adult patients, 24-h Holter monitoring was performed.
Echocardiography
All patients underwent a detailed echocardiographic evaluation (Sonos 5500 
or 7500 ultrasound system, Philips, Best, The Netherlands), performed by an 
experienced sonographer. The following data were acquired from M-mode 
recordings: left atrial dimension, LV end-diastolic and LV end-systolic dimension, 
LV septal and posterior wall thickness. As a measure of systolic function, fractional 
shortening or LV ejection fraction was used. LV mass index was calculated using the 
modified Devereux formula and indexed by body surface area.16
Statistical analysis
All variables were summarized using descriptive statistics comprising mean, SD, 
and range.
RESuLTS
Patient demographics and clinical features
A total of 68 patients (41 males, 27 females) from 58 families were included in 
this study. All patients except one were from Caucasian origin. The mean age of 
the patients at the time of the investigation was 38±19 years (range 3 months 
to 71 years) and at the time of diagnosis 29±18 years (range several days to 63 
years). Ten patients were diagnosed under 2 years of age. Twenty-three patients 
experienced symptoms of limb-girdle muscular weakness or respiratory problems 
before the age of 18. Within this group, delayed motor milestones were mentioned 
as first symptoms in five patients, while another seven patients were diagnosed 
presymptomatically due to elevated liver enzymes, an enlarged liver or an already 
known affected sibling. Other presenting symptoms in this group included feeding 
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difficulties, extreme fatigue and difficulty doing sports. In the patients with onset 
of symptoms in adulthood frequently mentioned first symptoms were: difficulty 
running/doing sports, difficulty climbing stairs, fatigue and muscle soreness or 
muscle cramps.
Twenty-seven patients (40%) had moderate to severe ambulatory problems for 
which either walking aids (n=8) or a wheelchair (n=19) were necessary. Fifteen 
patients (22%) used artificial ventilation: three patients were invasively ventilated 
24-h a day, 12 patients used non-invasive ventilation only at night or when they 
were in a supine position during the day. Eight patients used a wheelchair as well as 
respiratory support. The mean age at start of wheelchair use was 44 years (range 
3 to 67 years) and at start of using respiratory support 47 years (range 13 to 68 
years).
Cardiac evaluation
Electrocardiography
Rhythm abnormalities or impaired conduction were present in one 8-year-old 
child and five adult patients. The electrocardiographic and echocardiographic 
parameters of the whole group are summarized in Table 1. The 8-year-old girl 
(patient 1 in Table 2) had an intermittent sinus rhythm and atrial rhythm, a δ-wave 
and a non-specific interventricular conduction block. Of the adult patients, one 
(patient 2) had an atrial rhythm with a short PR-interval (114 ms; normal range 
120–200 ms) without evidence of a δ-wave. Three patients (patients 3, 4 and 5) 
had a prolonged QRS duration due to right or left bundle branch block, and one 
(patient 6) showed permanent atrial fibrillation which had been treated by His-
bundle ablation and pacemaker implantation. None of the patients had increased 
QRS-voltages consistent with left ventricular hypertrophy.
Holter monitoring
Holter monitoring was performed in a subset of 21 adult patients. All patients 
except one showed a sinus rhythm during the 24-h monitoring. One patient (patient 
6) had permanent atrial fibrillation, with 100% pacemaker rhythm. Nine patients 
showed rhythm alterations during monitoring. A low frequency of premature atrial 
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beats (<15/1000 beats) was seen in seven patients. Three patients had sporadic 
(<10/24 h) short lasting (<10 beats) atrial tachycardias. Transient nocturnal 
type I second degree atrio-ventricular block was noted in three patients. Apart 
from sporadic premature ventricular complexes in three patients, no ventricular 
arrhythmias were seen. All findings are within the normal range seen in the general 
population.21
 
Table 1. Electrocardiographic and echocardiographic parameters
Age 0–9 yearsa  
(n=8)
Mean±SD (range)
Age 10–18 years 
(n=9)
Mean±SD (range)
Age>18 years  
(n=50)
Mean±SD (range)
Electrocardiography
PR-interval, ms 129±10 (116–146) 151±17 (130–186) 152±19 (114–196)
QRS duration, ms 75±15 (55–104) 93±8 (82–110) 98±18 (74–160)
Echocardiography
Left atrial size, mm 32±4 (24–41)
LV end-diastolic dimension, mm 34±7 (21–43) 49±3 (45–53) 47±6 (29–58)
LV end-systolic dimension, mm 22±4 (14–27) 32±5 (23–37) 31±5 (20–44)
LV posterior wall, mm 5±1 (4–6) 8±2 (6–10) 9±1 (7–15)
LV interventricular septum, mm 6±1 (5–9) 8±1 (6–10) 9±2 (7–16)
LV systolic function
Ejection fraction, % 65±9 (48–84)
Fractional shortening, % 35±4 (30–42) 36±7 (26–50)
LV mass index, g/m2
Females 54±8 (48–60) - 73±9 (58–95)
Males 32±18 (47–98) 79±15 (55–101) 81±25 (47–134)
The values indicated in bold are outside the normal range according to age.16-20
a Age at the time of investigation.
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Echocardiography
In all patients with symptom onset before the age of 18, atrial and ventricular 
dimensions, LV systolic function and LV mass index were normal. In one 15-year-old 
boy cardiac ultrasound revealed a congenital anomaly (quadricuspid aortic valve). 
Two patients with onset in adult life had an abnormal echocardiogram. One (patient 
5) had mild right and left ventricular hypertrophy (septum 16 mm, LV posterior wall 
15 mm), without signs of LV outflow obstruction. A second ultrasound 1.5 years after 
the start of enzyme replacement therapy with recombinant human α-glucosidase did 
not show any alterations. The patient known with atrial fibrillation and pacemaker 
implantation (patient 6) had an increased end-diastolic LV dimension and reduced 
LV systolic function (LV ejection fraction=48%). One patient was excluded from the 
analysis due to the poor quality of the echocardiographic images.
The characteristics of the six patients in whom we found abnormalities during 
cardiac evaluation are presented in further detail in Table 2.
DISCuSSIOn
We evaluated cardiac dimensions and electro-physiological properties in a cohort 
of 68 children and adults with Pompe disease sharing the common c.-32-13T>G 
genotype. Cardiac abnormalities were present in one child and five adults.
One 8-year-old child (patient 1) had an intermittent sinus rhythm and atrial rhythm, 
a δ-wave and a non-specific interventricular conduction block corresponding with 
a Wolff-Parkinson-White (WPW) pattern. This girl had no clinical manifestations 
of arrhythmias. An atrial rhythm and short PR-interval, but no δ-wave or other 
abnormalities indicating cardiac disease, was also seen in one adult patient (patient 
2). Recently, in a study in 38 German adolescents and adults with Pompe disease, 
the frequent occurrence of symptomatic Wolff-Parkinson-White syndrome (in 8% 
of patients) was attributed to Pompe disease.22 However, altered atrio-ventricular 
conduction is also quite common in the general population (reported frequency 
up to 3%23) and disappearance of the δ-wave later in life can occur due to changes 
in autonomic tone, maturation of the conduction system and aging.24 The WPW-
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pattern in the young girl could well be related to Pompe disease since alterations in 
the composition of the atrio-ventricular conduction system may lead to accelerated 
conduction.25 Further clinical follow-up is necessary. The short PR-interval in the 
adult patient is most likely caused by the atrial rhythm (atrial ectopy originating 
close to the atrio-ventricular node).
One severely affected patient (patient 5), who was wheelchair bound and ventilator 
dependent for 24 h a day, had a mild hypertrophic cardiomyopathy and conduction 
disturbances in both bundle branches. This patient had a history of hypertension 
which may in part explain the left ventricular hypertrophy. Furthermore, pulmonary 
hypertension as a result of chronic hypoxemia may lead to right ventricular 
hypertrophy. However, right ventricular hypertrophy was not found in any of the 
other (invasively) ventilated patients. Unfortunately, it was difficult to obtain a 
clear tissue doppler signal in this patient and we are therefore unable to exclude 
the effect of the patient’s pulmonary status on the right ventricular hypertrophy. A 
second echocardiography performed 1.5 years after start of enzyme replacement 
therapy did not show any decrease of right and left ventricular wall thicknesses. 
This is in contrast to the response observed in severely affected infants treated with 
enzyme therapy, in whom the massively enlarged heart in most cases diminishes 
to (almost) normal values.26-28 The lack of response to treatment could be due to 
the prolonged existence of the hypertrophy leading to fibrosis, other secondary 
changes or an unrelated genetic cause for the cardiomyopathy. For the moment it 
remains unclear whether this patient’s hypertrophic cardiomyopathy is related to 
Pompe disease.
Two more patients (patient 3 and 4) showed conduction disturbances in the 
bundle branches in the absence of structural echocardiographic abnormalities. 
These patients had no history of cardiac disease or any known cardiac risk factors, 
but showed signs of hypertension at the time of investigation. The frequency of 
conduction disturbances in the bundle branches in our study group (4%) does not 
exceed that in the general population (reported prevalence 2.5–8.5%).27-30
The last patient (patient 6) had permanent atrial fibrillation, which had been 
treated by His bundle ablation and pacemaker implantation at the age of 59 
years. Apart from atrial fibrillation, this patient had reduced systolic function and 
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increased LV end-diastolic dimensions, probably related to the before mentioned 
cardiac pathology and unrelated to Pompe disease.
All patients in our study group carried the c.-32-13T>G mutation on one allele. 
This mutation is present in 68–90% of all patients with milder phenotypes14,31,32 
Despite this homogeneous genotype, our patient showed a wide variety in clinical 
severity, age at first symptoms and disease duration. Eight patients were both 
wheelchair and respirator dependent and 17 patients had a disease duration of 
more than 15 years. Therefore, the low frequency of cardiac abnormalities is not 
likely due to the lack of severely affected patients in our study group. In the large 
group of patients we studied, the patients with disease onset under 18 years of age 
were neurologically not more severely affected than the adult patients, suggesting 
that the subgroup of younger patients with a more severe phenotype15 does not 
have the c.-32-13T>G genotype. Therefore we cannot draw conclusions on the 
occurrence of cardiac involvement in patients who do not express the c.-32-13T>G 
mutation.
The observed cardiomyopathy in one of our patients was relatively mild, in contrast 
to the severe hypertrophic cardiomyopathy resulting in cardiac failure seen in 
neonates. The difference in the prevalence and severity of cardiac involvement 
in infants compared to adults is likely due to the higher amount of residual 
α-glucosidase activity in adults.33 A low level of enzyme activity seems sufficient 
to prevent intralysosomal accumulation of glycogen in cardiomyocytes, but not in 
skeletal muscle, since all patients showed skeletal muscle weakness, ranging from 
mild to severe involvement. This may be due to differences in storage capacity 
and metabolism of heart and skeletal muscle.34 The more abundant presence of 
cytoplasmic glycogen in skeletal muscle fibers compared to cardiomyocytes may 
lead to more extensive lysosomal glycogen accumulation in the skeletal muscles 
through autophagy, resulting in more muscle fiber damage.35,36
In spite of this apparent low frequency of cardiac involvement within our study 
group, several observations suggest an increased cardiovascular morbidity in 
adults with Pompe disease. We recently reported the presence of increased aortic 
stiffness in a subset of patients from this study compared to controls, possibly due 
to glycogen deposition in the smooth muscle cells of the aortic wall.37 In addition, 
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there are several reports on the occurrence of aneurysms in Pompe disease which 
maybe related to the same phenomenon.38,39 At present, the clinical consequences 
of these findings are not fully clear and need further research.
In conclusion, cardiac evaluation in 68 children and adults with Pompe disease 
sharing the common c.-32-13T>G genotype showed abnormalities possibly related 
to Pompe disease in only two cases (one child, one adult). Since all patients with 
abnormal cardiac parameters were detected by electrocardiography, we advise 
to perform an electrocardiogram at least once in routine clinical follow-up. 
Additional echocardiography seems indicated only in those patients with abnormal 
electrocardiographic findings, a history of cardiac disease or evident cardiac 
symptoms.
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ABSTRACT
Pompe disease (type 2 glycogenosis, acid maltase deficiency) is a disorder affecting 
skeletal and cardiac muscle, caused by deficiency of acid α-glucosidase. In 2006 
enzyme therapy with recombinant human α-glucosidase received marketing 
approval based on studies in infants. Results in older children and adults are 
awaited.
Earlier we reported on the 3-year follow-up data of enzyme therapy in two 
adolescents and one adult. In the present study these patients were followed for 
another 5 years.
Two severely affected patients, wheelchair and ventilator dependent, who had 
shown stabilization of pulmonary and muscle function in the first 3 years, maintained 
this stabilization over the five-year extension period. In addition patients became 
more independent in daily life activities and quality of life improved. 
The third moderately affected patient had shown a remarkable improvement in 
muscle strength and regained the ability to walk over the first period. He showed 
further improvement of strength and reached normal values for age during the 
extension phase. The results indicate that both long term follow up and timing of 
treatment are important topics for future studies.
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InTRODuCTIOn
Pompe disease (acid maltase deficiency, glycogen storage disease type II) (OMIM 
232300) is an autosomal recessive neuromuscular disorder, caused by a deficiency 
of the enzyme acid α-glucosidase. This deficiency results in lysosomal glycogen 
accumulation in skeletal muscle and other tissues.1,2 The disease encompasses a 
wide spectrum of presentations.3-6 
The classic infantile form is at the severe end of this spectrum. The patients show 
a rapidly progressive course of disease with muscle weakness, a hypertrophic 
cardiomyopathy and death before the first year of age.1,5,6 Acid α-glucosidase 
activity is virtually absent. A more slowly progressive myopathy affecting mobility 
and respiratory function is found in children and adults.1 The time of onset and 
progression of symptoms is heterogeneous7,8 and patients with this form of disease 
can express up to 30% residual α-glucosidase activity.9 
Since Spring 2006, a registered therapy has been available (recombinant human 
acid a-glucosidase, Myozyme™, Genzyme Corporation). The initial clinical trials 
focused mainly on infants with the classic infantile form of Pompe disease.10-17
The results of an 18-month randomized placebo controlled trial in a large cohort of 
older children and adults are currently awaited. 
In 1999, we started treatment in two older children and one adult. Over 3 years, 
these patients received α-glucosidase derived from the milk of transgenic rabbits 
(rabbit-AGLU). After this period they were switched to the product registered in 
2006, i.e. recombinant human acid α-glucosidase derived from Chinese hamster 
ovary cells (CHO-AGLU). The results of the initial 3 years were described in ref.18 
By now, after eight years of therapy, each patient has received approximately 380 
infusions. All patients have reached adult age. This report provides the results of 
their eight years of therapy, focusing especially on the last five years. 
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PATIEnTS AnD METHODS
After patients had completed the first 3-year study period they entered an extension 
phase during which the safety and efficacy of recombinant human α-glucosidase 
was continued to be followed. Study assessments were performed in a standardized 
manner essentially as described before.7,18-20 The extension protocol was approved 
by the Institutional Review Board and all patients (and parents if necessary) gave 
their written informed consent.
At start of the extension period, patients were transitioned from rabbit-AGLU 
(20 mg/kg/week, see18 for details) to CHO-AGLU. CHO-AGLU was introduced 
in a stepwise manner starting with a dose of 10 mg/kg/week (week 1‒12), 
20 mg/kg/biweekly (week 13‒26) and 30‒40 mg/kg/biweekly thereafter. 
The following infusion rates were applied: 0.1‒0.2 mg/kg/h for the first hour, 
0.7‒0.8 mg/kg/h for the second hour and 15‒17 mg/kg/h until the end of the 
infusion. The total infusion duration was 4 h. 
Information on the diagnosis of the three patients, including enzyme analysis and 
genotyping as well as a detailed description of the medical history can be found in 
ref.18 
Muscle biopsy
Muscle sections taken at initiation of therapy and 6 months thereafter were 
available for all three patients. For patient 3 extra muscle biopsies were taken 
from the quadriceps muscle at start of the extension phase (3 years after start 
of therapy) and after a total treatment period of 5.5 years using a standard open 
surgical procedure. The samples were prepared for histological examination as 
described in.2,21
Statistical analysis
The relation between various outcomes and treatment duration for the different 
patients was evaluated using least-squares regression. In case of non-linear 
relations, Spearman’s correlation coefficients were used. P-values <0.05 were 
considered significant. 
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RESuLTS
Patients
Patient 1 was 16 years old when enzyme replacement therapy (ERT) was started. 
She had a severe scoliosis, was wheelchair and ventilator dependent. Muscle 
function and pulmonary function had shown a rapid decline over the previous 4 
years (vital capacity decreased on average 4% per year). 
During the first 3 years of treatment pulmonary function stabilized (Figure 1) and 
the number of mechanical non-invasive ventilation hours was reduced from 18 to 
11‒12 h per day (Table 1). Total muscle strength showed no significant change. 
Muscle function improved slightly (Table 1, Gross Motor Function Measure 
(GMFM)). The patients’ scoliosis was surgically corrected during this period. 
5000
4000
3000
2000
1000
0
0 100 200 300 400 500
Vi
ta
l c
ap
ac
ity
 (m
l)
treatment (weeks)
extension period
Figure 1. Effect of enzyme therapy on expiratory vital capacity over 8 years. Different symbols 
represent different patients (o=patient 1, =patient 2, *=patient 3). The vertical dotted line 
marks the start of the 5-year extension phase.
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Table 1. Overview of test results at baseline, 3 and 8-year follow-up including reference 
values for two children and one adult with Pompe disease 
Baseline 3-year ERT 8-year ERT Ref. values
Patient 1  
Age (y) 16 19 24 ‒
Ventilation hours 16‒18 11‒12 11‒12 ‒
HHD (Newton) 751 848 1371 3356a
GMFM (sitting) 47% 80% 83% 100%
GMFM (lying) 67% 78% 73% 100%
GMFM (crawling) 21% 33% 36% 100%
FSS ‒ 5.6 3.9 2.9b 
‒ ‒ ‒ 5.2c 
RHS ‒ 16 25 ‒
Patient 2  
Age (y) 32 35 41 ‒
Ventilation hours 24 23.5 23.5 ‒
HHD (Newton) 199 305 349 4759a
GMFM (total) 12% 13% 12% 100%
FSS ‒ 6 4.2 2.9b
‒ ‒ ‒ 5.2c 
RHS ‒ 18 20 ‒
Patient 3  
Age (y) 11 14 20 ‒
HHD (Newton) 255 4310 4823 4759a
GMFM (total) 56% 100% 100% 100%
Running 10m (s) ‒ 3 2.3 ‒
HHD=Hand Held Dynamometry.27,28 HHD values represent the sum score of the following muscle groups: 
neck flexion, neck extension, shoulder abduction, elbow flexion, elbow extension, wrist extension, hip 
flexion and abduction, knee extension and flexion, ankle dorsiflexion and plantar flexion. GMFM=Gross 
Motor Function Measurement.29 FSS=Fatigue Severity Scale.19 RHS=Rotterdam 9-item Handicap Scale.7 
a Reference values for age at 8 years ERT. b General population. c Untreated patients.
Over the last 5 years pulmonary function and ventilation hours have remained 
stable (Figure 1, Table 1). Muscle strength increased with approximately 500 N 
spread over 6 muscle groups: shoulder abductors left, and elbow flexors (p<0.02); 
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hip flexors left ((p<0.05); knee flexors left, foot dorsal flexors and foot plantar flexors 
(p<0.01) (Figure 2). Scores on the GMFM and PEDI questionnaire did not change 
(Table 1). The overall level of handicap decreased as reflected by higher scores on 
the following functional activities of the Rotterdam 9 item handicap scale (RHS): 
mobility indoors, domestic tasks indoors and outdoors and the ability to perform 
work and study (Table 1). After the patient had resumed her education in 2001, she 
graduated from college and a Masters degree program and started Law School in 
2007. She became less fatigued as reflected by lower score on the Fatigue Severity 
Scale (FSS) (Table 1). Quality of life assessed via the SF-36 showed improvements 
on the physical health and to a lesser extent on the mental health domains.
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Figure 2. Effect of enzyme therapy on muscle strength as measured by Hand Held 
Dynamometry over 8 years. The y-axis represents the sum score of the following muscle 
groups: neck flexion, neck extension, shoulder abduction, elbow flexion, elbow extension, 
wrist extension, hip flexion and abduction, knee extension and flexion, ankle dorsiflexion 
and plantar flexion.  Different symbols represent different patients (o=patient 1, =patient 
2, *=patient 3). The vertical dotted line marks the start of the 5-year extension phase.
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Patient 2 was 32 years old when ERT was initiated. He was virtually quadriplegic 
and was bedridden for 21 h per day. From the age of 8 years onwards, he had lost, 
on average, 2.6% of vital capacity per year and had become completely dependent 
of invasive ventilation. 
During the first 3 years of ERT, respiratory function stabilized (Figure 1). He could be 
weaned from the ventilator for 30 minutes per day (Table 1). Total muscle strength 
showed a minimal, but significant improvement (Figure 2). GMFM scores did not 
change (Table1). The patient performed slightly better on the self-care items of the 
PEDI questionnaire. At the end of the 3-year period he was able to stay up for 13 h 
per day. 
Over the last 5 years pulmonary function (Figure 1), mechanical ventilation hours, 
muscle strength (Figure 2) and muscle function assessed by the GMFM (Table 1)
and the PEDI questionnaire have remained stable. 
The overall level of handicap (RHS) decreased slightly and the patient is now able 
to perform domestic activities outdoors and leisure activities independently (Table 
1). He became less fatigued (FSS) (Table 1), leads an active life, and he experiences 
no limitations in participating in social activities. Quality of life (SF-36) improved, 
especially on the domains bodily pain and general health. 
Patient 3 was 11 years at initiation of ERT. He had become wheelchair dependent 2 
years earlier but could bear some weight on his legs. His pulmonary function was 
normal for age and height (FVC: 94% of normal).
During the first 3 years of treatment the patient showed an enormous improvement 
in muscle strength and function. Muscle strength (Figure 2) increased significantly 
in all muscle groups tested (p<0.01) except for the elbow extensors, but the total 
muscle sum score remained below the average of the general population (Figure 
3). Muscle function assessed by GMFM reached a 100% score, but it was noted that 
he had difficulties rising from a squatting position.
Over the last 5 years muscle strength has reached normal values for age for all 
muscle groups (Figure 3) and rising from a squatting position is no longer difficult. 
Cycling against resistance, a measure for endurance, improved slightly (180 to 
220 W). Currently there are no limitations in sports and other social activities. The 
patient works as a gardener. Pulmonary function remained within normal limits 
(Figure 1). 
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Figure 3. Effect of enzyme therapy on muscle strength as measured by Hand Held 
Dynamometry in patient 3. Age related reference values27 are plotted for comparison. 
----- =reference values           =patient 3  
The y-axis represents the sum score of the following muscle groups: neck flexion, shoulder 
abduction, elbow flexion, wrist extension, hip flexion and abduction, knee extension and 
flexion and ankle dorsiflexion.
Muscle biopsies
The baseline muscle biopsy of patient 3 showed a homogeneous pattern of 
abnormalities (Figure 4A and C). Most muscle fibers contained small PAS positive 
deposits of glycogen over the entire fiber length, but the gross muscle morphology 
was well preserved. In addition, fibers stained positive for acid phosphatase. After 
3 (start extension phase) and 5.5 years of treatment, acid phosphatase reactive foci 
had decreased in number (Figure 4D and E). Also the PAS-stained section obtained 
after 5.5 years of treatment showed diminished staining intensity (Figure 4B). Fiber 
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size increased with age (Figure 4C-E) and cross-striation was normal (Figure 4B). 
In comparison to patient 3, muscle biopsy sections from patient 1 and 2 taken at 
start of therapy showed more severe pathology. Most fibers contained multiple 
vacuoles, numerous glycogen deposits (PAS positive material) and stained strongly 
positive for acid phosphatase. The muscle pathology varied substantially between 
fibers. The pathology after 6 months of treatment had not changed. 
Figure 4. Effect of enzyme therapy on muscle morphology for patient 3. The upper two panels 
are stained with Periodic Acid Schiff reagent (PAS), the lower three panels for lysosomal acid 
phosphatase activity. (A and C) Sections obtained at baseline; (D) section obtained after 3 
years of treatment; (B and E) sections obtained after 5.5 years of treatment.
Safety
Treatment with recombinant human α-glucosidase derived from CHO cells was 
tolerated well during the 5-year extension phase. In the first few months after 
transition, one patient experienced mild infusion related reactions, namely chills, 
during part of the infusion. No prophylactic medication was required and side 
effects disappeared gradually. Two patients are currently receiving the enzyme 
infusions at home. 
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DISCuSSIOn
The present study shows the long-term effects of enzyme therapy in patients with 
an attenuated form of Pompe disease. Three patients with different severities of 
disease who completed a 3-year pilot study were followed for another 5 years. 
All three patients had substantially more residual a-glucosidase activity than 
measured in classic infantile Pompe patients and two of the three patients had 
the c.-32-13T-->G mutation in combination with a null allele. The latter genotype is 
most common among children (53%) and adults (77%) with a protracted course of 
disease,22-24 and not found in patients with the classic infantile form.
At initiation of therapy, two of our patients (patient 1 and 2) were severely affected 
with respect to motor function and pulmonary function. During the first 3 years of 
treatment, further loss of muscle function was prevented and pulmonary function 
stabilized. Both patients showed some decrease in mechanical ventilation hours. 
This situation was maintained during the 5-year follow-up. Most remarkable was 
that patients became more confident about their physical condition and more 
independent in daily life activities. This was reflected by a better score on the 
Rotterdam 9-item Handicap Scale, the SF-36 and the Fatigue Severity Scale. 
The third and least affected patient, who had shown significant improvements in 
muscle strength and function over the first 3 years of therapy, needed 2 more years 
of enzyme therapy to catch up with healthy peers.
The functional gains of the three patients were reflected by changes in muscle 
morphology. Unlike the severely affected patients, most of the glycogen deposits 
of the best responder disappeared during treatment. The fact that minimal residual 
lysosomal staining remained present in this patient, illustrates the continuous 
balance between glycogen storage and clearance.
In untreated patients with the attenuated form of Pompe disease, muscle strength 
and pulmonary function deteriorate over time,7,8,25,26 the odds for wheelchair use 
increase by 13%, and for respiratory support by 8% per year since diagnosis.8 In a 
2-year follow-up study four out of 52 adult patients died at a relatively young age.7 
The three patients described here had followed a similarly progressive course prior 
to treatment. Two of them had shown a steady decrease of 2.6% and 4% FVC per 
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year. All three had become wheelchair dependent and one patient had progressed 
to end stage disease, he was bed ridden and completely ventilator dependent. The 
long-term stabilization and sustained improvement of the three patients after the 
start of enzyme therapy is therefore a significant finding.
None of the patients experienced severe side effects during the enzyme infusions 
and two are currently receiving enzyme therapy at home. During the 5-year 
extension period they received 30‒40 mg/kg recombinant human a-glucosidase 
every other week. This dose was based on the amount of rabbit-AGLU that was 
administered every week during the first 3 years of treatment and is higher than 
the registered dosage of 20 mg/kg every other week. The results of this study 
indicate that even a higher dose may have limits in changing the clinical course of 
severely affected patients. 
Obviously, our limited observations cannot be taken as proof that enzyme therapy 
exerts long-term beneficial effects in children and adults with Pompe disease, 
but they provide an important guideline for the broader application of enzyme 
replacement therapy. 
The results of an 18-months randomized placebo-controlled trial in a large cohort 
of older children and adults are awaited soon. Our report indicates that follow-up 
should be continued for several years to assess the full effect of therapy.
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ABSTRACT
Pompe disease is a rare neuromuscular disorder caused by deficiency of acid 
α-glucosidase. Treatment with recombinant human α-glucosidase recently 
received marketing approval based on prolonged survival of affected infants. The 
current open-label study was performed to evaluate the response in older children 
(age 5.9–15.2 years). The five patients that we studied had limb-girdle muscle 
weakness and three of them also had decreased pulmonary function in upright and 
supine position. They received 20 mg/kg recombinant human α-glucosidase every 
two weeks over a 3-year period. No infusion-associated reactions were observed. 
Pulmonary function remained stable (n=4) or improved slightly (n=1). Muscle 
strength increased. Only one patient approached the normal range. Patients 
obtained higher scores on the Quick Motor Function Test. None of the patients 
deteriorated. Follow-up data of two unmatched historical cohorts of adults and 
children with Pompe disease were used for comparison. They showed an average 
decline in pulmonary function of 1.6% and 5% per year. Data on muscle strength 
and function of untreated children were not available. Further studies are required.
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InTRODuCTIOn
Pompe disease (glycogenosis type II, acid maltase deficiency) (OMIM 232300) 
is a rare neuromuscular disorder caused by deficiency of the lysosomal enzyme 
acid α-glucosidase. As a result, glycogen accumulates in lysosomes of many cell 
types, but predominantly in skeletal muscle fibers. The process is progressive and 
finally destroys the muscle architecture and function.1-4 The disease encompasses a 
clinical spectrum.5-8 The classic infantile form is characterized by progressive cardiac 
hypertrophy and rapid loss of muscle function. Symptoms manifest shortly after 
birth and patients usually die within the first year of life.1,3,6,7 Childhood, juvenile 
and adult phenotypes may present any time from infancy to late adulthood. The 
disease course is less progressive and cardiomyopathy is usually absent. Patients 
eventually become wheelchair and ventilator dependent. Respiratory failure is the 
major cause of early demise.9-11 An intermediate non-typical infantile variant with 
cardiac hypertrophy and respiratory failure in early childhood has been described 
as well.12 The nature of the acid α-glucosidase gene mutations is largely decisive for 
the degree of enzyme deficiency and clinical severity.1,13
Until recently there was no therapy for patients with Pompe disease other than 
supportive care. This has changed with the introduction of Enzyme Replacement 
Therapy. So far clinical trials with recombinant human acid α-glucosidase have 
mainly focused on infants and there have been incidental reports on effects in 
adults.14-22 Treatment of infants was shown to increase survival, to diminish cardiac 
hypertrophy and to improve motor outcome. Based on positive results recorded 
in these trials, enzyme therapy with recombinant human acid α-glucosidase was 
approved for all patients, but it was explicitly stated that the safety and efficacy of 
the therapy still had to be proven across the clinical spectrum. The present study 
was designed to test the safety and efficacy of enzyme therapy in juvenile patients 
over a three-year treatment period.
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MATERIALS AnD METHODS
Study design
This study was conducted as an 18-month single-center, open-label, phase II study 
followed by an 18-month extension period and was approved by the Institutional 
Review Board of the Erasmus MC-Sophia Children’s Hospital. Informed consent was 
obtained from patients and parents.
The endpoints of the study were exploratory and included safety, and the effect of 
treatment on pulmonary function, muscle strength and function. All assessments 
were performed at baseline and every three months thereafter.
Inclusion and exclusion criteria
Inclusion criteria were:
 – Confirmed diagnosis of Pompe disease documented by deficient α-glucosidase 
activity in fibroblasts and/or DNA analysis
 – Age between 5 and 18 years
 – Demonstrable muscle weakness by manual muscle testing
 – Able to provide 3 reproducible FVC measurements in sitting position (within 5% 
of one another)
 – Able to walk 10 m
Patients were excluded if they required invasive ventilation or non-invasive 
ventilation whilst awake or in upright position. None of the patients had previously 
received enzyme therapy. Patient characteristics are described in Table 1.
Treatment
Patients received every other week, intravenously, 20 mg/kg recombinant human 
α-glucosidase from Chinese hamster ovary cells (Genzyme Corporation, Cambridge) 
in a step-wise manner: 0.2, 0.8, and 3.5 mg/kg/h each for 30 min and 10 mg/kg/h 
for the remainder of the infusion. Total duration of the infusion was approximately 
3.5 h.
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Safety variables
Physical examination, vital signs, and adverse event recording were performed 
at every visit. Echocardiograms and standard 12 lead electrocardiograms (ECG) 
were performed at baseline and at regular intervals thereafter along with safety 
laboratory measurements (complete blood count with differential, blood urea 
nitrogen, creatinine, glucose, uric acid, calcium, phosphorus, albumin, total 
protein, sodium, potassium, chloride, serum glutamic oxaloacetic transaminase/
aspartate transaminase (SGOT/AST), serum glutamic pyruvic transaminase/alanine 
transaminase (SGPT/ALT), alkaline phosphatase, total bilirubin, creatine kinase 
(CK), creatine kinase with MB fraction (CK-MB), and urinalysis). Anti-recombinant 
human α-glucosidase IgG antibodies were measured from week 0 through week 74.
Pulmonary function
Pulmonary function (Forced vital capacity (FVC)) was assessed by spirometry23 in 
the upright and supine position. The maximum value of three reproducible tests 
was used for analysis. The effect of therapy on pulmonary function in patients with 
an FVC <80% predicted at baseline was compared with two cohorts of untreated 
patients. Historical cohort 1 comprised 8 untreated children with Pompe disease 
that had an FVC <80% predicted at their first visit to our hospital. Historical cohort 
2 consisted of 16 adult patients that were followed for a mean duration of 16±7 
years (published in part by24).
Muscle strength
Muscle strength was assessed by Manual Muscle Testing (MMT)25 and Hand-Held 
Dynamometry (HHD).26-28 MMT was scored by an 11-point modified version of the 
Medical Research Council (MRC) scale.29 HHD was conducted using a hand-held 
dynamometer (CT3001, C.I.T. Technics, Groningen, the Netherlands). Muscle groups 
tested by HHD and MMT were: neck flexors, shoulder abductors, elbow flexors, 
wrist extensors, hip flexors, hip abductors, knee extensors, knee flexors, foot dorsal 
flexors. Individual scores for each muscle group were summed to calculate a total 
score for MMT (maximum score 45) and for HHD (Newton). The HHD sumscore was 
compared with reference values of age related peers.26
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Muscle function
A 6-min walk test (6MWT) was performed according to the guidelines of the 
American Thoracic Society.30 The maximum walking distance achieved in 6 min was 
measured at comfortable pace and at fast speed. Functional activity assessments 
included two timed tests: 10 meter running and rising from supine position to 
standing position.29 The Quick Motor Function Test, a test that was specifically 
designed and validated for Pompe patients, was performed on regular intervals.31 
The scale consists of 16 specific motor function items. A total score is achieved by 
summing the scores for each item.
Patient and parent reports
All patients and their parents were interviewed at baseline and every three months 
thereafter. The interviews were scheduled before the different assessments and 
consisted of relevant issues such as mobility, fatigue, muscle pain, and self-reported 
changes from baseline.
Statistical analysis
The individual relationships between various outcomes and treatment duration for 
the different patients were evaluated using least-squares regression. In case of non-
linear relations, Spearman’s correlation coefficients’ were used. For each patient, 
HHD% predicted values were estimated by linear interpolation of the reference 
data. Mean values of FVC % predicted according to age in an untreated historical 
control group was calculated by repeated measures ANOVA. On group level the 
various repeated measurements were analyzed by mixed model ANOVA (random 
coefficients models) (SAS PROC MIXED 8.2). p-values <0.05 were considered 
significant.
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RESuLTS
Patient characteristics study group
Five juvenile patients, three males and two females, were enrolled in the study 
(Table 1). They ranged in age from 5.9 to 15.2 years. All presented with mobility 
problems early in life (0.8–6.5 years). They were diagnosed between 1.1 and 
11.6 years of age. The diagnosis was confirmed by mutation analysis (see Table 
1 for details), and deficient α-glucosidase activity in cultured fibroblasts (range 
2.8–17.9 nmol/mg/h). The α-glucosidase activity was clearly below the normal 
range (45–160 nmol/mg/h).
Safety
Patients were treated with 20 mg/kg α-glucosidase every two weeks. The three 
years of treatment were well tolerated. No infusion-associated reactions occurred 
during 390 infusions in total. None of the patients received premedication with 
antihistamines or corticosteroids. All patients developed IgG antibodies against the 
recombinant human enzyme between week 8 and week 38. The highest titers were 
observed between week 38 and week 74 and ranged from 800 to 6400 units (Figure 
1). Lab safety parameters remained stable. There were no apparent changes in the 
condition of the patients in the two weeks between sequential infusions.
Pulmonary function
At baseline, two of the five patients (patient 1 and 3) had normal pulmonary 
function in both sitting and supine position (Figure 2). Their ‘postural drop’, defined 
as the difference between the forced vital capacity in sitting and supine position 
(∆FVC), was 4% and 3%.
The other three patients (patient 2, 4 and 5) had a decreased pulmonary function 
(Forced Vital Capacity (FVC) of <80% predicted) at baseline (Figure 2), with a 
postural drop of 9.9%, 18.0%, and 33.3%. According to the ATS/ERS guidelines a 
postural drop of >25% is indicative for weakness of the diaphragm.32,33 Patient 5 
required nocturnal non-invasive ventilation (Bi-level Positive Airway Pressure).
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Figure 1. Anti-recombinant human α-glucosidase IgG antibody titers over 74 weeks of treatment. ◊=patient 
1, =patient 2, =patient 3, =patient 4, ○=patient 5.
During treatment, pulmonary function of patients 1 and 3 remained within normal 
limits (Figure 2A and B). The FVC predicted remained stable in patients 2 and 4 and 
increased significantly in patient 5 (p=0.01, sitting and p<0.01, supine, Figure 2A 
and B). The postural drop remained unchanged.
Muscle strength
At baseline, muscle weakness was more pronounced in the proximal muscles than 
the distal muscles and more in the lower extremities than the upper extremities. 
Hip muscles (flexors, extensors and abductors) and neck flexors were most affected.
Table 2 shows the results of the individual patients obtained over three years 
therapy. On a group level, both muscle strength assessed by MMT and HHD 
increased significantly (MMT 0.07% (=0.08 MMT point)/week (p=0.007), HHD 3.0 
Newton/week (p=0.01)).
However, whilst all patients reached near-normal sum scores applying MMT, 
muscle strength measured with HHD remained below that of healthy peers. One 
patient showed significant catch-up growth towards normal values (Figure 3), the 
other patients did not but did not deteriorate either.
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Table 2. Results of the individual patients at baseline and after three years of treatment.
Baseline 3 year ERT
Patient 1 HHD sumscore (Newton) 521.5 750 p=0.008
MMT sumscore (%) 86 92 p=0.015
6MWT (km/hr) 3.4 5.3 p=0.006
Rising (sec) 4.4 3.94 n.s.
Running (sec) 4.1 4.0 n.s.
QMFT (%) 70.3 95.3 p=0.001
Patient 2 HHD sumscore (Newton) 521 865 p=0.004
MMT sumscore (%) 79 93 p=0.07
6MWT (km/hr) 4.7 5.8 p=0.07
Rising (sec) 5.1 4.13 n.s.
Running (sec) 4.2 4.0 n.s.
QMFT (%) 73.4 92.2 p=0.002
Patient 3 HHD sumscore (Newton) 605 1202 p=0.002
MMT sumscore (%) 87 100 p=0.001
6MWT (km/hr) 5.2 5.9 n.s.
Rising (sec) 4.4 3.0 p=0.06
Running (sec) 3.9 3.0 p=0.005
QMFT (%) 89.1 100 p=0.006
Patient 4 HHD sumscore (Newton) 608 1158 p=0.006
MMT sumscore (%) 79 100 p=0.06
6MWT (km/hr) 4.0 5.7 p=0.06
Rising (sec) 6.2 3.2 p=0.01
Running (sec) 4.5 3.8 p=0.037
QMFT (%) 67.2 92.2 p<0.001
Patient 5 HHD sumscore (Newton) 992 1505 p=0.01
MMT sumscore (%) 83 96 p=0.016
6MWT (km/hr) 5.5 6.5 n.s.
Rising (sec) 3.91 2.8 p=0.011
Running (sec) 3.59 2.9 p=0.024
QMFT (%) 79.7 92.2 p<0.001
All assessments were performed at baseline and at three months intervals thereafter. The individual 
changes over the three-year treatment period were evaluated using least-squares regression. All data 
points gathered every three months over three years time were used in this analysis. ERT=enzyme 
replacement therapy, HHD=Hand-Held Dynamometry, MMT=Manual Muscle Testing, 6MWT=Six-Minute 
Walk Test, QMFT=Quick Motor Function Test, n.s.=not significant.
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Figure 3. Effects of enzyme therapy on muscle strength measured by Hand-Held 
Dynamometry. Results of nine muscles were grouped together to calculate a total sum score. 
The sum score was plotted for all patients: ◊=patient 1 (boy), =patient 2 (girl), =patient 
3 (girl), =patient 4 (boy), ○=patient 5 (boy). Age related reference values are plotted for 
comparison [27]. Reference values boys: –•–•–•–•–•–•. Reference values girls - - - - - -. 
Patients’ muscle strength was measured with an upper limit of testing of 180 Newton per 
muscle group. The resulting outcomes for these patients therefore underestimate the 
true outcome (right-censored values). Data points representing right-censored values are 
represented by arrows.
Muscle function
Walking at comfortable pace appeared insufficiently challenging for the children 
and the results did not show any consistency over the different assessment days. 
This was different for the 6MWT at fast pace. At baseline the patients ran with an 
average speed of 3.4 to 5.5 km/h (see Table 2 for individual data). At the end of 
the study they managed to increase their distance with 64–184 m (mean increase 
120 m). This increase was significant on group level (0.7 m/week (p=0.045)).
Unfortunately there are very few data available to compare with. One study 
reported healthy children between 12 and 14 years of age to run with mean 
velocities of 11.8 km/hour (range 10.3–13.4 km/h)34 during a 6 min test. Three of 
our patients were in or above this age category.
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At baseline, rising from supine to standing position took on average 4.4 times 
longer for the patients compared to healthy peers (see35 for reference values age 
5–12 years and Table 2 for individual data). On a group level, the results showed a 
trend towards significance (p=0.07 for rising and 0.096 for running). 
Quick motor function test (QMFT)
Patients were regularly tested on 16 motor items that were specifically difficult for 
patients with Pompe disease.
Before start of treatment, patients had difficulty with most motor items tested, 
except for reaching hands over midline in supine position and stretching both arms 
simultaneously upward in sitting position.
Over three years of therapy, there was a significant increase in QMFT score on a 
group level (p=0.04, Table 2). Improvements were predominantly found in lifting 
head 45° in supine position (patients 1, 2, and 4), flexing hips through full range in 
supine position (all patients), doing a sit-up from supine position (patients 1, 2, 3, 
and 4), attaining standing position through half knee on the other knee (patients 1, 
2, 4, and 5) and climbing four steps (patients 1, 2, 4, and 5).
Cardiac evaluation
Cardiac evaluation showed no signs of hypertrophic cardiomyopathy. Cardiac 
dimensions and diastolic and systolic function were normal. Cardiac ultrasound 
revealed a quadricuspid aortic valve in one patient. A second patient showed minor 
deformations of the tricuspid valve with a slight prolapse of the anterior leaflet, 
leading to minimal tricuspid regurgitation. A third patient showed the following 
ECG abnormalities: an intermittent sinus and atrial rhythm, a delta wave and a non-
specific interventricular conduction block. These findings did not change during 
the study.
Patient and parent reports
Parents reported that their children had become more active during the day. They 
were able to participate more easily in activities such as running, playing sports, 
playing outdoors and cycling and had more energy left in the evening. Regular 
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headaches, muscle pain and fatigue present at start of therapy subsided. Two 
patients reported that frequent loose stools no longer occurred.
Surgical interventions
During the study, two patients (patient 2 and 4) received a unilateral Achilles tendon 
release. For patient 4, this was performed 6 months after start of treatment and for 
patient 2, 1.5 years after start of treatment. They recovered well without sequelae.
To judge the significance of our findings we compared the FVC data of the study 
cohort with those of two untreated historical cohorts. Follow-up data on muscle 
strength and function of untreated children with Pompe disease were insufficiently 
available.
Patient characteristics historical cohort 1
Eight patients with Pompe disease, six males and two females, who did not receive 
treatment comprised historical cohort 1 (Table 3). All patients in this cohort had 
a decreased FVC (less than 80%) when first seen in our hospital. Age range of the 
patients at their first pulmonary function test was 5.4 to 14.1 years. In total 30 
FVC measurements were performed in sitting position. Patients were ambulant 
and presented with mobility problems between 0.8 and 13 years (mean 5.8). They 
were diagnosed between 1.1 and 14 years. Two of the patients required respiratory 
support at night. Mutations and α-glucosidase activities are shown in Table 3.
Patient characteristics historical cohort 2
Sixteen untreated patients with Pompe disease, ten females and 6 males comprised 
historical cohort 2. Full details of this cohort have been published in [24]. Fifteen 
of these patients were compound heterozygotes (c.-32-13T>G in combination with 
a severe mutation (c.525delT (n=8), c.1548G>A (n=2), c.1115A>T (n=2), c.172C>T 
(n= 2), c.925G>A (n=1))). The genotype of the remaining patient was c.1634C>T 
(intermediate) /c.525delT (severe) functionally comparable to genotype c.1634C>T/
delexon18 of patient 1 of the study group. Cohort 2 included patients with normal 
and decreased pulmonary function at first assessment. Mean age at first symptoms 
was 24±11 years (range 1–40 years); mean age at diagnosis was 27±12 years. All 
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were ambulant at their first visit, and one patient required respiratory support at 
night. Four patients were diagnosed before they were 18 years old. Age range at 
the first pulmonary function test was 11–57 years. In total 95 measurements of 
vital capacity (VC) in sitting position were performed. Mean follow-up duration of 
pulmonary function was 9 years (range 2–15 years).
For only one patient pulmonary function measurements were available before the 
age of 18 years. The first test was performed when the patient was 11 years old. 
VC at that time was 70% of predicted. Over the next 5 years, his VC decreased to 
32%. The patient with genotype c.1634C>T/c.525del, had a VC of 24% predicted at 
the first available measurement when she was 22 years old. These patients became 
ventilator dependent at the age of 15, and 20 years.
Comparison of pulmonary function
The average decline of FVC predicted was 5% per year for historical cohort 1 (Figure 
1C) and 1.6% per year for cohort 2. This was significantly different from the study 
group.
DISCuSSIOn
The present study assessed safety and efficacy of three years treatment with 
recombinant human α-glucosidase in five juvenile Pompe patients. All patients 
were ambulant and free of ventilator support during the day.
Treatment with recombinant human α-glucosidase was well tolerated. In a recent 
study on enzyme therapy in 18 patients with classic infantile Pompe disease, 
infusion-associated reactions were reported to occur in approximately 60% of the 
cases.16 In the present study none of the patients experienced infusion-associated 
reactions, even though all five patients developed antibodies. The antibody titers 
did not reach the high levels that were observed in some infants. These differences 
might be explained by residual α-glucosidase activity expressed in juvenile patients, 
as opposed to the virtual absence of enzyme activity in classic infantile patients. 
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The presence of residual activity also explains the more slowly progressive disease 
course of the study patients prior to start of therapy.
Insight in the natural course of Pompe disease is essential to evaluate effects of 
treatment. There are several reports on pulmonary function in untreated adults 
with Pompe disease. They all indicate that pulmonary function declines with 
disease duration.10,36-38 Limited data have been published on children. For that 
reason we compared the pulmonary function of the patients in this study with two 
historical cohorts. Both cohorts were unmatched. Historical cohort 1 consisted of 
eight children who all had an FVC predicted of <80% at their first visit. Mean age 
at first symptoms, age at diagnosis, time lag between diagnosis and age at first 
assessment were comparable with the study cohort. Five of 8 patients in cohort 1 
compared to 3 of 5 patients in the study group had the common c.-32-13T>G/null 
genotype, that is found in 53% of children over 1 year of age and 77% of adults.39,40 
The other genotypes of patients in cohort 1 and the study group are more severe 
and clinical effects difficult to compare. It can therefore not be ruled out that the 
5% predicted FVC decline per year in untreated children is slightly overestimated. 
On the other hand, historical cohort 2, which consisted of 15 patients with the 
milder c.-32-13T>G/null genotype and only one patient with a combination of a 
severe and intermediate mutation, showed an average decline of 1.6% predicted 
FVC per year. Also this course was significantly different from the study cohort.
All five patients in our study group had moderate muscle weakness at baseline. 
During treatment, improvements in strength were recorded with MMT and HHD. 
All children reached near-normal scores on MMT. Muscle strength assessed with 
HHD remained below the strength of healthy peers and confirms that MMT is 
less reliable and sensitive than HHD to give full information about the strength of 
muscles.41-44 In particular this is the case for MMT grade 4 that covers a wide range 
of forces (10–250 Newton).42 Applying HHD, one child significantly caught up with 
healthy peers, while the others did not. Earlier we found that a moderately affected 
11-year-old patient needed five years of enzyme therapy before he reached normal 
strength.45 This may indicate that long-term treatment may be required to obtain 
full effects.
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Despite the fact that muscle strength remained below normal values, several 
functional improvements were observed in the patients. They were able to run 
longer distances in 6 min, or were able to rise faster from the floor. In addition, 
all patients performed significantly better according to QMFT scores. Part of these 
improvements may be explained by growth or by the Achilles tendon release 
operation that was performed in two patients. The fact that several patients 
learned to lift their head from the surface or to do a sit-up without use of hands, 
skills particularly difficult for untreated Pompe patients5, cannot be explained by 
growth or surgery.
The results of the present study extend previously reported effects of treatment in 
classic infantile patients,14-18,20,22 but should be interpreted with caution.
Limitations of our study are the small number of patients and the fact that our 
study was not placebo controlled. To overcome the latter problem we used two 
historical cohorts that only partly matched the treated patients. Cohort 2 mainly 
comprised adults. Historical data of untreated children with Pompe disease were 
only available for pulmonary function and not for muscle strength and function. We 
could therefore not fully rule out that untreated children might also have shown 
improvements of muscle strength and function over a certain period of time, for 
example with onset of puberty.
We found it encouraging, that none of the patients deteriorated over a three-year 
period. Some patients showed moderate improvements. All patients tolerated 
the enzyme infusions well. Long term follow-up studies with more patients are 
required.
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ABSTRACT
Background
Pompe’s disease is a metabolic myopathy caused by a deficiency of acid alpha-
glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset 
Pompe’s disease is characterized by progressive muscle weakness and loss of 
respiratory function, leading to early death. We conducted a randomized, placebo-
controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment 
of late-onset Pompe’s disease.
Methods
Ninety patients who were 8 years of age or older, ambulatory, and free of invasive 
ventilation were randomly assigned to receive biweekly intravenous alglucosidase 
alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers 
in the United States and Europe. The two primary end points were distance walked 
during a 6-minute walk test and percentage of predicted forced vital capacity (FVC).
Results
At 78 weeks, the estimated mean changes from baseline in the primary end points 
favored alglucosidase alfa (an increase of 28.1±13.1 m on the 6-minute walk test 
and an absolute increase of 3.4±1.2 percentage points in FVC; p=0.03 and p=0.006, 
respectively). Similar proportions of patients in the two groups had adverse events, 
serious adverse events, and infusion-associated reactions; events that occurred 
only in patients who received the active study drug included anaphylactic reactions 
and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest 
discomfort, vomiting, and increased blood pressure (each of which occurred in 5 
to 8% of the patients).
Conclusions
In this study population, treatment with alglucosidase alfa was associated with 
improved walking distance and stabilization of pulmonary function over an 
18-month period. (ClinicalTrials.gov number, NCT00158600.)
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BACKGROunD
Pompe’s disease is a rare, autosomal recessive, progressive neuromuscular disease 
caused by a deficiency of acid α-glucosidase (GAA), which degrades lysosomal 
glycogen. In patients with the classic infantile form, the deposition of glycogen 
in the heart, skeletal, and respiratory muscles causes severe cardiomyopathy, 
hypotonia, and respiratory failure, typically leading to death within the first year of 
life.1-5 Children and adults, in contrast, have variable rates of disease progression. 
Glycogen deposition is confined mainly to skeletal and respiratory muscles, causing 
progressive limb-girdle myopathy and respiratory insufficiency.2,5-9 Respiratory 
failure is a major cause of death.6,10,11
No disease-specific treatment was available for Pompe’s disease until 2006, when 
enzyme-replacement therapy with alglucosidase alfa (Myozyme, Genzyme) was 
approved for all patients with Pompe’s disease in the United States and the European 
Union, on the basis of open-label studies of infantile-onset Pompe’s disease.12 
Trials involving infants showed improvements in survival and motor outcomes 
as compared with untreated historical controls.12-16 Preliminary studies showed 
positive effects in children and adults but were small and not controlled.11,17-19 We 
report the results of a randomized, controlled trial of alglucosidase alfa in late-
onset Pompe’s disease.
METHODS
Study design
The protocol was designed by Genzyme, with input from the authors and an 
independent statistical center (Cytel). The protocol and all amendments were 
approved by local review boards, ethics committees, and health authorities. 
Genzyme employees analyzed the data in accordance with the statistical plan and 
with additional suggestions from the investigators. Study conduct was monitored 
by an independent data and safety monitoring board. Primary efficacy analyses 
were ratified by the independent statistical center. All the authors collected the 
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data, had access to the data, and decided to submit the manuscript for publication. 
The first author and the coauthors wrote the manuscript, with the assistance of 
medical writers at Genzyme, and the first author determined the final content of 
the manuscript. All authors vouch for the completeness and veracity of the data 
and analyses.
This was a randomized, double-blind, placebo-controlled, multicenter study of 
the safety and efficacy of alglucosidase alfa in 90 patients with late-onset Pompe’s 
disease. The study began in early September 2005 and was completed at the end 
of September 2007. Patients were screened and, after providing written informed 
consent (by patients 18 years of age or older and by guardians for younger 
patients), underwent a full baseline evaluation. Those who qualified were randomly 
assigned in a ratio of 2:1 to receive biweekly infusions of alglucosidase alfa (20 mg 
per kilogram of body weight) or placebo. The Pocock and Simon minimization 
algorithm20 was used to balance the baseline distance walked on a 6-minute walk 
test (<300 or ≥300 m) and the baseline percentage of the predicted forced vital 
capacity (FVC) in an upright position (<55 or ≥55%) between study groups at each 
site.
Patients
All eligible patients had a confirmed diagnosis of Pompe’s disease (GAA deficiency 
and two GAA gene mutations); were 8 years of age or older; were able to walk 40 m 
on the 6-minute walk test (with assistive devices permitted); had a percentage 
of the predicted FVC within the range of 30% to less than 80% in the upright 
position, with a postural drop in FVC (in liters) of 10% or more (from upright to 
supine); and had evidence of muscle weakness in the lower extremities, defined 
as bilateral knee extension less than 80% of predicted performance, as measured 
by quantitative muscle testing (QMT). Patients were excluded if they required any 
invasive ventilation or if they required noninvasive ventilation while awake and 
upright (see the Supplementary Appendix).
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Assessments of clinical efficacy
Coprimary efficacy end points were meters walked on the 6-minute walk test and 
percentage of the predicted FVC in the upright position. Secondary and tertiary 
efficacy end points included changes in the percentage of the predicted QMT leg 
score and QMT arm score, maximum inspiratory pressure, and maximum expiratory 
pressure. Changes in walking distance on the 6-minute walk test were evaluated 
according to American Thoracic Society guidelines.21
Spirometric and manometric assessments of pulmonary function and respiratory 
muscle strength were performed according to American Thoracic Society and 
European Respiratory Society guidelines.22-24
The quantitative measurement system of the Cooperative International Neuro-
muscular Research Group was used to perform QMT to assess muscle force 
production during maximal voluntary isometric contraction of bilateral shoulder 
and hip adductors, elbow and knee flexors and extensors, and grip.25,26 Data were 
reported as composite QMT leg and arm scores (i.e., the average of the percentage 
of predicted scores for bilateral knee flexors and extensors and bilateral elbow 
flexors and extensors).25
The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) was 
administered to patients 14 years of age or older. The scores for the Physical 
Component Summary are reported.27
Antibody monitoring
Serum samples were obtained every 4 weeks for the first 52 weeks and again at 
weeks 64 and 78. IgG antibodies to alglucosidase alfa were assessed by means of 
the enzyme-linked immunosorbent assay (ELISA), and results were confirmed on 
radioimmunoprecipitation, as described previously.28 Patients who tested positive 
for IgG antibodies were evaluated for antibodies that inhibit enzyme activity or 
uptake into cells.29 Twofold dilution series of serum samples were preincubated 
with a fixed amount of enzyme. These samples were then analyzed to determine 
whether the antibodies interfered with the enzyme-substrate interaction. Similarly 
diluted samples were also preincubated with fluorescence-labeled enzyme and 
analyzed by means of flow cytometry to determine their ability to interfere with 
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enzyme internalization into fibroblasts (an easily grown cell type that expresses 
mannose-6-phosphate receptors, which mediate enzyme uptake). The last serum 
dilution that inhibited enzyme activity relative to the established assay cutoff point 
was recorded as the titer.
Safety assessments
All adverse events, serious adverse events, and infusion-associated reactions were 
recorded. The site investigator and the study sponsor determined whether an 
adverse event was related to the study drug.
Statistical analysis
We calculated that a minimum sample of 63 patients would be required to 
detect a treatment difference of 0.75 SD with 80% power (on the basis of a two-
sample t-test with a significance level of 5% and a 2:1 ratio for randomization). 
Enrollment of at least 72 patients was planned, assuming a 10 to 15% dropout 
rate. The planned model for the primary efficacy analysis was a linear mixed-effects 
model with random intercepts and slopes. The estimated treatment effect was the 
absolute difference in the linear slopes of change between the alglucosidase alfa 
and placebo groups.
An adaptive design was implemented (under a protocol amendment) in which the 
initial 52-week treatment period could be extended by 3 or 6 months on the basis 
of an interim estimate of the standard error of the treatment effect on the 6-minute 
walk test; the estimate was used to determine the length of follow-up required to 
ensure adequate power for assessment of this end point. Because only the interim 
estimate of the standard error was used, no adjustment of the type I error rate 
was needed (see the Supplementary Appendix).30 An interim analysis of the data 
on the 6-minute walk test was performed by an independent statistical center 
after all patients had completed week 38. On the basis of this interim analysis, the 
data and safety monitoring board recommended that the study be extended to 78 
weeks; there were no interruptions in the study regimens during the 78-week trial. 
Neither the study sponsor nor the investigators had access to the interim results 
until the conclusion of the study.
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The efficacy analysis was performed for the intention-to-treat population, defined 
as all patients randomly assigned to either alglucosidase alfa or placebo. A fixed-
sequence testing procedure was used to account for multiple testing and to 
preserve the overall significance level of 5% for both coprimary end points. Formal 
testing for a treatment effect on FVC in the upright position was performed only 
after the significance of the treatment effect on the 6-minute walk test had been 
shown by means of a two-sided test. Prespecified testing of the assumptions for 
the linear mixed-effects model indicated that use of this model was not warranted; 
therefore, the primary efficacy analysis was an analysis of covariance (ANCOVA) for 
the change from baseline to week 78. The last-observation-carried-forward method 
was used for the ANCOVA model, with adjustment for randomization strata and 
baseline scores. Treatment effects were also estimated in predefined subgroups, 
and a post hoc sensitivity analysis with the use of mixed models for repeated 
measures and nonparametric tests was conducted to assess the robustness of the 
efficacy findings (see the Supplementary Appendix). Secondary and tertiary end 
points were analyzed by means of ANCOVA. The reported p values are two-sided 
and were not adjusted for multiple testing.
RESuLTS
Characteristics of the patients
A total of 90 patients between 10 and 70 years of age were randomly assigned to 
either alglucosidase alfa (60 patients) or placebo (30 patients). Of this group, 81 
completed the study; 5 in the alglucosidase alfa group and 4 in the placebo group 
dropped out (see Figure 1 in the Supplementary Appendix). The demographic 
and baseline characteristics of the patients are summarized in Table 1. In the 
alglucosidase alfa group, there were more men, the patients were slightly older, 
and fewer patients used a walking device at baseline. The only significant difference 
between the groups in disease-related characteristics was age at symptom onset 
(p=0.02). In both groups, the mean SF-36 Physical Component Summary scores 
were more than 1.5 SD below the norm for the U.S. general population (50±10), 
indicating that baseline physical health status was substantially diminished.
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Table 1. Demographic and baseline characteristics of the study populationa
Characteristic Alglucosidase Alfa 
Group (n=60)
Placebo Group
(n=30)
P value
Age at first infusion, years
Mean 45.3±12.4 42.6±11.6 0.32
Range 15.9–70.0 10.1–68.4
Sex, no. (%)
Male 34 (57) 11 (37) 0.12
Female 26 (43) 19 (63)
Race, no. (%)b
White 57 (95) 27 (90) 0.40
Other 3 (5) 3 (10)
Age at onset of symptoms, years
Mean 30.3±12.3 23.9±11.0 0.02
Range 5.3–58.6 2.7–42.6
Duration of disease, years
Mean 9.0±6.3 10.1±8.4 0.48
Range 0.3–24.8 0.5–31.3
Normal GAA activity, %
Mean 10.8±8.2 10.1±7.8 0.71
Range 0–47.4 0–32.2
Use of walking device, no. (%) 23 (38) 16 (53) 0.19
Use of ventilatory support, no. (%) 20 (33) 11 (37) 0.82
Score on SF-36 Physical Component Summary 34.33±8.93 34.91±7.26 0.23
Performance on 6-min walk test
Distance walked, m
Mean 332.2±126.7 317.9±132.3 0.62
Range 77.0–626.0 41.0–608.0
% of predicted value
Mean 52.5±19.0 50.3±20.5 0.61
Range 9.8–82.2 6.2–99.0
FVC, % of predicted value
Mean 55.4±14.4 53.0±15.7 0.47
Range 31.0–78.0 30.0–78.0
a Plus-minus values are means ±SD. Fisher’s exact test was used for comparisons of binary variables, and 
Student’s t-test for comparisons of continuous variables. FVC denotes forced vital capacity, GAA acid α 
glucosidase, and SF-36 Medical Outcomes Study 36-Item Short-Form Health Survey.
b Race was reported by the patient.
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Efficacy
By 78 weeks, treatment with alglucosidase alfa had significantly increased both the 
distance walked on the 6-minute walk test and the percentage of the predicted 
FVC (Table 2 and Figure 1). The alglucosidase alfa group had a mean increase of 
25.1 m on the 6-minute walk test (the average baseline was 332.2 m), whereas the 
placebo group had a decrease of 3.0 m (the average baseline was 317.9 m), for an 
estimated differential treatment effect of 28.1 m (p=0.03). The estimated change in 
FVC, expressed as a percentage of each patient’s predicted value, was an increase 
of 1.2 percentage points for the patients who received alglucosidase alfa and a 
decrease of 2.2 percentage points for the patients who received placebo, for an 
estimated treatment effect of 3.4 percentage points (p=0.006).
For each subgroup evaluated, the patients who received alglucosidase alfa had 
numerically better results (Figure 2 in the Supplementary Appendix). Subgroup 
analyses showed a greater difference between the study groups among patients 
with better baseline status – that is, patients whose baseline distance on the 
6-minute walk test was 300 m or greater and whose baseline FVC was 55% or more 
of the predicted value. In addition, sensitivity analyses with the use of alternative 
statistical methods showed that the results were consistent and robust across 
analytic methods (Table 1 in the Supplementary Appendix).
The pattern of response with respect to QMT leg and arm scores and the percentage 
of the predicted maximum expiratory and inspiratory pressures support the findings 
for the two coprimary end points, although only the change in the percentage of 
the predicted maximum expiratory pressure differed significantly between the 
groups (Table 2 and Figure 2).
Safety
Patients in the two groups had similar frequencies of adverse events, serious adverse 
events, treatment-related adverse events, and infusionassociated reactions. Most 
adverse events were mild or moderate in severity and were not considered to be 
related to the study drug (Table 3, and Table 2 in the Supplementary Appendix). 
The most frequently reported events (falls, nasopharyngitis, and headache) 
were similar between groups. Infusion-associated reactions occurred in 28% of 
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Table 2. Results of analysis of covariance for changes from baseline to week 78 for primary 
and secondary end points*
Alglucosidase Alfa 
Group (n=60)
Placebo Group  
(n=30)
Difference between 
Groups 
P Value
End Point
Distance walked on 6-min walk test – m
Baseline 332.2±126.7 317.9±132.3
Week 78 357.9±141.3 313.1±144.7
Change (95% CI) 25.13 (10.07 to 40.19) -2.99 (-24.16 to 18.18) 28.12 (2.07 to 54.17) 0.03
Forced vital capacity – % of predicted
Baseline 55.4±14.4 53.0±15.7
Week 78 56.7±16.3  50.7±14.9
Change (95% CI) 1.20 (-0.16 to 2.57) -2.20 (-4.12 to -0.28) 3.40 (1.03 to 5.77) 0.006
Quantitative muscle testing, leg – % of predicted
Baseline 37.7±18.9 32.5±18.2
Week 78 39.1±21.8 30.4±20.5
Change (95% CI) 1.18 (-1.07 to 3.42) -2.00 (-5.16 to 1.17) 3.18 (-0.73 to 7.08) 0.11
Quantitative muscle testing, arm – % of predicted
Baseline 55.9±20.4 56.9±18.2
Week 78 60.9±21.7 58.3±20.9
Change (95% CI) 5.05 (1.91 to 8.18) 1.47 (-2.92 to 5.87) 3.57 (-1.83 to 8.97) 0.19
Maximum inspiratory pressure – % of predicted
Baseline 40.0±19.7 42.6±21.0
Week 78 43.7±21.0 41.7±19.3
Change (95% CI) 3.48 (0.91 to 6.04) -0.35 (-3.95 to 3.25) 3.83 (-0.60 to 8.26) 0.09
Maximum expiratory pressure – % of predicted
Baseline 32.0±12.1 30.8±12.0
Week 78 35.1±13.3 30.5±13.1
Change (95% CI) 3.24 (1.19 to 5.29) -0.56 (-3.43 to 2.31) 3.80 (0.27 to 7.33) 0.04
Score on SF-36 Physical Component Summary†
Baseline 34.3±8.9 34.9±7.3
Week 78 35.1±9.8 36.5±9.6
Change (95% CI) 0.80 (-1.22 to 2.82) 1.16 (-1.64 to 3.97) 0.37 (-3.83 to 3.09) 0.83
* Plus-minus values are means ±SD. CI denotes confidence interval.
† The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) consists of an interview and 
self-administered questionnaire designed to assess generic health-related quality of life in healthy and ill 
adult populations.
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Figure 1. Changes from baseline in distance walked and in Forced Vital Capacity, according 
to study group.
The graphs show the changes from baseline to week 78 for the two study groups. On the 6-minute walk 
test (Panel A), the alglucosidase alfa group had an increase of 25 m, whereas the placebo group had a 
decrease of 3 m – a difference of 28 m. The percentage of predicted forced vital capacity (FVC) (Panel 
B) increased by 1.2% in the alglucosidase alfa group but decreased by 2.2% in the placebo group – a 
difference of 3.4%. These values represent estimates of the mean on analysis of covariance.
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alglucosidase alfa recipients and 23% of placebo recipients. Most of the reactions 
were not serious or were mild to moderate in severity and resolved with no 
need to withdraw the study treatment (Table 3 in the Supplementary Appendix).
Anaphylactic, allergic, and infusion-associated reactions that involved urticaria, 
flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure 
occurred in 5 to 8% of the patients treated with alglucosidase alfa but were 
not reported in the placebo group. Of the 60 patients in the alglucosidase alfa 
group, three (5%) had anaphylactic reactions, two of whom tested positive for IgE 
antibodies to alglucosidase alfa; two had respiratory and cutaneous reactions, and 
the third had severe tongue edema. Two of these three patients withdrew from the 
study. One patient in the placebo group withdrew owing to headaches. During the 
study, one patient in the alglucosidase alfa group who was receiving clinical care 
for two broad-based basilar-artery aneurysms died from brain-stem ischemia due 
to basilar-artery thrombosis.
Anti-alglucosidase alfa IgG antibodies developed in all 59 patients in the treatment 
group who underwent at least one post-treatment assessment, with a median time 
to seroconversion of 4 weeks (range 3.6 to 12). After seroconversion, the median 
time to the peak titer was 12 weeks; the median peak titer was 6400, and the 
median final titer (last sample or sample at week 78) was 1600. The geometric 
mean titer of anti-alglucosidase alfa IgG antibodies on ELISA increased from 
baseline through week 44 (2925) and declined slightly through week 78 (1607) 
(Figure 3 in the Supplementary Appendix). In 36 of 59 patients (61%) with one or 
more post-treatment assessments, there was a trend toward decreasing titers by 
a factor of two or more, whereas titers in the remaining patients plateaued. No 
consistent association was found between the serum IgG antibody titer and the 
coprimary efficacy end points or the incidence of adverse events, serious adverse 
events, and infusion-associated reactions (Tables 4 and 5 in the Supplementary 
Appendix).
No patients tested positive for inhibition of enzyme activity. Of the 59 patients who 
were positive for anti-alglucosidase alfa IgG antibodies, 18 (31%) tested positive 
for inhibition of enzyme uptake. The mean time to the first detection of inhibitory 
antibodies was 36 weeks after the first infusion.
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Figure 2. Changes from baseline in Quantitative Muscle Testing (QMT) arm and leg scores 
and Maximum Expiratory and Inspiratory Pressures.
The graphs show changes in the percentage of predicted values from baseline to week 78 for the 
alglucosidase alfa group and the placebo group. On QMT (Panel A), the changes in leg scores were 1.2% 
for the alglucosidase alfa group and -2.0% for the placebo group; the corresponding values for the arm 
scores were 5.1% and 1.5%. In Panel B, the changes in maximum expiratory pressure (MEP) were 3.2% 
for the alglucosidase alfa group and -0.6% for the placebo group; the corresponding changes in maximum 
inspiratory pressure (MIP) were 3.5% and -0.4%. These values represent estimates of the mean on analysis 
of covariance.
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Table 3. Serious adverse events during the treatment perioda
Adverse Event Alglucosidase Alfa Group
(n=60)
Placebo Group
(n=30)
No. of patients (%)
Any event 13 (22) 6 (20)
Infections 2 (3) 1 (3)
Diverticulitis 0 1 (3)
Gastroenteritis 1 (2) 0
Pneumonia 1 (2) 0
Cardiac disorders 2 (3) 0
Coronary artery disease 1 (2) 0
Supraventricular tachycardia 1 (2) 0
Immune system disorders 2 (3) 0
Hypersensitivity 2 (3) 0
General disorders and conditions at site of 
administration
2 (3) 0
Chest discomfort 1 (2) 0
Noncardiac chest pain 1 (2) 0
Respiratory, thoracic, and mediastinal disorders 2 (3) 0
Lung disorder 1 (2) 0
Throat tightness 1 (2) 0
Injury, poisoning, and complications of procedure 1 (2) 1 (3)
Fall 1 (2) 1 (3)
Fracture (humerus) 1 (2) 1 (3)
Musculoskeletal and connective-tissue disorders 1 (2) 1 (3)
Intervertebral disk protrusion 1 (2) 0
Flank pain 0 1 (3)
Gastrointestinal disorders 1 (2) 1 (3)
Generalized abdominal pain 1 (2) 0
Upper abdominal pain 0 1 (3)
Nervous system disorders 1 (2) 1 (3)
Brain-stem ischemia 1 (2) 0
Headache 0 1 (3)
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Adverse Event Alglucosidase Alfa Group
(n=60)
Placebo Group
(n=30)
No. of patients (%)
Skin and subcutaneous-tissue disorders 1 (2) 1 (3)
Angioedema 1 (2) 0
Septal panniculitis 0 1 (3)
Metabolism and nutritional disorders 1 (2) 0
Dehydration 1 (2) 0
Vascular disorders 1 (2) 0
Aneurysm 1 (2) 0
a Patients may have had more than one adverse event.
DISCuSSIOn
In this randomized, controlled trial of alglucosidase alfa in patients with late-onset 
Pompe’s disease, significant differences were observed at 78 weeks between the 
alglucosidase alfa and placebo groups in the distance walked on the 6-minute walk 
test and in the percentage of the predicted FVC. Alglucosidase alfa treatment was 
associated with improvements in walking distance and stabilization of pulmonary 
function; therefore, the coprimary end points of the study were met. Treatment 
effects were supported by the consistently favorable pattern of response in 
proximal and respiratory muscle strength among the patients who received 
alglucosidase alfa. Of these secondary and tertiary end points, the percentage of 
predicted maximum expiratory pressure (a surrogate marker of expiratory muscle 
strength) differed significantly between the study groups. These results indicate 
that alglucosidase alfa has a positive effect on the complex process that leads 
to impaired ambulation and respiratory failure in late-onset Pompe’s disease. 
Whether alglucosidase alfa exerts a differential effect on the various respiratory 
muscles (diaphragm or intercostal muscles) requires further investigation.
Natural history studies of late-onset Pompe’s disease indicate that it is defined by 
progressive deterioration in proximal arm, leg, and respiratory muscle strength and 
function.2,6,7,9,31-33 Two recent natural history studies showed mean annual declines 
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of 4.6% and 1.7% in the percentage of predicted FVC, measured in the upright 
position;9,33 these findings are consistent with the 2.2% decline that occurred over 
a period of 18 months in the placebo group in our study. Important clinical benefits 
can be provided if further deterioration in pulmonary and motor function can be 
prevented, and the patient’s independence can be maintained by preventing the 
need for a ventilator or a wheelchair.
The estimated treatment response to alglucosidase alfa as compared with placebo, 
although variable in its magnitude, was consistently positive for all subgroups. 
Hypotheses about the nature and progression of muscle damage in Pompe’s disease 
led us to speculate that patients with less baseline impairment would benefit more 
from treatment. Subgroup analyses of the changes in the 6-minute walk test and 
the percentage of the predicted FVC suggest a more pronounced treatment effect 
in patients with better clinical status at baseline (all estimated treatment effects >0) 
(Figure 2 in the Supplementary Appendix). However, individual patients’ responses 
did not consistently show this effect, nor did the subgroup analyses identify any 
consistent predictor of a treatment response.
The effect of alglucosidase alfa treatment became apparent early; the greatest 
improvement in all end points in the treated group occurred during the first 26 
weeks, with those gains then generally being maintained. This response pattern 
may be due to the limited capacity to repair muscle tissue that has sustained 
substantial damage. Functional recovery may then be explained by the uptake of 
exogenous alglucosidase alfa and subsequent lysosomal glycogen clearance from 
muscle tissue that has not yet sustained endstage damage.34 The overall clinical 
response observed in our study may represent the balance between more mildly 
affected muscle fibers and those with potentially irreversible damage and might 
suggest that prevention of further loss of muscle tissue and function is an important 
treatment goal. Longer-term study of alglucosidase alfa in children and adults with 
Pompe’s disease would be needed to understand fully the potential of treatment.
Adverse events occurred in both groups of patients in our study. Anaphylactic 
reactions occurred in three of the 60 patients treated with alglucosidase alfa; 
two of these reactions were IgE-mediated. One patient who tested positive for 
IgE underwent a successful rechallenge with the use of a modified regimen and 
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remained in the study. After discontinuing the study, the second IgE-positive patient 
was successfully rechallenged with alglucosidase alfa and was able to continue 
treatment. IgG antibodies to alglucosidase alfa were detected in all the patients who 
received alglucosidase alfa, with a trend toward decreasing levels with continued 
treatment. Although we found no consistent effect of these antibodies on clinical 
response or safety variables, such an effect may emerge over time. Anaphylactic 
reactions are a serious potential complication of treatment with any recombinant 
human protein and have previously been reported to occur with alglucosidase 
alfa.12 Antibodies, particularly neutralizing antibodies, have a negative effect on 
clinical response in some diseases treated with infused proteins, but this effect has 
been inconsistent across patient populations.29 Patients treated with alglucosidase 
alfa who have persistently high antibody titers should be followed closely until the 
effect of the antibodies is more fully understood.
Our study has several limitations. Although 90 patients is a large population for a 
clinical trial designed to study an orphan disease, the number is relatively small 
when the goal is to judge the progression of a clinically heterogeneous disease. 
Before the start of this trial, no longitudinal data were available on changes in the 
6-minute walk test over time in patients with untreated Pompe’s disease, and the 
mean decline in the distance walked was minimal in the patients in our study who 
received placebo. Longer follow-up will be needed to confirm our results, given the 
variable presentation and rate of deterioration among the patients in our study 
and the possible effect of the degree of muscle destruction at baseline on their 
response to treatment.
In summary, our data indicate that alglucosidase alfa treatment, as compared 
with placebo, has a positive, if modest, effect on walking distance and pulmonary 
function in patients with late-onset Pompe’s disease and may stabilize proximal 
limb and respiratory muscle strength.
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ABSTRACT
Pompe disease or glycogen storage disease type 2, is a rare inheritable metabolic 
disease caused by a deficiency of the lysosomal enzyme acid a-glucosidase. Patients 
with the classic infantile form of Pompe disease present with symptoms during the 
first three months after birth, and most will die within their first year. Recently, 
enzyme replacement therapy (ERT) with recombinant human a-glucosidase became 
commercially available for Pompe disease. This is a case report of an 8-year-old girl 
with the infantile form of Pompe disease who is one of the longest survivors through 
ERT. The patient was tetraplegic when she started ERT. At age 3 years, she developed 
massive gingival overgrowth and could not close her mouth, prompting a reduction 
of the gingival overgrowth surgically. We expected that massive accumulation of 
glycogen would explain the gingival overgrowth. However, histopathology of the 
gingiva tissue showed marked glycogen accumulation in smooth muscle cells of 
the arteries, but the glycogen content in fibroblasts did not exceed that of control 
individuals. Further, there was an increase of immature collagen in the connective 
tissue, and signs of a mild chronic inflammation. We concluded that glycogen 
storage is not a direct causative factor of gingival overgrowth in our patient. Chronic 
inflammation, dryness of the gingiva, or even the minimal glycogen accumulation 
in the fibroblasts may have played a role.
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InTRODuCTIOn
Pompe disease, also known as glycogen storage disease type 2 or acid maltase 
deficiency is a rare, inheritable metabolic disease.1 Its transmission is autosomal 
recessive, with a similar occurrence in men and women. Mutations in the 
a-glucosidase gene, located on chromosome 17, cause a total or partial deficiency 
of the lysosomal enzyme acid a-glucosidase. Deficiency of this enzyme leads to 
accumulation of glycogen in cells throughout the body, but most notably in skeletal 
and cardiac muscles.2-4 
The incidence of Pompe disease is estimated to be 1:40.000 births in the Western 
world.5,6 The first description of the classic infantile form of Pompe disease was 
made by the Dutch pathologist JC Pompe.7 Classic infantile Pompe patients present 
early in life, at a median age of 1.6 months, with hypertrophic cardiomyopathy 
and severe generalized hypotonia. Without treatment, most patients die within 
their first year of life.8,9 Children and adults with Pompe disease present with a 
more slowly progressive proximal myopathy, usually without cardiac involvement. 
The age of onset and disease progression varies widely in this group of patients. 
Patients eventually need respiratory support, a percutaneous gastrostomy, and they 
become wheelchair dependent. The main cause of death is respiratory failure.2,4,9-11 
Since 2006, enzyme replacement therapy (ERT) with recombinant human 
a-glucosidase has become commercially available for Pompe disease. This treatment 
has been shown to have an effect on survival, hypertrophic cardiomyopathy, and 
motor function.12-20
An 8-year-old girl with classic infantile Pompe disease who survived because of 
ERT is presented in this case study. During the course of treatment, she developed 
hypertrophic masses of the gingiva (30‒45 mm).
Case Report
The patient was admitted at the age of 3 months for evaluation of severe hypotonia, 
hepatomegaly and cardiomegaly. She was diagnosed with classic infantile Pompe 
disease. At the age of 7 months, she was enrolled in the first ERT study with 
recombinant human α-glucosidase.17 At the time of her first infusion, the patient 
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was in the end stage of Pompe disease. She was tetraplegic, completely dependent 
on invasive ventilation, and had symptoms of cardiac failure. 
After the start of therapy, the cardiac hypertrophy improved, but the patient 
remained tetraplegic and completely ventilator dependent. She appeared to have 
normal mental development and attended school daily. Because of complete 
paralysis of the facial musculature, she was enterally fed via percutaneous 
gastrostomy. She could not close her mouth, was unable to speak, and could 
only move her mandible laterally for 2 to 3 millimeters. This small movement of 
her mandible was mandatory to control her wheelchair. She used the following 
medications: budesonide, cotrimoxazole, furosemide, spironolactone, and 
recombinant human a-glucosidase.
At the age of 3 years, an enlargement of the palatal gingiva was noted, and the 
patient was referred to the department of oral and maxillofacial surgery. Intraoral 
examination revealed generalized gingival overgrowth in the molar region of the 
palatal aspect of the maxilla and of the lingual and buccal sides of the mandibula. 
The patient had class III malocclusion, a small maxilla, and impaired eruption of the 
molars. The temporomandibular joint was in place. She was referred to a pediatric 
dentist and dental hygienist to improve oral hygiene. 
At the age of 5 years, the patient returned to our department with progression 
of the masses in all 4 quadrants. Although the masses interfered with occlusion, 
the patient did not experience any discomfort. In addition, oral hygiene was good, 
and permanent teeth eruption was normal. On the basis of the patient’s condition 
and the risk for anesthesia, as well as in consideration of her well-being, surgical 
intervention was not performed, and the patient remained under supervision of 
the pediatric dentist and dental hygienist. 
At the age of 8 years, progression of the masses made it impossible for the patient 
to move her mouth, and hence she was unable to control the wheelchair. The four 
masses that ranged from 30 mm to 45 mm were therefore excised under general 
anesthesia, and sent for histopathological examination (Figures 1, 2).
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Figure 1. Gingival overgrowth in all 4 quadrants.
Figure 2. Excised mass.
Histopathology
Resection and biopsy specimens from the patient and control cases were fixed 
with buffered formalin for 12 to 24 hours and processed for routine sections from 
paraffin- embedded tissue. Stainings for haematoxylin and eosin (HE), periodic 
acid-Schiff (PAS), PAS after diastase digestion, and alcian blue (AB) were carried 
out according to standard protocols. PAS staining was performed to visualize 
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glycogen and compared with PAS after diastase digestion, which removes glycogen. 
AB staining was applied to visualize myxoid changes of the collagenous matrix of 
the connective tissue. The resection specimens of the patient showed acanthotic 
nonkeratinizing squamous epithelium with elongated rete ridges. The submucosal 
connective tissue contained marked lymphoid and plasma cell infiltrations. The 
connective tissue had a loose appearance with large quantities of Alcian blue-
positive myxoid matrix (Figure 3). PAS-stained sections showed marked glycogen 
accumulation in arterial smooth muscle cells (Figure 4). Some glycogen could also 
be noted in fibroblasts (Figure 5). Glycogen was absent in the sections stained with 
PAS after diastase digestion. We compared the sections of our patient with HE, 
PAS, PAS after diastase digestion, and AB-stained gingiva sections of 6 patients 
seen in our hospital for inflammatory papillary hyperplasia, irritation fibroma (2 
patients), chronic gingivitis (2 patients), and a gingival cyst. In the sections of the 
latter patients, glycogen was also found in fibroblasts, but not in arterial smooth 
muscle cells. In addition, no excessive myxoid extracellular matrix was found.
Figure 3. Gingival hypertrophy: expansion of the submucosal connective tissue has 
evoked a pseudoepitheliomatous hyperplasia of the nonkeratinizing squamous epithelium 
(hematoxylin and eosin, x40). Inset: abundant myxoid matrix in between collagen bundles 
(alcian blue, x40).
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Figure 4. (A) artery of patient showing deposition of glycogen in vacuolated smooth muscle 
cells of the wall (periodic acid-Schiff [PAS], x400); (B) same artery after diastase digestion 
(PAS after diastase digestion, x400); (C) artery of control patient with chronic inflammation 
without glycogen deposition and no vacuolization of muscle cells (PAS, x400); (D) same 
artery after diastase digestion (PAS after diastase digestion, x400).
Figure 5. (A) fibroblasts of patient showing some deposition of glycogen (periodic acid-Schiff 
[PAS], x400); (B) fibroblasts of control patient with similar amount of glycogen (PAS, x400).
166
Chapter 8
DISCuSSIOn
Before enzyme therapy became available, patients with infantile Pompe disease 
died before the age of 1 year.4,8 In this case report, we present one of the longest 
survivors with classic infantile Pompe disease, achieved through enzyme therapy. 
The patient started to receive therapy in the end stage of the disease when she 
was completely tetraplegic and her skeletal muscles severely damaged. This 
explains, in retrospect, why the effect of enzyme therapy on motor performance 
was poor. Paralysis also included facial muscle weakness, and the patient could 
barely open and close her mouth. From the age of 3 years, she started to develop 
gingival overgrowth. Gingival overgrowth has not been described in patients 
diagnosed with Pompe disease thus far but has been found in other lysosomal 
storage disorders, such as mucopolysaccharidosis,21,22 aspartylglucosaminuria,23 
mucolipidosis type 2,24,25 and lysosomal glycogen storage disease type 1b.26 For 
the mucopolysaccharidoses, gingival hyperplasia was shown to be related to the 
presence of non-degradable glycosaminoglycans.27 In the other cases, chronic 
inflammation of the gingiva was a frequent finding. 
We expected that the excessive gingival overgrowth in our patient with Pompe 
disease was caused by glycogen storage. However, we found that the amount 
of glycogen in fibroblasts was not different from that of patients with gingival 
inflammation who did not have Pompe disease. The marked glycogen accumulation 
in the arterial smooth muscle cells was insufficient to explain the occurrence of 
the gingival hypertrophy. Diffuse gingival overgrowth has also been described for 
diseases other than lysosomal storage disorders. The most common causes known 
in children are drug-induced gingival hyperplasia, hereditary gingival fibromatosis 
and neurofibromatosis type 1, and inflammatory gingival enlargement or as part 
of a systemic disease such as leukemia.28 These causes could be excluded in our 
patient. Because prominent infiltration of inflammatory cells was observed in the 
excised gingival masses of our patient, chronic inflammatory gingivitis may explain, 
in part, the gingival overgrowth. The inflammatory response was confined to the 
submucosal connective tissue and did not affect the deeper connective tissue; 
furthermore, mild inflammation is not uncommon in healthy persons. Therefore, it 
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is unlikely that inflammation was the only cause of the abnormalities. The patient’s 
oral hygiene has been closely monitored by a specialized dental hygienist over the 
years. There was no history of bleeding or redness of the gingiva. In conclusion, 
we cannot fully explain the gingival overgrowth in our patient. We have ruled 
out massive storage of glycogen as a direct cause. The fact that glycogen was 
abundantly present in smooth muscle cells of the arterial walls indicates that 
ERT did not clear all tissues of glycogen storage, but the quantities of storage 
material were insufficient to fully explain the gingival overgrowth. The abuncance 
of immature collagen in the extracellular matrix suggests that the homeostasis 
of collagen synthesis and degradation was disturbed. We hypothesize that a 
combination of chronic inflammation, dryness of the gingiva, and even the minimal 
glycogen accumulation in the fibroblasts may have played a role in the etiology of 
the patient’s gingival overgrowth. Whatever the cause, we wish to focus attention 
on the fact that gingival overgrowth may be a complication in long survivors with 
infantile Pompe disease who show a poor motor response to enzyme therapy.
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ABSTRACT 
Classic infantile Pompe disease is an inherited generalized glycogen storage disorder 
caused by deficiency of lysosomal acid α-glucosidase. If left untreated, patients die 
before one year of age. Although enzyme-replacement therapy (ERT) has significantly 
prolonged lifespan, it has also revealed new aspects of the disease. For up to 11 
years, we investigated the frequency and consequences of facial-muscle weakness, 
speech disorders and dysphagia in long-term survivors. Sequential photographs 
were used to determine the timing and severity of facial-muscle weakness. Using 
standardized articulation tests and fibreoptic endoscopic evaluation of swallowing, 
we investigated speech and swallowing function in a subset of patients. This study 
included 11 patients with classic infantile Pompe disease. Median age at the start 
of ERT was 2.4 months (range 0.1–8.3 months), and median age at the end of 
the study was 4.3 years (range 7.7 months – 12.2 years). All patients developed 
facial-muscle weakness before the age of 15 months. Speech was studied in four 
patients. Articulation was disordered, with hypernasal resonance and reduced 
speech intelligibility in all four. Swallowing function was studied in six patients, the 
most important findings being ineffective swallowing with residues of food (5/6), 
penetration or aspiration (3/6), and reduced pharyngeal and/or laryngeal sensibility 
(2/6). We conclude that facial-muscle weakness, speech disorders and dysphagia 
are common in long-term survivors receiving ERT for classic infantile Pompe 
disease. To improve speech and reduce the risk for aspiration, early treatment by a 
speech therapist and regular swallowing assessments are recommended.
Facial muscle weakness, speech disorders and dysphagia in classic infantile Pompe disease
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InTRODuCTIOn
Pompe disease (glycogen storage disease type II, acid maltase deficiency, OMIM 
# 232300) is a rare autosomal recessive lysosomal storage disorder caused by 
mutations in the gene-encoding acid α-glucosidase (EC 3.2.1.20).1,2 Severe mutations 
cause complete enzyme deficiency, resulting in the classic infantile form of Pompe 
disease, which was first described by Pompe in 1932.3 Symptoms are caused by 
glycogen accumulation, mainly in skeletal, cardiac and smooth muscle, but also 
in other tissues, including the central and peripheral nervous system. In the first 
months of life, patients present with progressive muscle weakness, hypertrophic 
cardiomyopathy, respiratory problems and feeding difficulties. If untreated, this 
leads to death before the age of one year.4,5
Although the lifespan of classic infantile Pompe patients has been significantly 
prolonged, and although motor functioning is improved by enzyme-replacement 
therapy (ERT), various extents of muscle weakness remain.6-16 This study focuses 
on weakness of the facial and bulbar muscles.
We simultaneously examined the prevalence and consequences of facial-muscle 
weakness, speech disorders and dysphagia in a cohort of patients with classic 
infantile Pompe disease who had been treated with ERT over a long period, in 
some cases up to 11 years. 
PATIEnTS AnD METHODS
Patients
The study comprised 11 patients with classic infantile Pompe disease treated with 
ERT between 1999 and 2010 at Erasmus MC University Medical Center, Rotterdam, 
the Netherlands. Classic infantile Pompe disease was defined as 1.) symptoms of 
muscle weakness within six months of birth, 2.) hypertrophic cardiomyopathy, 
and 3.) severe GAA (the gene-encoding acid α-glucosidase) mutations on both 
alleles. The diagnosis was confirmed by an enzyme-activity assay in leukocytes or 
fibroblasts. Patients were enrolled in clinical trials that investigated the safety and 
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efficacy of ERT with recombinant human α-glucosidase (20 mg/kg/two weeks to 
40 mg/kg/week). The Institutional Review Board approved the studies, and written 
informed consent was obtained from all parents. 
Facial-muscle weakness
To examine the onset of facial-muscle weakness, we collected photographs of the 
face taken over a period of 24 months from the start of ERT. For this we used 
standardized photographs and videos taken every three months. The photographs 
were ordered arbitrarily and evaluated independently by three neurologists. The 
evaluators stated whether facial-muscle weakness was present, and, whether it was 
mild or severe. Facial-muscle weakness was defined as an expressionless face with 
an open drooping or tent-shaped mouth.17 To accept any judgment, the agreement 
of at least two evaluators was needed. If this was impossible, the evaluation was 
considered not to be applicable. 
To further characterize facial-muscle weakness, the evaluators scored whether 
the following clinical features were present, absent or impossible to judge: ptosis, 
sunken cheeks, drooping of the lower lip, absence of the nasolabial folds, and 
absence of horizontal forehead lines. Ptosis was considered to be present when 
the upper eyelid was less than 2 mm from midpupil, or when asymmetry between 
the left and right upper eyelid was greater than 2 mm. A recent photograph of each 
patient was collected to analyze progression over time. 
Speech and swallowing function 
Between 2008 and 2010, speech was assessed in patients older than 24 months or 
in those who spoke more than ten words (n=4). Swallowing function was assessed 
in patients who were not fed by percutaneous endoscopic gastrostomy (n=6). 
Assessments were repeated after at least one year.
Speech
First, a speech therapist conducted a thorough orofacial observation to detect 
whether speech was impaired by weakness or reduced movements of the lip and 
tongue. To evaluate speech, a modified form of the Dutch Schisis Articulation 
Facial muscle weakness, speech disorders and dysphagia in classic infantile Pompe disease
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Examination was used, which examines spontaneous language, and the repetition 
of phonemes and words. The following items were examined: 1.) articulatory 
disorders (i.e. mispronunciation of speech sounds), 2.) hypernasal resonance (i.e. 
increased resonance by the nasal cavity), and 3.) speech intelligibility.
Additionally, a neuropsychologist tested for dysarthria using the Mayo Clinic Lists,18 
which also investigates respiration, phonation (i.e. the characteristics of voice 
production by the larynx), and prosody (i.e. speed and rhythm of speech). 
Swallowing function
The speech therapist obtained a feeding history from all parents.
Pharyngeal swallowing function was assessed by an experienced otolaryngologist 
using fiberoptic endoscopic evaluation of swallowing (FEES).19 First, the masticatory 
pattern was investigated. Then, after the fiberscope had been introduced, the 
anatomy and function of the swallowing apparatus were examined: Velopharyngeal 
closure (i.e. sealing of the nasal cavity by the soft palate) was examined during 
speech, and the pharynx and larynx were screened for deviant anatomy, reduced 
pharyngeal squeeze, and impaired laryngeal function.
Next, pharyngeal swallowing function was examined while patients ingested 
food in a sitting position. Observation of swallowing function included premature 
spillage of food, delayed swallowing, nasal regurgitation, pharyngeal food residue, 
and penetration and aspiration of the food or pooling secretions. Penetration was 
defined as leakage of food into the laryngeal vestibule up to the level of the true 
vocal cords; aspiration was defined as leakage into the laryngeal vestibule below 
this level.20 Finally, we observed the sensory reaction of the pharynx and larynx.
Associated clinical outcome measures
At the time of speech and swallowing assessments, relevant clinical data on feeding 
(orally or tube feeding), airway infections, motor development, and hearing loss21 
were collected. 
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RESuLTS
Patients
Eleven patients participated in this study. Table 1 summarizes each patient’s clinical 
features. At the start of ERT all patients had symptoms of Pompe disease. All were 
hypotonic, and eight were fed by nasogastric tube.
Facial muscle weakness
In total, 96 photographs were collected of 11 patients. The median age at the first 
photo was 2.3 months (age range 0.1‒8.8 months); the median age at the last was 
49.2 months (age range 6.9 months ‒ 11.6 years).
Between the ages of 1.0 and 15.0 months (Table 1, median 6.6 months), all patients 
developed evident signs of facial-muscle weakness, even when ERT was started 
very early. When such weakness was first observed, its severity in most patients 
(9/11) was considered to be mild. The main characteristics were sunken cheeks 
(8/11) and a drooping lower lip (9/11). While the absence of the nasolabial fold 
and forehead lines were difficult to judge, four patients clearly had diminished 
nasolabial folds. Only one patient had ptosis. 
The final photographs show that, despite ERT, facial-muscle weakness became 
severe in 7/11 patients (Figure 1). While the main features were still sunken cheeks 
(10/11) and drooping of the lower lip (9/11), facial expression was clearly reduced 
by diminished nasolabial folds (7/11) and forehead lines (5/11). The number of 
patients with ptosis rose to four.
Speech and swallowing function
Speech
Speech was assessed in four patients at a median age of 4.1 years (age range 
2.0‒9.9 years, supplementary Table 2). Orofacial observation showed that the 
speech of all four was impaired by reduced movement and/or weakness of 
the lip and/or tongue. Their articulation was disordered, featuring consonant 
substitutions, consonant omissions and cluster reductions, mild to moderate 
hypernasal resonance, and significantly impaired speech intelligibility. Together, 
this suggested velopharyngeal incompetence. 
Facial muscle weakness, speech disorders and dysphagia in classic infantile Pompe disease
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Figure 1. Development of facial muscle weakness over time in four patients with classic 
infantile Pompe disease treated with ERT. 
Per patient, comparison of the first photograph which showed the first signs of facial-muscle weakness 
(A-D) with the most recent photograph (E-H) showed that facial muscle weakness remained mild in two 
patients (A and B compared to E and F), but became severe in one patient (C compared to G). One patient 
presented with severe facial muscle weakness at the age of 1 month; this persisted over time (D compared 
to H).
Three patients were reassessed at a median age of 5.5 years (age range 
5.1‒11.1 years). In the period between the first and second assessment, no major 
changes in orofacial hypotonia or speech were observed, although speech therapy 
had improved the active articulatory compensation. Additional investigation of 
dysarthria in these three patients showed disorders in respiration, phonation and 
prosody. They spoke in short sentences in a monotone, hoarse wet voice with 
monoloudness. These features are specific for flaccid dysarthria. 
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Swallowing function
Swallowing function was assessed in six patients at a median age of 3.0 years 
(age range 8.0 months to 9.9 years). Feeding difficulties were reported (5/6), and 
comprised all parameters (see supplementary Table 2). Patient 9 was fed completely 
by nasogastric tube, and ingested only water orally. Observation of mastication 
revealed impaired mastication in two patients.
Fibreoptic endoscopic examinations of swallowing showed that five of the six 
patients had varying extents of dysphagia; only the youngest had no swallowing 
abnormalities. Reduced velopharyngeal closure was found in four patients, and 
caused nasal regurgitation in two. Although the anatomy of the swallowing 
apparatus and function of the larynx were normal, pharyngeal muscle contraction 
was reduced (5/6). This resulted in pooling secretions in the pharynx (4/6), which, 
in two patients, contained remnants of a previous meal (Figure 2a).
Figure 2. FEES examination in a 6-year old boy with classic infantile Pompe disease treated 
with ERT. 
Pooled secretions in the pharynx containing saliva and remnants of previously eaten food at FEES 
examination (A), and pharyngeal food residue with penetration and aspiration directly after food intake 
(B).
Swallowing of various textures of food could be examined in four patients, whereas 
swallowing function of two patients who refused to eat during the examination (9 
and 10) was evaluated on the basis of dry swallows. In all patients with insufficient 
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muscle contraction of the pharynx (5/6), residues of food or saliva remained 
present at the valleculae, pharyngeal wall, pyriform sinuses and postcricoid. 
Because patients used no protective reflexes such as coughing or swallowing to 
try to clear the food, it was clear that the sensory reaction of the pharynx was 
impaired (2/6). In three patients, pharyngeal residues resulted in penetration of 
food or saliva (Figure 2b). In two of the six patients, the sensory reaction of the 
larynx was impaired.
Swallowing function was reassessed in four patients, at a median age of 5.3 years 
(age range 2.0‒11.1 years). In three patients it remained stable; in the other 
(Patient 7), it deteriorated, leading to aspiration, premature spillage of food, and 
delayed onset of swallowing. 
Associated clinical outcome measures
At the start of ERT, feeding through a nasogastric tube (NGT) was required by eight 
of the 11 patients. By the end of the study, five patients were completely orally 
fed. Their ages were 2, 3, 6, 6, and 11 years. Two patients have never required NGT 
feeding since ERT began. 
Hearing was impaired in all patients except Patient 9, their hearing deficits ranging 
from 30‒90 dB.21 Three of the four patients whose speech was evaluated already 
had hearing aids at first evaluation. The other patient (7) needed hearing aids later; 
he had a mild hearing loss of 30‒40 dB. 
Five of the six patients whose swallowing function was assessed, learned to walk 
(see Table 1 and supplementary Table 2 for motor outcome), and three of the same 
six patients had recurrent respiratory infections.
DISCuSSIOn
The longest survivors receiving enzyme-replacement therapy for infantile Pompe 
disease are currently 12 years old. It is evident not only that ERT has significantly 
increased survival, but also that it greatly affects these children’s motor performance. 
However, this longer survival has also highlighted previously unrecognized aspects 
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of the disease. Noting that many children had developed facial-muscle weakness 
over time, we investigated the frequency and consequences of facial-muscle 
weakness, speech disorders and dysphagia in long-term survivors. 
In all 11 patients, facial-muscle weakness had developed before the age of 
15 months. When first observed, its main features were poor facial expression, 
sunken cheeks and drooping of the lip. Over the years, all facial muscles seemed to 
become affected. FEES examinations showed weakness of the bulbar muscles, with 
velopharyngeal incompetence and reduced muscular contraction of the pharynx. 
This muscle weakness affected daily functioning in four main ways. 1.) All patients 
had poor facial expression. 2.) Four children developed a bilateral ptosis over time, 
which was so severe in one child that surgical correction was required.22 3.) Speech 
was abnormal, characterized by disordered articulation, hypernasality, and lower 
intelligibility ‒ all typical of velopharyngeal incompetence,23 as suggested earlier by 
Muller et al.10 4.) Swallowing was generally weak and ineffective, leaving residues 
of food around the larynx, with penetration in three out of six patients. As some 
patients lack protective sensory reactions of the pharynx and larynx, aspirations 
and micro-aspirations may easily occur and go unnoticed. In retrospect, we 
suspect that this phenomenon explains the recurrent airway infections in three 
patients in our study. As respiratory muscle weakness can easily lead to respiratory 
insufficiency, such aspirations and aspiration pneumonias may be life threatening. 
As it has proved difficult to wean patients with classic infantile Pompe off the 
ventilator, this is particularly important. Earlier studies have shown that, despite 
treatment with ERT, 50% of classic infantile patients eventually become ventilator 
dependent, and that respiratory insufficiency is the main cause of death.8 
We found no clear relationship between the age at start of ERT and the point at which 
facial-muscle weakness developed, although the severest facial muscle weakness 
was found in patients who started ERT late ‒ at 7 and 8 months of age. ERT seemed 
to reduce feeding difficulties in some patients. During enzyme therapy, nasogastric 
tube feeding could be discontinued in three of eight patients who needed NGT 
at start. At the end of the study, five patients in age ranges from 2‒12 years were 
completely orally fed. Still, four of these patients showed some signs of dysphagia. 
It is noteworthy that the patients who were fed orally were the best performers. 
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Four of these five patients learned to walk and were still walking at the end of 
the study. ERT could not prevent disordered speech, although the severest speech 
problems were observed in those with the poorest motor outcome. 
Our study indicated that parents often underreport signs of choking and 
swallowing difficulties. Given the findings of our study, we attach paramount 
importance to assessments of swallowing function especially in young patients. To 
prevent aspiration and pneumonia, it may be advisable to modify dietary texture, 
or even to discontinue oral feeding in high-risk patients. A low maintenance dose 
of antibiotics may also be helpful. To improve speech, feeding and swallowing 
difficulties as much as possible, we recommend early examination and treatment 
by a speech therapist. In patients with severe hypernasal resonance, however, only 
slight gains on speech can be achieved by behavioral exercises. Other options to 
improve speech include a palatal lift prosthesis, or surgical interventions such as 
pharyngoplasty or a pharyngeal flap.24 But as these may also increase swallowing 
difficulties or cause obstructive sleep apnea, they should be used with caution. 
Their overall effect may also be limited by the residual pharyngeal muscle weakness 
that remains in patients with classic infantile Pompe disease. 
Hearing loss is common in classic infantile Pompe patients, and may also impact 
speech development. We earlier recommended regular auditory tests, and early 
implementation of hearing aids.21 
The exact cause of bulbar muscle weakness is unknown. In infants with Pompe 
disease, it has been shown that glycogen accumulates in the tongue of an untreated 
infant,25 but the effect of ERT on bulbar muscle pathology in these infants has not 
been studied. Only one case report addresses the effect of ERT on bulbar muscle 
pathology in an adult patient with Pompe disease and showed that, 21 months after 
treatment with ERT, residual storage of glycogen remained in the oesophagus.26 
This is in line with results obtained in Pompe knock-out mice, which showed that 
extensive glycogen storage present in bulbar muscles was not completely cleared 
by ERT.27
Together, these findings suggest that residual muscle pathology of the bulbar 
muscles almost certainly plays a major role in the speech and swallowing problems 
described in this study. It cannot be excluded that a role is also played by glycogen 
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storage in the nervous system. Autopsies of untreated patients with classic infantile 
Pompe disease have shown glycogen accumulation in the glial cells of the cortex, 
thalamus, brainstem, and spinal anterior motor horns.28-30 Since ERT cannot cross 
the blood-brain barrier, ERT is unlikely to affect the glycogen storage in the central 
nervous system.31
Certain features of the speech of the children in our study may reflect flaccid 
dysarthria,18,23 a condition caused by damage to the lower motor neurons emerging 
from the brainstem. The lower sensibility of the larynx and pharynx and the delayed 
swallowing seen in some patients might also indicate involvement of the nervous 
system. Further research is required. 
All in all, we could not fully explain why obvious bulbar muscle weakness developed 
even in good responders to ERT with a good motor outcome. If muscle pathology 
indeed underlies the clinical problems, this may imply that bulbar muscles respond 
less to ERT than the muscles of the limbs and trunk. 
Several studies have sought to explain the differential response of muscles to 
ERT. One potential explanation involved variation in response by different muscle-
fiber types. It was shown in mice with Pompe disease that type 2 muscle fibers 
were largely resistant to ERT.32 In humans, type 1 and type 2a muscle fibers both 
responded to enzyme therapy.33 Comparison of skeletal muscles from the limb and 
trunk with bulbar muscles shows that bulbar muscles have a wider repertoire of 
contractile proteins, including developmental and specialized isoforms of myosin 
and hybrid fibers that express two or more isoforms.34-36 This might contribute to a 
lower response to ERT in these muscles. While the results of our studies in knock-
out mice with Pompe disease have not confirmed a smaller response of the bulbar 
muscles, the situation might be different in humans.27
In conclusion, we have shown that facial-muscle weakness, speech disorders and 
dysphagia are prominent in patients with classic infantile Pompe disease who 
survive due to enzyme therapy. Bulbar muscle weakness caused speech disorders, 
severely reducing speech intelligibility, thereby affecting communication and 
social interaction. Early treatment by a speech therapist might help to improve 
articulation and speech. Similarly, because ineffective swallowing puts patients at 
risk for the development of aspiration pneumonias and respiratory insufficiency, 
184
Chapter 9
early and regular swallowing assessments and development of a safe feeding 
plan are recommended. Further research is necessary to elucidate the exact 
pathophysiology. 
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Hearing loss in Pompe disease revisited: 
results from a study of 24 children
C.I. van Capelle, A. Goedegebure, N.C. Homans, H.L.J. Hoeve,  
A.J. Reuser, A.T. van der Ploeg 
J Inherit Metab Dis 2010; 33: 597-602
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ABSTRACT
Little information is available regarding the auditory function in Pompe patients. 
Hearing loss has been reported in classic infantile patients, but it is still unknown 
whether central nervous system involvement interferes with auditory function and 
whether enzyme replacement therapy can improve hearing loss. Auditory function 
has not been studied in children with milder forms of the disease.
We analyzed repetitive auditory brainstem response measurements and pure tone 
audiometry in 24 children with Pompe disease. 
Only one of 13 patients with milder phenotypes showed recurrent conductive 
hearing loss, while ten out of eleven classic infantile patients had sensorineural 
hearing defects. These patients also had a high prevalence of conductive hearing 
loss. Five patients showed evidence of mild retrocochlear pathology, suggestive of 
glycogen accumulation in the central nervous system. Hearing loss persisted during 
therapy in all patients. The results emphasize the need for careful monitoring of 
auditory function in classic infantile Pompe patients, and for early implementation 
of hearing aids to protect speech and language development. 
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InTRODuCTIOn
Hearing deficits have been found in several lysosomal storage disorders including 
Gaucher disease,1-3 Fabry disease,4-7 and Mucopolysaccharidoses.8-10 Previously, we 
have detected hearing loss (HL) in four classic infantile Pompe patients as a new 
finding.11
Pompe disease (also called glycogen storage disease type II or acid maltase 
deficiency) (OMIM 232300) is caused by deficiency of the lysosomal enzyme acid 
alpha-glucosidase (EC 3.2.1.20). This leads to progressive glycogen storage in several 
tissues, among which skeletal and cardiac muscle are the most important.12,13 The 
disease occurs in infants, children, and adults with a variable degree of disease 
severity and progression of muscle weakness. The clinical condition of patients 
with the so-called classic infantile form rapidly deteriorates, leading to death 
before the age of one year.14,15 Patients with other phenotypes show a more slowly 
progressive disease course.16 In the past, no treatment other than supportive care 
was available, but the recent introduction of enzyme replacement therapy has 
changed the prospect for patients.17-21 
Although hearing loss is now increasingly recognized in classic infantile patients, 
the exact prevalence and type of hearing loss has never been investigated in a large 
group of patients, especially not in patients with more slowly progressive forms of 
the disease. 
In this study, we analyzed repetitive auditory brainstem response measurements 
(ABRs) and pure tone audiometries before and after start of enzyme therapy in a 
cohort of 24 children: 11 patients with the classic infantile form and 13 patients 
with a less severe, juvenile form of the disease. 
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PATIEnTS AnD METHODS
 
Subjects
Twenty-four patients, eleven classic infantile and thirteen juvenile patients, were 
enrolled in the present study. All patients were diagnosed with Pompe disease by 
detecting enzyme deficiency in leukocytes or fibroblasts, and by mutation analysis. 
Inclusion criteria for the infantile group were: symptoms of muscle weakness 
within three months after birth, hypertrophic cardiomyopathy at diagnosis, and 
severe GAA (the gene encoding acid a-glucosidase) mutations on both alleles. 
Inclusion criteria for the juvenile group were: all other children with Pompe 
disease having one GAA mutation on one allele, at least one of which not severe. 
Eleven of the juvenile patients and all classic infantile patients were enrolled in 
a prospective study investigating the safety and efficacy of enzyme replacement 
therapy with recombinant human acid a-glucosidase (20‒40 mg/kg). The other 
two juvenile patients were diagnosed pre-symptomatically, and were enrolled in 
an observational study that monitored disease progression in untreated patients. 
Both studies were approved by the Institutional Review Board of the Erasmus 
Medical Center, and all patients and parents gave written informed consent. All 
hearing assessments were performed before start of enzyme therapy and at 
regular intervals thereafter, if applicable.
Hearing assessments
In the juvenile patients, routine pure-tone audiometry was performed. When 
abnormalities were detected, the test was repeated at regular intervals, and 
patients were seen by an ENT (ear, nose and throat) specialist. 
In the classic infantile patient group, auditory brainstem evoked responses, oto-
acoustic emissions, and impedance audiometry were performed before the start of 
treatment and at regular intervals thereafter. An experienced audiologist evaluated 
the test results. 
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Auditory tests
Pure tone audiograms were made with a Madsen OB 822 audiometer (Copenhagen, 
Denmark) in a sound-proof room. Pure-tone threshold testing was performed 
for both air conduction and bone conduction. The average hearing threshold at 
frequencies 500, 1000, 2000 and 4000 Hz was used to classify the type of hearing 
loss (conductive component in case of an air-bone gap >15 dB) and to grade the 
amount of hearing loss according to the WHO definition of hearing impairment.22
Auditory brainstem evoked responses were determined using the Euphra-1 system, 
and a Jaeger-Toennies pre-amplifier. Click stimuli were presented at different levels 
with a repetition rate of 23/s via a TDH 49 headphone. The waveform was analyzed 
by an experienced audiologist, defining peak latencies of waves I (distal cochlear 
part of the VIIIth nerve), III (in between cochlear nucleus and the superior olivary 
complex) and V (between the superior olivary complex and the inferior colliculus). 
The amount of hearing loss was estimated from the detection threshold of peak V. 
The time interval between peaks I, III and V at stimulus level of 90 dB was used to 
identify retrocochlear dysfunction.
To assess cochlear function, transient evoked otoacoustic emissions (OAE) were 
carried out using the ILO288 (Otodynamics, UK). Otoacoustic emissions are 
vibrations presumably produced by the outer hair cells in the cochlea. Presence 
of otoacoustic emissions indicates a normal reponse to auditory stimuli of the 
middle ear, and cochlea. To assess middle ear function, impedance audiometry was 
performed with a standard clinical impedance meter (AT260, Interacoustics, USA). 
An abnormal result indicates middle ear dysfunction. The origin of the hearing 
deficit (conductive, cochlear, retrocochlear) was estimated by the combined 
interpretation of the ABR, otoacoustic emissions, and impedance audiometry. 
Statistical analysis
ABR waveform latencies and inter-peak time intervals were compared to reference 
values obtained in 150 children with normal hearing in the Erasmus MC Sophia 
Children’s hospital, and were expressed as z-scores. A z-score represents the 
number of standard deviations from the mean. Waveform latencies and inter-peak 
time intervals were considered abnormal if the measured value was above a z-score 
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of 1.96. The individual relationship between the different outcome measures and 
treatment time were analyzed using least-squares regression.
All data analyses were performed using SPSS for Windows version 15.
RESuLTS
 
Classic infantile Pompe patients
Hearing loss
Eleven classic infantile Pompe patients were included in the present study. Table 
1 summarizes the clinical features of each of the patients. Table 2 tabulates the 
type of hearing loss found in each individual patient before start of treatment 
and after 1 to 6 years of treatment. Hearing loss was detected immediately after 
birth in some patients. There was no significant correlation between the age of 
the patients at their first hearing test and the severity of hearing loss. Baseline 
measurements were performed before start of enzyme therapy and revealed a 
sensorineural hearing loss in nine of the eleven patients (for details see Table 2). In 
all these patients, latencies of peaks I and V as function of stimulus level suggested 
a cochlear origin of the hearing loss. Absent OAEs with normal middle ear function 
confirmed the cochlear dysfunction in six patients, while abnormal tympanograms 
prohibited a reliable interpretation of the OAE results in two patients. Two patients 
had normal cochlear function but showed evidence of retrocochlear pathology, as 
inter-peak latencies between waves I and V were significantly prolonged. 
Ten patients were followed for a maximum period of six years. One patient died at 
the age of 8 months. During the period that patients received enzyme therapy, the 
sensorineural hearing loss persisted in all with the exception of one patient, who 
had normal hearing at baseline. In addition, variable degrees of conductive hearing 
loss ranging from 15 to 60 dB were repeatedly found in nine patients (Figure 1). 
Insertion of ventilation tubes in two patients did not improve their hearing levels. 
All patients (except patient 8) received hearing aids and/or speech therapy. 
 
Neurological involvement
Waves I, III, and V were identified in all patients. Baseline nerve conduction 
patterns appeared to be close to normal for most of the patients. Inter-peak 
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latency between peak I and peak V (IPLI-V) was prolonged in 3 patients (Table 2A, 
patients 6, 8, and 9). 
During follow-up assessments, IPLI-V remained prolonged in these three patients. 
Two other patients, who both had normal values at baseline, showed prolongation 
of IPLI-V at the age of 1.5 years (patients 3 and 7). One of these patients started 
receiving enzyme therapy in the first month of life, the other at the age of 8 months 
when she was in an end stage of the disease. In both patients, IPLI-V remained 
prolonged during the entire follow-up period. Further examination showed that a 
prolongation of the inter-peak latency was mainly found between peaks III and V. 
Juvenile Pompe patients
Age of the patients at their baseline hearing test ranged from 3 to 16.4 years (mean 
11.4). Age at first symptoms ranged from 6 months to 10 years, and age at diagnosis 
ranged from 0.8 to 11.6 years. Baseline characteristics are presented in Table 3.
Pure-tone audiometry showed conductive hearing losses in patients 2 and 5. No 
hearing deficits were found in the other patients. Patient 2 had a mild unilateral 
conductive hearing loss of 33.3 dB. This patient exhibited mobility problems in 
early childhood, and was diagnosed with Pompe disease at the age of 3.5 years. 
At the age of 6 years, his auditory function was measured for the first time. At 
that moment, the patient was able to walk, and his pulmonary function was 
within normal limits. During follow-up examinations, the conductive hearing loss 
subsided, and test results became normal. 
Patient 5 showed mild bilateral hearing loss during the first assessment in our 
hospital, at the age of 13 years. The patient was diagnosed with Pompe disease at 
the age of 2 years. In the following years, she followed a rapidly progressive disease 
course, became completely wheelchair bound, and was invasively ventilated at the 
age of 6. Severe weakness of the facial muscles caused dysarthria and dysphagia, 
for which she received feeding by percutaneous endoscopic gastroscopy tube. 
There was a medical history of persistent otitis media, for which she had received 
ventilation tubes at the age of 3 years. Additional examinations revealed a recurrent 
bilateral otitis media, and the hearing loss of 35 dB persisted during follow-up 
assessments.
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Table 2. Summary of audiometric results of the 11 classic infantile patients at baseline, 
and after a maximum period of 6 years of enzyme replacement therapy with recombinant 
human alpha-glucosidase
Patient Age Right ear Left ear
EHTTymp OAE I-V III-V EHTTymp OAE I-V III-V
Baseline
1 3 m 30 normal abnormal normal N.A. 60 normal abnormal normal N.A.
2 7 m 70 normal abnormal normal N.A. 90 abnormal abnormal normal N.A.
3 8 m 40 normal abnormal normal N.A. 40 normal abnormal normal N.A.
4 2.5 m 40 abnormal abnormal normal N.A. 60 abnormal abnormal normal N.A.
5 2 m 80 normal abnormal normal N.A. 60 normal abnormal normal N.A.
6 1 m 20 normal normal abnormal2.2 20 normal normal abnormal2.7
7 0.5 m 50 normal abnormal normal N.A. 40 normal abnormal normal N.A.
8 0.1 m 10 normal normal abnormal3.6 10 normal normal abnormal2.5
9 2 m 60 ? ? abnormal3.3 60 normal abnormal normal N.A.
10 2.5 m 40 normal abnormal normal N.A. 40 normal abnormal normal N.A.
11 3.5 m 70 abnormal abnormal normal N.A. 70 abnormal abnormal normal N.A.
After maximum 6 years of enzyme replacement therapy
1 6 y 80 abnormalabnormal normal N.A. 80 abnormalabnormal normal N.A.
2 6 y 70 normal abnormal normal N.A. 70 normal abnormal normal N.A.
3 2 y 60 abnormalabnormal abnormal2.3 80 abnormalabnormal abnormal3.3
4 4 y 80 abnormalabnormal normal N.A. 90 abnormalabnormal normal N.A.
5 4 y 80 normal abnormal normal N.A. 90 abnormalabnormal normal N.A.
6 5 y 40 abnormalabnormal abnormal2.3 50 abnormalabnormal abnormal3.4
7 5 y 70 abnormalabnormal abnormal2.2 50 abnormalabnormal abnormal1.0
8 3 y 20 normal normal abnormal2.3 20 normal normal abnormal2.3
9 3 y 80 abnormalabnormal abnormal2.3 80 abnormalabnormal abnormal2.9
10 1 y 40 abnormalabnormal normal N.A. 40 abnormalabnormal normal N.A.
11 died
m:Months, y:years, EHT estimated hearing threshold (dB HL, decibels hearing level), Tymp:tympanogram 
result, OAE:otoacoustic emission result, I-V:auditory brainstem response inter-peak interval I to V, III-
V:auditory brainstem response inter-peak interval III to V (data are represented by z-scores, >1.96 is 
considered abnormal), N.A. not applicable.
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Table 3. Characteristics of 13 children with Pompe disease, and the amount of hearing loss
Patient Age at 
hearing test 
(years)
Gender 
(M/F)
Motor status a Respiratory 
function a
Hearing loss (dB)a
(right ear) (left ear)
1 13.1 M Ambulant, prox weak Normal nh nh
2 6.0 M Ambulant, prox weak Normal 33.3 cond nh
3 12.7 F Ambulant, prox weak Diminished nh nh
4 11.9 M Partially wheelchair dep. Normal nh nh
5 12.7 F Tetraplegic Invasive 
ventilation
35 cond 35 cond
6 5.2 M Ambulant Normal nh nh
7 3 M Ambulant, prox weak Normal nh nh
8 16 M Ambulant Diminished nh nh
9 13 M Ambulant, prox weak Diminished nh nh
10 9 F Ambulant, prox weak Normal nh nh
11 15.2 M Ambulant, prox weak Diminished, 
BIPAP
nh nh
12 16.4 F Paresis legs, scoliosis Invasive 
ventilation
nh nh
13 9.2 F Partially wheelchair dep. Diminished, 
BIPAP
nh nh
dB:Decibels, nh:normal hearing, cond:conductive hearing loss, prox weak:proximal weakness, BIPAP:bi-
level positive airway pressure. a Before start of enzyme replacement therapy.
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Figure 1. Percentage of auditory brainstem responses (ABR) in which conductive hearing 
losses were found per patient. The number of ABRs performed per patient ranged from 1 
(patient died at 5 months of age) to 18 and was on average 9.
DISCuSSIOn
The present study confirms our previous finding that hearing disorders are a 
major concern in patients with the classic infantile form of Pompe disease.11 
These problems are rarely found in children with milder forms of the disease. The 
reason why hearing loss selectively occurs in classic infantile patients is not fully 
understood, but may be explained by the less severe mutations and higher levels 
of residual alpha-glucosidase activity in juvenile patients. 
The hearing deficits that we detected in ten of eleven classic infantile patients 
ranged from 30 to 90 dB. As reported earlier, cochlear dysfunction was frequently 
found. But we also discovered additional conductive hearing losses in 75% of all 
hearing tests performed (in 90% of the patients). This is suggestive of chronic 
middle ear dysfunction. The etiology of chronic otitis media is multifactorial, and 
includes infectious, allergic, and immunologic factors, resulting in Eustachian tube 
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dysfunction and middle ear effusion.23,24 Our patients did not have clinical evidence 
for allergic or infectious middle ear problems, but we found severe weakness of the 
facial muscles in all classic infantile patients25 (personal communication). The tensor 
veli palatini muscle is the principal muscle involved in opening the Eustachian tube. 
Weakness of this muscle has been reported to cause a pressure drop in the middle 
ear and may very well be the cause of the high incident of the conductive hearing 
loss found in infantile patients with Pompe disease. 
To elucidate whether retrocochlear pathology was present in our classic infantile 
patient group, we studied repetitive ABRs. We found prolongations of inter-peak 
latencies in five patients. The most frequent finding was prolongation of between 
peaks III and V. This is suggestive for pathology of the central part of the auditory 
pathway.
It was anticipated that glycogen storage in the brain and other parts of the central 
nervous system might cause sensorineural hearing loss,11 since glycogen storage 
has been found in nuclei of the brain stem, thalamus, anterior horn cells, and 
neurons of the spinal ganglia. Glycogen storage was also reported to be present 
in several parts of the brain of a patient that died during treatment with enzyme 
therapy. This finding was not unexpected since the intravenously administered 
enzyme cannot pass the blood-brain barrier.26 
Of note, three of the five patients with a prolongations of the inter-peak latencies 
belonged to the best responders to enzyme therapy. They were able to walk and 
had adequate cognitive abilities. Compared to other lysosomal storage disorders, 
like Gaucher type 3, the abnormalities in inter-peak latencies were relatively mild. 
It is therefore suggested that glycogen storage, although undoubtedly present 
in brains of infants with Pompe disease, only minimally interferes with auditory 
functioning. 
Hearing deficits were present shortly after birth. The extent of hearing loss did 
not decrease over time. This suggests the storage of glycogen in the cochlea 
already commences during gestation and that enzyme therapy does not have 
an effect on it. It should be noted, however, that there were variable degrees of 
conductive hearing loss, which interfered with the test results and prevented us 
from estimating the exact degree of sensorineural hearing loss. 
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In conclusion, our data emphasize that hearing problems are a major concern for 
patients with classic infantile Pompe disease, and are only sporadically present 
in children with milder forms of the disease. We therefore advise the monitoring 
of auditory function on a regular basis in infants with the disease, while regular 
examinations of auditory function are not required in older children. Retrocochlear 
pathology may be present, but does not seem to be a major contributor to the 
hearing loss. In addition to the previously reported cochlear hearing loss in infants, 
we found frequent conductive hearing losses in our patients. It is our experience 
that insertion of ventilation tubes does not consistently improve the hearing 
deficit. We therefore recommend early implementations of hearing devices and 
speech therapy, in order to save precious time, especially since the first two years 
of life are most important for speech and language development.27 
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ABSTRACT
Introduction: Cardiorespiratory failure before the age of one year is the main 
cause of death in untreated patients with classic-infantile Pompe disease, an 
inheritable metabolic myopathy with a characteristic progressive hypertrophic 
cardiomyopathy. Since the introduction of enzyme replacement therapy (ERT), 
survival has increased significantly; mainly by reduction of cardiac hypertrophy and 
improvement cardiac function. But it’s insufficiently known whether these effects 
sustain. Therefore the aim of our study was to investigate the long term effects of 
ERT on cardiac parameters and function.
Methods: Fourteen patients who had started ERT between 1999 and 2012 and 
who had been treated for at least 12 months were included in this single-center 
observational study. Cardiac dimensions, cardiac function, and conduction and 
rhythm disturbances were evaluated at baseline and regular intervals thereafter 
using echocardiography, electrocardiography and Holter monitoring. 
Results: The median treatment duration was 4.8 years (range 1.1 to 13.9 years) 
at study end. All patients had an increased left ventricular mass index (LVMI) at 
baseline (median 225 g/m2, range 98 to 599 g/m2). Six patients showed an increase 
of LVMI during the first four weeks of treatment, thereafter LVMI started to reduce. 
Normalization of LVMI was observed in 13 patients after a median follow-up period 
of 38 weeks (range 4 to 724 weeks). In one patient cardiac size never reached normal 
values and in another, after initial LVMI normalization, LVMI started to increase 
again during a period of clinical deterioration leading to invasive ventilation. Both 
patients died at the age of four years. PR-interval was below normal values in five 
patients at baseline and in 9 patients at study end. Six patients showed a delta 
wave pattern on ECG, which resulted in documented periods of SVT in 2 patients 
requiring medication and surgery. 
Conclusion: In the present study it was shown that cardiac improvements were 
maintained over 14 years of treatment. Time to normalization seemed to be 
related to clinical status at baseline. LVMI may deteriorate during treatment in 
patients that show clinical decline and become ventilator dependent The risk 
of tachyarrhythmias deserves attention, particularly in those in whom ERT had 
been initiated relatively late. Based on our results we advise to perform cardiac 
evaluations at regular intervals.
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InTRODuCTIOn
Prior to the introduction of enzyme replacement therapy, cardiorespiratory failure 
was the main cause of death in patients with the classic-infantile form of Pompe 
disease (OMIM 232300), a lysosomal storage disorder caused by deficiency of the 
enzyme acid alpha-glucosidase (EC 3.2.1.20). Progressive accumulation of glycogen 
in different tissues throughout the body, but predominantly in skeletal and cardiac 
muscle, is the hallmark of the disease. Pompe disease presents as a spectrum of 
clinical phenotypes. Complete deficiency of alpha-glucosidase results in the most 
severe “classic-infantile” form. Patients present with a progressive generalized 
myopathy and cardiac hypertrophy. Motor milestones are not achieved and 
patients rarely survive beyond one year of age. Cardiac failure is the major cause 
of death.1-4
Since the introduction of enzyme replacement therapy (ERT) with recombinant 
human alpha-glucosidase (rhGAA), survival has significantly improved, mainly 
by reducing cardiac hypertrophy and improving cardiac function. Nevertheless, 
not all patients respond equally well. Results of ERT on respiratory function and 
muscle strength are more variable.5-8 Now that classic-infantile patients survive far 
beyond their first year of life, it is important to determine whether the previously 
described benign cardiac effects are sustained over a longer period of time.9 The 
present report describes the effect of enzyme replacement therapy on cardiac size, 
cardiac function, and conduction pattern in fourteen classic-infantile patients over 
a maximum period of thirteen years of treatment.
MATERIAL AnD METHODS
This study is part of an ongoing clinical study, investigating safety and efficacy of ERT 
with rhGAA in classic-infantile Pompe patients. Between 1999 and 2012, seventeen 
patients were enrolled and evaluated in our hospital. All patients were diagnosed 
with classic-infantile Pompe disease, confirmed by deficiency of endogenous 
α-glucosidase in fibroblasts <1% of the normal mean, mutation analysis, and the 
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presence of a hypertrophic cardiomyopathy. Since we were mainly interested in 
long-term effects, only patients that received ERT for at least 12 months at the end 
of the study period (December 31st, 2012) were enrolled. Fourteen patients fulfilled 
this criteria. Two were still too young and one died after 3 months of therapy due 
to insufficient response of therapy both on cardiac and other parameters.
Patients received enzyme replacement therapy with rhGAA. The dose ranged from 
20 mg/kg every other week to 40 mg/kg weekly. 
Study design
The study was performed at the Erasmus Medical Center Sophia Children’s Hospital 
Rotterdam, the Netherlands, and was approved by the Institutional Review Board. 
Written informed consent was obtained from parents or legal guardians.
Standardized assessments were performed before the start of ERT and every three 
months thereafter. Cardiac assessments are described below. 
Echocardiography
Conventional echocardiography including trans-thoracic M-Mode and two-
dimensional echocardiography as well as conventional echo-Doppler measurements 
were performed by an experienced sonographer (JP) using a Philips iE33 xMAtrix 
Echocardiography System (Philips Medical Systems, Andover, MA, USA). Recordings 
were performed according to the recommendations of the American Society of 
Echocardiography10 at baseline and every three months thereafter.
The following parameters were documented: end-diastolic left ventricular internal 
cavity dimension in diastole (LVIDd), inter-ventricular septum thickness in diastole 
(IVSd), left ventricular posterior wall thickness in diastole (LVPWd), left and right 
ventricular pre-ejection periods (LVPEP and RVPEP), left and right ventricular 
ejection times (LVET and RVET), and trans-mitral and tricuspid E and A wave peak 
velocities.. These values were compared with normal reference values according 
to Kampmann et al.11 Left ventricular mass index (LVMI) was calculated by the 
Devereux formula and indexed by body surface area.12 Left ventricular hypertrophy 
was considered to be present if the LVMI was above the p95 for age related 
peers.11,13
Cardiac outcome after 13 years of treatment in classic infantile Pompe disease
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Systolic function was examined by calculating the shortening fraction (SF). Values 
between 28–44% were considered normal.14 Diastolic function was assessed by 
examining the E/A ratio by measuring the peak early (E) and late (A) transmitral 
filling velocities with conventional Doppler imaging. An E/A ratio <1 was considered 
abnormal. Relative wall thickness (RWT) was calculated as RWT = ((IVSd + LVPWd)/
LVIDd). A cut-off value of 0.42 has been proposed to divide LV hypertrophy into 
concentric (RWT >0.42) and eccentric hypertrophy (RWT <0.42).14 Cases without LV 
hypertrophy were divided into either normal (RWT <0.42) or concentric remodelling 
(RWT >0.42). 
Electrocardiography
Standardized 12-lead electrocardiograms (ECGs) were made using a Mortara ELI 
350, Mortara instrument inc. Milwaukee, USA. ECGs were obtained for all patients 
at baseline and every three months thereafter to determine PR-interval, QT interval 
corrected for heart rate, LV voltages and rhythm or conduction disturbances. The 
QT interval was measured in lead II, V5, or V6. The corrected QT interval was 
determined by dividing the measured QT interval by the square root of the RR 
interval (Bazett’s formula). LV voltages were calculated by the sum of the R wave 
in lead V6 and the S wave in lead V1. Pediatric reference values were obtained 
from Rijnbeek et al and were corrected for age and heart rate.15 24-hour Holter 
monitoring was performed in a subset of 3 patients. Two investigators examined all 
ECGs and Holter ECGs (CvC, IF).
Statistical analysis
All values obtained by echocardiography were transformed into a Z-score 
calculated as the difference between the measured value and the mean reference 
value divided by the standard deviation from the reference value. Z-scores>2 
were considered abnormal. Variables were summarized using descriptive statistics 
comprising median and range. The Wilcoxon rank signed test was used to evaluate 
differences in cardiac dimensions over time. p-values <0.05 were considered 
statistically significant. Statistical analyses were performed using SPSS version 21.0.
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RESuLTS
Patients
A total of fourteen patients were included. Baseline characteristics of the patients 
are summarized in Table 1. Age at start of treatment ranged from 3 days to 8.3 
months (median age 2.7 months). Duration of ERT treatment ranged from 1.1 to 
13.9 years (median 4.8 years). Two patients died during follow up at the ages of 4.4 
and 4.3 years (patients 3 and 5). At study end eight patients had received ERT for 
more than 4 years (range 4.1 to 13.9 years). 
Concentric left ventricular (LV) hypertrophy was present in all patients at start of 
therapy (Table 1). Two patients had LV outflow tract obstruction, and two other 
patients had accelerated mid-ventricular velocity. Four patients (patients 2, 3, 4 
and 12) experienced symptoms of congestive heart failure. At start of therapy only 
four out of fourteen patients did not receive any cardiac medication (patients 1, 
8, 9 and 11), four patients were treated with diuretics (patient 2, 3, 4 and 14), 
two patients with beta-blockers (6 and 10) and one patient with an ACE-inhibitor 
(patient 7). The remaining three patients received a combination of these drugs. 
The general clinical condition varied between patients at start of treatment. Two 
patients (patient 2 and 4) had profound generalized hypotonia and could hardly lift 
their arms from the surface in supine position and were considered to have end 
stage disease. The other patients could all move their limbs against gravity to some 
extent. Nine of 14 patients scored below p5 for motor development as assessed 
by the Alberta Infant Motor Scale (AIMS, patients 2, 3, 4, 6, 10, 11, 12, 13 and 
14). Four patients required oxygen via nasal prongs (patients 4, 7, 8 and 13). One 
became ventilator-dependent before start of treatment (patient 2). At the study 
end two patients had died and three others were ventilator dependent.
Echocardiography
At baseline, LVMI was profoundly elevated in all patients (median 225 g/m2, 
range 98 to 599 g/m2) (Table 1). There was a good response to therapy (Fig 1). 
However, during the first four weeks of treatment cardiac size initially increased 
in six patients. Median increase in LVMI was 79.0 g/ m2 (range 12.4–149 g/m2) in 
Cardiac outcome after 13 years of treatment in classic infantile Pompe disease
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these patients. Thereafter LVMI started to decline also in these patients. At final 
assessment the median LVMI was 70.4 g/ m2 (range 48.2 to 119.6 g/m2). 
In thirteen patients cardiac dimensions normalized (Table 2). Median time to 
normalization was 38 weeks (range 4 to 724 weeks). One patient never reached 
normal values and died at the age of 4.3 years. In another patient normal LVMI 
values were initially reached, but thereafter a significant increase in cardiac size 
and decline in motor function was observed after he became ventilator dependent 
following a severe pneumonia at the age of two. This patient eventually died at the 
age of 4.4 years due to respiratory failure. 
For two patients (patients 2 and 4) it took 13 years of treatment before LVMI was 
within normal limits.
Systolic and Diastolic function
Four patients showed a decreased SF (patients 3, 4, 12, 14), in the other ten 
patients systolic function was normal at baseline (Table 2). During treatment SF 
normalized in all. 
At baseline, diastolic function as measured by E/A ratio was normal in all patients 
(Table 2). At follow-up, two patients showed abnormalities in diastolic function. 
Patient 3 showed a decline of diastolic function after her clinical condition 
deteriorated. Patient 2, who started ERT at the age of 7.2 months, had abnormal 
E/A ratios in most measurements (median 1.20, range 0.63 to 1.90), with the last 
MV E/A ratio being 1.70. E/A ratios are shown in Table 2. 
Electrocardiography
During follow-up a total of 118 ambulant ECGs from 14 patients and 5 Holter ECGs 
from 3 patients were evaluated. At baseline, 9 patients had a normal PR interval 
and 5 patients had a shortened PR interval (median PR interval 80 ms, range 60 
to 100 ms) (Table 2). At study end, the PR interval was within normal limits in 5 
patients: in 2 patients the PR interval remained normal (patients 5 and 6), in 3 
other patients the PR interval normalized (patient 9, 11 and 12), and in 7 patients 
the PR interval shortened after having a normal interval at baseline (patients 1, 
4, 7, 8, 10, 13 and 14) (Table 2). The median PR-interval remained below normal 
values at 80 ms (range 50 to 250 ms). 
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Figure 1. Left Ventricular Mass Index (LVMI) z-score during a maximum period of 13.9 years 
of enzyme replacement therapy (ERT).
LV voltages were substantially increased at baseline (median 4.8 mV, range 2.2 to 
8.6 mV) and showed a significant reduction after start of ERT (median 3.9 mV, range 
1.7 to 6.2 mV, p=0.023). All patients showed repolarisation disturbances (strain) 
at baseline. These disturbances normalized in all patients except patient 2. Four 
patients (patient 1, 9, 10 and 13) had an incomplete right bundle branch block. 
At baseline, the corrected QT-interval was normal in 10 patients (median: 390 
ms, range 340 to 430 ms). In 4 patients the corrected QT-interval was shortened 
(patients 1,4, 13 and 14). At study end corrected QT-interval was normal in 10 
patients, shortened in 3 patients (patients 4, 5 and 11) and increased in 1 patient 
(patient 2 had an increase to 520 ms). 
Delta waves, suggestive for Wolff-Parkinson-White (WPW) pattern, were found 
in six patients (patient 2, 4, 6, 7, 9 and 10). In the years after start of therapy, 
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arrhythmias were documented in two patients (patients 2 and 4) as multiple 
episodes of supraventricular tachycardia. The tachyarrhythmias were successfully 
converted by adenosine and rhythm control was established by Sotalol in patient 
2 and by Atenolol and Flecainide in patient 4. Because of frequent relapses patient 
4 underwent ablation of three aberrant pathways. The most recent Holter ECG 
of patient 2 revealed severe sinus bradycardia with a minimum of 35 per minute. 
More than 6000 pauses were recorded over 24 hours, with a maximum duration of 
3.5 seconds. Because of the poor clinical condition of the patient the decision was 
made to refrain from implanting a pacemaker. 
DISCuSSIOn 
Now that patients with classic-infantile Pompe disease treated with ERT survive 
far beyond their first year of life, an important question is whether the short-term 
positive effects on cardiac structure and function, closely related to prolonged 
survival and decreased morbidity, sustain.6,8,16,17 The present study in 14 patients 
with classic-infantile Pompe disease confirms that enzyme replacement therapy 
(ERT) significantly reduces left ventricular mass index and improves cardiac 
function. Moreover, these beneficial effects were maintained over at least 13.9 
years. This is in line with the results of a recently published study in 11 patients 
with classic-infantile Pompe disease followed for a maximum period of 12 years9 
with the exception that LVMI in two of our patients did not remain within normal 
limits. These patients first showed improvements of cardiac size but after they 
clinically deteriorated and became ventilator dependent, LVMI worsened. Both 
patients died at the age of 4 years. Two other patients, who did not reach normal 
values of LVMI until 13 years of treatment, were both in an end-stage of the disease 
when treatment was initiated (paresis of the arms and paralyzed legs, ventilator-
dependent). Both had recurrent SVTs, and patient 2 showed episodes of severe 
bradycardia on Holter monitoring and had an abnormal diastolic function. These 
results may suggest that a relation exists between LVMI and clinical status, though 
Cardiac outcome after 13 years of treatment in classic infantile Pompe disease
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other previously published studies did not find an association between motor 
outcome and LVMI.7,18,19 Whether the deterioration of LVMI despite ERT in the 
previously described patients was influenced by a limited effect of the treatment 
itself, or by patient related factors such as immune responses, remains unknown. 
Both patients did not have higher peak antibody titers than the other patients.20 Of 
note, these patients were the only CRIM negative patients in this study. 
Despite ERT, rhythm disturbances remained present throughout treatment. The 
short PR interval that is characteristic for Pompe disease and is also found in other 
storage diseases such as Fabry disease, Danon disease and patients with PRKAG2 
mutations, was below normal values in 60% of our patients at study end.21,22 This 
is in contrast to a study by Ansong et al., in which 19 Pompe patients showed 
normalization of PR interval during treatment.23 The mechanism that causes the 
short PR interval is not completely understood; an interesting hypothesis was raised 
by Bharati et al. in 1982, who correlated electrophysiological abnormalities to 
pathological post mortem findings in the conduction system of untreated patients 
with classic-infantile Pompe disease. They found marked glycogen infiltration, 
vacuolization and an increase in cell size of the Purkinje cells and suggested that 
the short PR interval could reflect enhanced conduction caused by de deposition 
of glycogen.24 The electrophysiological finding that the atrium-His interval was 
shortened and the His-ventricular interval was normal, while enlarged cells filled 
with glycogen were found in all parts of the conduction system including the bundle 
of His, challenges this hypothesis. A more applicable theory was reported by Arad 
et al. They studied a mouse model with a human PRKAG2 mutation, which leads 
to excessive glycogen accumulation in myocytes. They observed that the annulus 
fibrosis was disrupted by glycogen-filled myocytes, allowing atrioventricular 
activation by bypassing the AV node. 25,26 A non- reversible disruption of the annulus 
fibrosis might explain that the PR interval remains shortened despite treatment, 
as found in most of the patients presented in this study. It might also explain the 
WPW pattern that is often found in classic-infantile Pompe disease, including 6 of 
14 patients in the present study. Yet, neither of the two hypotheses can completely 
explain the variability of the PR interval between the patients in our study. 
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The fact that two of our patients showed recurrent supraventricular tachyarrhythmia 
(SVT) despite ERT should be noted. Several publications report that arrhythmias, 
including fatal arrhythmia, may occur in patients with classic-infantile Pompe 
disease, even though ERT improves cardiac size and function.23,27-31 While Wang 
et al described a correlation between arrhythmias and elevated LVMI, Ansong et 
al did not. In our study both patients with recurrent SVTs were already severely 
affected at start of treatment. Both became ventilator dependent within their first 
year of life and are currently tetraplegic. Cardiac hypertrophy reduced, but the 
heart did not regain a normal size during most of the study period. 
In the present study we did not find diastolic dysfunction at baseline, although 
pseudo-normalization of E/A ratio cannot be ruled out since at the start of the 
study measurement of mitral annular motion by TDI was not performed regularly. 
A recently published study by Chen et al, which followed 9 patients with classic-
infantile Pompe disease for a maximum period of 3.2 years, found impaired global 
LV function and synchronicity with a close relationship between LVMI and diastolic 
dyssynchrony at baseline.32 Since TDI appears to be more sensitive in detecting 
abnormalities in systolic and diastolic function than conventional echocardiography, 
we added this measurement to our follow-up protocol. The 9 patients described by 
Chen et al. showed normalization of LV function after start of treatment, while in 
the present study two patients had abnormal diastolic functioning after 4 and 13 
years of treatment respectively. The relatively young age at start of treatment in 
the patient group followed by Chen et al. and the shorter follow-up period of these 
patients may explain the differences between the study results. To detect early 
signs of deterioration of cardiac function, TDI measurements may play a pivotal 
role.
Since the introduction of ERT many advances have been made in the treatment of 
Pompe disease. The present study shows that cardiac improvements are maintained 
over 14 years of treatment. In conclusion, LVMI reached normal values in all but one 
patient. Time to normalization seemed to be related to clinical status at baseline. 
LVMI may deteriorate during treatment in patients that show clinical decline and 
become ventilator dependent. On the ECG, PR interval remained shortened in 60% 
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of the patients whereas 6 of the 14 patients had a delta wave. A delta wave was 
also found in mildly affected patients, even in one of the best responders to ERT. 
The possible occurrence of cardiac arrhythmias remain a threat to these patients, 
particularly in those in whom ERT has been initiated relatively late. Cardiac follow-
up, including regular ECGs and Holter assessment, would therefore be advised. 
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ABSTRACT
Pompe disease is a lysosomal storage disorder characterized by progressive muscle 
weakness. With the emergence of new treatment options, psychometrically robust 
outcome measures are needed to monitor patients’ clinical status. We constructed 
a motor function test that is easy and quick to use. The Quick Motor Function Test 
(QMFT) was constructed on the basis of the clinical expertise of several physicians 
involved in the care of Pompe patients; the Gross Motor Function Measure and 
the IPA/Erasmus MC Pompe survey. The test comprises 16 items. Validity and 
test reliability were determined in a cohort of 91 Pompe patients (5 to 76 years 
of age). In addition, responsiveness of the scale to changes in clinical condition 
over time was examined in a subgroup of 18 patients receiving treatment and 
23 untreated patients. Interrater and intrarater reliabilities were good (intraclass 
correlation coefficients: 0.78 to 0.98 and 0.76 to 0.98). The test correlated strongly 
with proximal muscle strength assessed by hand held dynamometry and manual 
muscle testing (ρ=0.81, ρ=0.89), and showed significant differences between 
patient groups with different disease severities. A clinical-empirical exploration to 
assess responsiveness showed promising results, albeit it should be repeated in a 
larger group of patients. In conclusion, the Quick Motor Function Test can reliably 
rate clinical severity and motor function in children and adults with Pompe disease.
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InTRODuCTIOn
Pompe disease (OMIM #232300) is a rare neuromuscular disorder caused by 
deficiency of the lysosomal enzyme acid α-glucosidase. This deficiency induces 
glycogen to accumulate in the lysosomes of many tissues, albeit mainly in skeletal 
muscle. Its major clinical manifestation is progressive muscle weakness, which 
eventually impairs motor and respiratory function.1,2 The disease manifests 
across a spectrum of severity, and affects infants, children and adults.3-5 Patients 
with the classic infantile form present with severe generalized hypotonia and a 
hypertrophic cardiomyopathy shortly after birth; the disease progresses rapidly, 
and the patients usually die in their first year of life from cardiorespiratory failure. 
Childhood, juvenile, and adult forms of the disease are characterized by a more 
slowly progressive proximal myopathy. Respiratory muscles are affected as well. In 
these patients, onset of symptoms, disease severity and rate of disease progression 
varies. Cardiomyopathy rarely occurs. The majority of patients eventually become 
wheelchair and respirator dependent.6-8
In our centre we follow more than 100 children and adults with Pompe disease. The 
disease severity of these patients shows large differences. Some are ambulant and 
others completely wheelchair dependent. Currently there is no functional scale 
that has been standardized for Pompe disease and is capable to rate differences 
in muscle function sufficiently. This has become even more important since 
marketing approval was given to recombinant human alpha-glucosidase as enzyme 
replacement therapy for Pompe disease.
The aim of the present study was to construct a functional motor scale specific 
for Pompe disease that is easy to apply and sufficiently sensitive to assess disease 
severity and to detect clinically important changes over time, so that it can be used 
both in clinical practice to monitor disease progression and to evaluate therapeutic 
effectiveness. For this purpose, we constructed and psychometrically tested the 
scale in a large cohort of children and adults with Pompe disease.
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METHODS
Construction of the test Motor function items that were difficult specifically for 
patients with Pompe disease were derived from the clinical expertise of several 
neurologists, paediatricians, and physical therapists involved in the treatment and 
care of Pompe patients; the Gross Motor Function Measure,9 an 88-item motor 
function test that has been validated for Cerebral Palsy; and the IPA/Erasmus MC 
Pompe survey, an international questionnaire study performed in over 300 Pompe 
patients.10,11
The final version of the test consisted of 16 items and was named the Quick Motor 
Function Test (Appendix B). Administering this test takes approximately 10 to 
15 minutes. An evaluator observes the performance of a patient and scores the 
items separately on a 5-point ordinal scale (ranging from 0 to 4). If items can be 
performed on both left and right extremities, the right side is taken. A total score 
is obtained by adding the scores of all items. The total score ranges between 0 and 
64 points. 
Psychometric testing
Subjects
A total of 91 child and adult patients with Pompe disease who had attended the 
Erasmus Medical Center between February 2005 and February 2008 were included 
in the present study. All patients were diagnosed with Pompe disease through the 
measurement of acid α-glucosidase activity in cultured fibroblasts or leukocytes, 
and mutation analysis. They were enrolled in either one of two observational 
studies. One study investigated the rate of disease progression in untreated 
patients; the other study monitored the disease course after start of treatment 
with recombinant human alpha-glucosidase. Both studies were approved by the 
Institutional Review Board of the Erasmus MC. All patients (and/or parents if 
necessary) gave signed informed consent.
The Quick Motor Function Test
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Design
In both studies, the newly constructed Quick Motor Function Test (QMFT) was part 
of a standardized follow-up protocol. The following assessments were performed 
at baseline and every 3 months thereafter: hand-held dynamometry (HHD),12,13 
manual muscle testing (MMT),14 pulmonary function testing in sitting and supine 
position,15 and the QMFT. A physical examination was performed at every visit.
The QMFT was administered by two pediatricians and two neurologists. Beforehand, 
all physicians were trained by testing at least five patients following standardized 
instructions, while being observed by one of the senior physicians who originally 
developed the test. The test was performed in a separate examination room and 
all assessments were videotaped. The scores were recorded on an QMFT scoring 
sheet.
Reliability
The internal consistency16 was measured by Cronbach’s α. To estimate intrarater 
reliability,17 three evaluators were shown the videotapes of the baseline 
assessments of 20 of their patients more than one year after the assessments and 
were asked to rescore the QMFT. The patients were randomly selected and the 
evaluators were blinded for their initial scoring.
To measure the interrater reliability,17 videotapes of assessments from 60 randomly 
selected patients were scored by all four evaluators.
Test-retest reliability17 was assessed in 24 patients. As we assumed that little change 
in functional performance had occurred in this period of time, each patient was 
evaluated at baseline and approximately three months thereafter. The evaluators 
had no access to their initial scoring.
Validity
Validity is defined as the extent to which an instrument measures the concept it 
is intended to measure.17 If no gold standard exists to compare the instrument, 
criterion validity16,18 may be assessed. Since Pompe disease predominantly presents 
as a proximal myopathy, we examined whether the QMFT would correlate with 
other tests that are used to measure proximal muscle weakness. For this purpose, 
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the strength of proximal muscle groups as assessed by both manual muscle 
testing14 and hand held dynamometry12,13 were compared with the QMFT score. The 
following proximal muscle groups were tested: neck flexors, shoulder abductors, 
elbow flexors, elbow extensors, hip flexors, hip abductors, knee extensors, and 
knee flexors. To demonstrate that the QMFT score correlated less well with the 
strength of other muscles, the following muscle groups were tested and compared 
with the QMFT: neck extensors, wrist extensors, wrist flexors, foot dorsal flexors, 
and foot plantar flexors. Finally, differential validity was assessed by comparing 
the QMFT scores of patients with different severities of disease. To this end, the 
patients were classified into three groups based on their ability to walk: patients 
who were completely ambulant, patients who were able to walk with aids, and 
patients who were completely wheelchair bound.
Responsiveness
To assess the responsiveness of the QMFT, a clinical-empirical exploration was 
performed. This analysis included a sub-sample of 18 patients who had been 
treated with recombinant human α-glucosidase for more than one year, and also 
a sub-sample of 23 untreated patients who were followed for more than one year. 
As no gold standard exists, several strategies for assessing responsiveness have 
been suggested.19-21 We therefore used three different methods to explore the 
responsiveness of the QMFT.
First, we compared the change in score at 12 months follow-up between the 
untreated and the treated group. Second, we calculated sensitivity to change using 
the standardized response mean,21,22 an effect size statistic that is equal to the 
mean of the change in score of treated patients divided by the standard deviation 
of the change score. Third, two physicians were asked to judge whether the motor 
function of individual patients in the treated group had to their opinion improved, 
remained stable, or deteriorated after 12 months of treatment.20,23 These physicians 
were involved in the care of either children or adults with Pompe disease but had 
not participated in the construction and administration of the QMFT.
The Quick Motor Function Test
231
12
Statistical analysis
All continuous variables are described as mean ± standard deviation, or as median 
and range; categorical data are presented as percentages. Internal consistency of 
the test was measured using Cronbach’s α. A Cronbach’s α>0.80 was considered 
good. Intrarater reliability, interrater reliability, and test-retest reliability of the 
test and the separate items were determined by calculating intraclass correlation 
coefficient (ICC) with a random effect ANOVA model. An ICC value of less than 
0.40 was considered poor; an ICC value between 0.40 and 0.80 was considered fair 
and an ICC value greater than 0.80 was considered excellent. Pearson correlation 
coefficients were used to determine criterion validity; Spearman rank correlation 
coefficients were used in case of non-normal distributions. For differential validity, 
group differences were analyzed by one-way analysis of variance followed by a 
Bonferroni post hoc correction for multiple testing. P-values <0.05 (two-tailed) 
were considered statistically significant.
Responsiveness was investigated by calculating the standardized response mean. 
A score between 0.50 and 0.80 was considered moderate, and a score greater 
than 0.80 represents high responsiveness.22 A Mann-Whitney test was used to 
test differences in QMFT scores between the treated patients and the untreated 
patients. A ROC curve was made by plotting the true-positive rate (sensitivity) 
against the false-positive rate (1-specificity). The area under the curve represents 
the ability of the test to correctly discriminate between improved and non-
improved patients. This area ranges from 0.5 (no discriminating ability) to 1.0 
(perfect discriminating ability).
Statistical analysis was performed using SPSS version 15.0.
RESuLTS
Study population
Clinical characteristics of the 91 patients enrolled in the study are shown in Table 1. 
Nineteen patients were younger than 18 years. The mean QMFT score at baseline 
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assessment was 36.9±16.6 (median 38.5, range 3 to 64), on a possible score range 
from 0 to 64.
Table 1. Clinical characteristics of the 91 study patients
Sex (m/f) 52/39
Age (median) 46.3 years (range 5–76 years)
Age groups Number of patients
5‒20 years 19
21–40 years 17
41–60 years 36
61–80 years 19
Motor status % of patients
Wheelchair bound 23
Using assistive devices 18
Fully ambulant 59
Respiratory status % of patients
Ventilation use 29.7
No ventilation 70.3
Reliability
The internal consistency of the QMFT was excellent: Cronbach’s α was 0.94. There 
were no substantial floor and ceiling effects: none of the patients reached the 
lowest possible score, and only two of the patients reached the highest possible 
score of 64. Both patients were diagnosed presymptomatically.
The intraclass correlation coefficient for intrarater reliability was 0.95 for the total 
scale. The ICCs for the separate items of the scale ranged from 0.78 to 0.98. The 
intraclass correlation coefficient for interrater reliability was 0.91 for the total test. 
The ICCs for the separate items of the scale ranged from 0.76 to 0.98.
The intraclass correlation coefficient for test-retest reliability was 0.98 for the total 
test. The ICCs for the separate items of the scale ranged from 0.84 to 1.00.
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Validity
The total QMFT score correlated strongly with the strength sum scores of proximal 
muscle groups assessed by MMT and HHD (ρ (MMT)=0.89 (p<0.001), ρ (HHD)=0.81, 
(p<0.01)). In sharp contrast, much lower correlations were found between the 
QMFT and strength sum scores of other muscle groups (ρ (MMT)=0.05 (p=0.33), 
ρ (HHD)=0.33 (p<0.01)) (Figure 1).
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Figure 1. Relationship of the QMFT score to manual muscle testing: (A) sumscore of proximal 
muscle groups; (B) sumscore of other muscle groups.
Differential validity was supported by significant differences between the three 
groups with different severities of disease (F (2,84)=66.29, p<0.001). Mean QMFT 
scores significantly decreased with the ability to walk: scores were highest in the 
group that was fully ambulant (47.1±10.7, p<0.01), followed by those for patients 
who were able to walk with aids (32.4± 11.0, p<0.01), and those for patients who 
were completely wheelchair bound (16.6±10.6, p<0.01) (Figure 2).
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Figure 2. Mean scores (95% CI) on the Quick Motor Function Test of the patients related to 
three grades of disease severity.
Responsiveness
Responsiveness was tested in 41 patients (18 treated; 23 untreated). Median age 
of the 18 patients that received recombinant human alpha-glucosidase was 51.5 
years (range 5 to 76 years). Eight of these patients were wheelchair bound, and ten 
patients were dependent on ventilation. Median age of the 23 untreated patients 
was 52.1 years (range 34 to 72 years). Two patients were wheelchair bound, and 
three used ventilation.
The QMFT scores of the treated patients (median change 4.15) showed a significant 
difference over one year period compared to the QMFT scores of the untreated 
patients (median change 0), (p<0.01). The standardized response mean was high 
(0.81). Figure 3 shows the ROC curve of the Quick Motor Function Test with an area 
under the curve of 0.88 (p<0.05).
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Figure 3. Receiver operating characteristic (ROC) curve to determine the responsiveness 
of the Quick Motor Function Test (QMFT), with clinical judgment as the external factor. 
Sensitivity was defined by dividing the number of patients, who had been identified by the 
QMFT to have changed, by the number of patients who had truly undergone change as based 
on the judgment of two physicians. Specificity was defined as the number of patients who 
had been identified by the QMFT to not have changed, divided by the number of patients 
who had not changed, based on the judgment of the same physicians.
DISCuSSIOn
This study shows that the Quick Motor Function Test is a reliable and valid test 
for assessing motor function in patients with Pompe disease. It is the first muscle 
function test designed and validated specifically for Pompe patients. The test had 
good psychometric properties, including good internal consistency, and good 
intrarater and interrater reliabilities over the entire test and the separate items. 
The QMFT score strongly correlated with proximal muscle strength as measured 
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by HHD and MMT, and significantly differentiated between patients with different 
levels of mobility. The test was evaluated in patients between 5 and 76 years of 
age, and was easy and quick to administer.
According to the World Health Organization, assessment of health should have 
a multi-dimensional approach. The International Classification of Functioning, 
Disability and Health (ICF)24 provides such an interdisciplinary framework and 
measures consequences of disease in three domains: impairments of body functions 
and body structures, activity limitations (individual level), and participation 
restrictions (societal level).
In Pompe disease, the approach towards evaluating disease severity and effect 
of treatment has become increasingly multi-dimensional over the past years. 
Measurement tools have been designed and validated for their use in Pompe 
patients. Currently, a battery of tests is used in the long-term follow-up of Pompe 
patients. For example, muscle strength, pulmonary function tests, echocardiography, 
timed tests and the 6-minute walk test are used to evaluate disease consequences 
and effect of treatment on the level of body functions and body structures. The 
Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI), SF-36, and the 
Rotterdam Handicap Scale are used to assess the level of participation restrictions 
and quality of life. However, a validated tool to measure activity limitations on an 
individual level is currently lacking.
In clinical practice, muscle strength tests have often been applied to assess muscle 
function. However, although closely related, muscle strength and muscle function 
represent two different entities of the muscle system, and correspond to different 
levels of the ICF.24 Both parameters should therefore be evaluated separately by 
valid and reliable assessment tools.
In a recent placebo-controlled clinical trial in 90 juvenile and adult patients with 
Pompe disease, primary outcome measures were the 6 minute walk test (distance 
walked in 6 minutes), and Forced Vital Capacity in seated position.25 Muscle 
function was not assessed, because a reliable motor function test validated for 
Pompe disease did not exist. Although it would have been possible to use scales 
that were designed for other neuromuscular disorders9,26-29 or a composite disease 
severity score that covers various domains of the ICF, as developed by Lue et al. for 
Duchenne Muscular Dystrophy,30 none of these scales were validated for Pompe 
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disease. Some were designed for children, while Pompe disease affects all age 
groups. Our study demonstrates that the QMFT can be used in both children and 
adults, with different levels of disease severity.
Another quality of the QMFT is that it is easy and quick to perform. The test takes 
approximately 15 minutes, does not require specialized equipment, and can be 
performed by a physician in a clinical setting. As opposed to other scales, that 
frequently need to be performed by a physical therapist. It is a practical tool that 
can be used in all patients including those who are confined to a wheelchair or 
dependent on artificial ventilation. The overall responsiveness of the QMFT appears 
to be good: the test accurately detected change when it had occurred and remained 
stable when no change had occurred. It also discriminated between varying levels 
of disease. This indicates that the QMFT can serve as a tool to estimate disease 
severity, but also as a longitudinal assessment tool to detect changes in motor 
function over time. This is useful, as the emergence of new treatment modalities 
such as enzyme replacement therapy and possibly chaperone therapy will make 
the (long-term) evaluation of therapeutic effects essential.
Four issues need further attention. First, while responsiveness to change, which 
was assessed in a subgroup of 18 treated and 23 untreated patients, showed 
promising results, it is recommended to perform a large scale empirical study. 
The current study was insufficient to demonstrate whether the changes observed 
over time were related to enzyme replacement therapy or not. Second, the test 
was validated for patients between 5 and 76 years of age. In the youngest and 
oldest patients, motor development and age-related motor limitation might have 
interfered with the test results. Therefore, reference values for age should be 
obtained. Third, to ensure tester reliability we recommend annual recertification 
of the physicians who perform the QMFT. Fourth, the present study validated the 
QMFT in Pompe patients, but the test may also be useful for other neuromuscular 
disorders, especially those with proximal muscle weakness.
In conclusion, this study shows that the Quick Motor Function Test has good 
psychometric properties and excellent clinical utility. Our findings indicate that this 
test can be used to assess motor function and response to treatment in children 
and adults with different levels of disease severity. The applicability of the test for 
other neuromuscular disorders deserves further investigation.
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Shortly after J.C. Pompe’s thesis Cardiomegalia glycogenica was published in 
1936,1 G.O.E. Lignac, a professor of Pathology, wrote a critique in the Nederlands 
Tijdschrift voor Geneeskunde wherein he stated that Dr. Pompe clearly defined in 
his thesis what was known till then about this disease, but that he was even more 
specific on what was still unknown 2. At that time both Lignac and Pompe could not 
have foreseen that more than 1500 publications would follow about the ins and 
outs of ‘Pompe disease’ over the next 80 years or so. Even at present, old questions 
remain and new have arisen since the introduction of enzyme replacement therapy. 
This thesis tries to answer some of these questions as it 1) describes the clinical 
spectrum of children with non-classic forms of Pompe disease and compares these 
children with adult Pompe patients; 2) evaluates the effect of enzyme-replacement 
therapy in these children; 3) investigates the long-term outcome of patients with 
classic-infantile Pompe disease treated with ERT and compares the response of 
children with classic and non-classic forms of Pompe disease; 4) introduces a new 
measurement scale to better assess the motor function of patients with Pompe 
disease. 
This chapter evaluates the main findings and discusses their significance in the 
context of previously published studies. Recommendations for clinical practice 
as well as suggestions for future research are presented in the format of final 
conclusions.
MAIn FInDInGS
1. Children with non-classic forms of Pompe disease
Presentation and clinical features 
Pompe disease is regarded as a broad spectrum of clinical phenotypes, with a 
wide range in age of onset and clinical progression.3,4 Distinct clinical subtypes 
are not clearly defined with the exception of classic-infantile Pompe disease.5 
Disease severity appears not to be related to the actual age of the patient, but to 
the disease duration counting from the onset of symptoms. Though this holds in 
general, a subgroup of patients diagnosed under the age of 15 years has a rapid 
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disease progression and becomes wheelchair bound and/or respiratory assisted 
before adulthood.6 
Our cross-sectional study including 31 affected children ranging in age from 0.1 
till 17.3 years, all with non-classic forms of Pompe disease, (Chapter 2) confirms 
these findings. The clinical severity varied profoundly in this patient group: five 
of the thirty-one patients were symptom-free, seven patients had become 
wheelchair dependent during childhood, six patients had started using a ventilator 
and two patients had died of respiratory failure at the age of 6 and 10 years. In 
over 50% of children difficulties were observed with standing up from supine 
position and flexing the neck in supine position, and 47%‒50% had an abnormally 
low Forced Vital Capacity (FVC) in sitting position versus 59% of the patients in 
supine position (Chapter 2 and 3). The c.-32-13T>G/’null’ genotype was the most 
prevalent genotype amongst these 31 children, whereby ‘null’ stands for any GAA 
mutation leading to total loss of acid α-glucosidase activity. It is the most common 
pathogenic GAA genotype in the Netherlands (95% of all adult patients and 68% 
of all children with less progressive forms of Pompe disease). Some children with 
the c.-32-13T>G/null genotype had a rapid deterioration of muscle and respiratory 
function while others presented a very slowly progressive disease, which adds to 
the previous findings that this genotype is associated with a broad spectrum of 
phenotypes 7,8. The clinical variation among children with other GAA genotypes 
was also substantial. Overall, children with these other genotypes were more 
severely affected than those with the common c.-32-13T>G/null genotype.
These results underline that Pompe disease is a true clinical spectrum and emphasize 
that the disease may already cause a significant burden of disease in childhood. 
In our group of 31 patients, 10 children stood out because of their rapid disease 
progression, similarly as a group of patients previously described by Hagemans 
et al.6 Two of our 10 children had a cardiomyopathy and actually conform to the 
definition of ‘atypical infantile variant of Pompe disease’ as introduced by Slonim 
et al.9 In these atypical patients a similar age at onset of symptoms was found as in 
classic-infantile Pompe disease, but the survival was well beyond the first year of 
life, and the degree of hypertrophic cardiomyopathy was less severe.
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To our surprise, we found the majority (89%) of affected children with the 
c.-32-13T>G/null genotype to be male (Chapter 2), as if the gender would somehow 
contribute to the phenotype. In addition, pulmonary function appeared to be more 
affected in males than in females (Chapter 3). In another study, Van der Beek et 
al found that more men than women had bulbar muscle involvement and that the 
shoulder-girdle muscles were more severely affected in males than in females.10 A 
study comparing the phenotypes of siblings with Pompe disease also revealed that 
males are more severely affected than females.11 Such a gender difference had not 
been previously described. Since Pompe disease inherits as an autosomal recessive 
trait, there is no immediate explanation why males would present symptoms 
earlier than females or would be more severely affected than females other than 
that gender related factors play a role in the clinical expression of Pompe disease. 
Effects of ERT 
Since the first three patients with non-classic forms of Pompe disease, then 11, 
16 and 32 years old, started to be treated with recombinant human α-glucosidase 
from rabbit milk in 1999,12 more than 20 clinical studies have been published 
describing the effects of ERT in these types of patients.13 Three of these studies are 
incorporated in this thesis (Chapter 5, 6, 7).
The most extensive study and the only placebo-controlled trial (LOTS) ever 
performed in Pompe disease is described in Chapter 7. The average age of the 
patients in this study was 44.4 years. All but three patients in this study were adults, 
while the youngest patient was 10 years old when she entered into the trial. This 
study named LOTS showed for the first time that ERT had a significant positive effect 
on distance walked in six minutes time and on pulmonary function as measured 
by FVC. A recently published follow-up study reported that positive effects were 
maintained over a total period of 104 weeks,14 whereas the disease is relentlessly 
progressive if left untreated. For example, the natural history of Pompe disease in 
adults teaches that approximately 50% of untreated patients become wheelchair 
bound or ventilator dependent within 10‒15 years after diagnosis.6 Furthermore, 
a recent observational study in 268 adults with Pompe disease has shown that 
untreated patients have a higher mortality rate than the general population.15 For 
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these reasons, stabilization of disease progression should be considered a positive 
outcome of treatment.
The effect of ERT in children with non-classic forms of Pompe disease is documented 
less well since only ten of the 98 patients that participated in the three studies 
included in this thesis were children and other reports on the effects of ERT in 
children are scarce. Nevertheless, there are some indications that younger patients 
benefit the same or more from ERT than adults. Six of the children described in 
Chapters 5 and 6 showed a continuous improvement of muscle strength over 3 to 
8 years, while several studies, including the LOTS study, suggest that some adult 
patients may reach a plateau after a few years of treatment.14,16,17 A three-year 
treatment study in 24 Italian patients supports this notion.16 The positive effect 
of ERT in children compared to adults with non-classic forms of Pompe disease 
may reflect a difference in muscle growth or a higher regenerative capacity of the 
damaged muscle in children compared to adults.18,19 
It is generally recognized that not all patients respond equally well to ERT. A recent 
systematic literature review including all published studies on enzyme replacement 
therapy in non-classic forms of Pompe disease showed that one third of patients 
do not show improvements of muscle strength or pulmonary function during 
treatment.13 Similarly, de Vries et al found a poor response to ERT in 9% of the 
69 adult patients with regard to muscle strength, in 15% of the patients with 
regard to FVC in sitting position and in 39% of the patients with regard to FVC in 
supine position.20 At present, it is not clear what causes this variation in response; 
phenotypic, genetic, epi-genetic, and age-related factors have been suggested. 
Gender related factors may also influence treatment potential: van der Beek et 
al. from our group, found a better response to treatment with respect to muscle 
strength in female patients than in males.20 All these aspects should be taken into 
account when considering the best timing to start treatment. The invasive character 
and the high costs of the treatment frequently withholds clinicians from starting 
enzyme therapy in a pre-symptomatic state of the disease.21 However, the findings 
that even asymptomatic patients have some degree of trunk muscle atrophy on 
MRI22 and a considerable number of myocytes with irreversible histopathologic 
changes,23 make it clear that additional and longer follow-up studies are necessary 
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to better define starting criteria for enzyme replacement therapy and prognostic 
factors to identify patients at risk for a poor outcome.
2. Patients with classic-infantile Pompe disease 
Many studies have demonstrated that enzyme replacement therapy evidently 
corrects the cardiomegaly and increases survival in classic-infantile Pompe disease. 
The effects of ERT on muscle strength and pulmonary function are more variable. 
Now that treated infants live longer, new aspects of the disease emerge and 
require attention. The following paragraph discusses to what extent patients with 
classic-infantile Pompe disease treated with ERT mimic untreated children with 
non-classic forms of Pompe disease. 
The heart
Patients with classic-infantile Pompe disease present with a marked cardiomegaly. 
Echocardiography shows an increased thickness of both ventricles and the 
inter-ventricular septum. The hypertrophy is already present at birth, increases 
steadily after birth commonly leading to left ventricular outflow obstruction, 
cardiac failure and eventually death. Histological examination reveals prominent 
glycogen deposits in the cardiac muscle and a characteristic loss of myofibrils 
within cardiomyocytes. In contrast to classic-infantile Pompe disease, the heart of 
children and adults with non-classic forms of Pompe disease is rarely affected. The 
vast majority of these patients do not develop a cardiomyopathy. A shortened PR 
interval and Wolff-Parkinson-White pattern are commonly reported (up to 10%) 
in this group of patients.24-26 The study described in Chapter 4 corroborates these 
findings and shows that cardiac involvement is rare in children and adults with 
only 2/68 patients showing conduction abnormalities/anomalies (WPW pattern) 
or ventricular hypertrophy possibly related to Pompe disease, but very young and 
severely affected children were not included in that study.
Chapter 2 is more informative about the cardiac manifestations in children as it 
describes the results of a cross-sectional study in 31 untreated children with non-
classic forms of Pompe disease. Two of the 10 patients with severe GAA genotypes 
survived significantly longer than patients with classic-infantile Pompe disease 
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but presented with hypertrophic cardiomyopathy, and both these patients as 
well as a third patient had a delta-wave suggestive for WPW syndrome. According 
to the terminology of Slonim et al., the two patients with the hypertrophic 
cardiomyopathy would fit the description of ‘atypical infantile Pompe patient’.6,9 
The finding of intermediate phenotypes between classic-infantile Pompe disease 
and non-classic childhood, juvenile and adult- cases highlights the continuity of the 
clinical spectrum.4 The presence or absence of cardiac involvement seems to be 
determined by the level of residual α-glucosidase activity4 (Chapter 4). 
The preferential involvement of skeletal muscle over cardiac muscle in Pompe 
disease may be due to organ specific differences in metabolism. In healthy human 
beings, cytoplasmic pools of glycogen are far more pronounced in liver and skeletal 
muscle than in cardiomyocytes. The liver uses large amounts of glycogen to maintain 
the caloric need of the whole body, while skeletal muscles need glycogen for quick 
action. In contrast, the heart mainly uses fatty acids (60‒90%) as substrate for 
oxidation and only a small amount of ATP is derived from carbohydrate metabolism 
(10‒40%). In fact, high levels of fatty acids inhibit glycolysis and glucose oxidation.27 
In a rat model it was found that only a small part of the total glucose uptake by the 
heart is converted to glycogen,28,29 leading to small glycogen pools in cardiac muscle 
(appr. 30 mmol/g wet weight) in contrast to skeletal muscle (appr. 150 mmol/g wet 
weight). 
It is not until 7‒10 days after birth that fatty acids become the main energy source 
of the heart. The fetal heart derives 60% of energy supply by lactate oxidation and 
the environment of the fetal myocardium is highly enriched in lactate compared 
to the newborn and adult milieu.30 The other 40% of energy is supplied by glucose 
oxidation. Although the circulating glucose levels in newborns and adults are 
almost equal, the rate of glucose influx into the fetal cardiomyocyte is substantially 
different from the rate of influx after birth. GLUT-1, the fetal isoform of the glucose 
transporter, is not dependent on insulin, but is mainly regulated by plasma 
glucose levels.30 This might explain the large amount of glucose present in the 
cardiomyocytes.31 The predominant use of glucose and lactate in the cardiomyocyte 
during fetal life and the high content of glycogen in cardiomyocytes27,32 might lead 
to the marked cardiomegaly with pronounced glycogen accumulation present in 
classic-infantile patients at birth.
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It has been described that in response to cardiac hypertrophy, cardiac metabolism 
is reprogrammed to a fetal-like metabolic profile. This profile is characterized 
by an increased use of glucose metabolism and decreased use of fatty acid 
oxidation as energy source in the heart.33 We hypothesize that the above 
described reprogramming and the suggestion that the fetal-like metabolic profile 
is maladaptive for sustaining myocardial energetics and function in cardiac 
hypertrophy, might both explain the quick progression of cardiac hypertrophy 
towards heart failure in untreated classic-infantile Pompe patients.34-37
The first clinical trials performed in classic-infantile Pompe disease showed that 
the cardiac hypertrophy responds very well to enzyme replacement therapy as 
expressed by reduction of the left ventricular mass and an improvement of cardiac 
function.38-41 Although respiratory function and motor development showed a more 
variable response to ERT, patients with classic-infantile Pompe disease nowadays 
survive far beyond their first year of life. Hence, it is important to determine 
whether the earlier described therapeutic effects on cardiac mass and function are 
sustained over a longer period of time. 
The study presented in chapter 11 describes the effects of enzyme replacement 
therapy on cardiac size, cardiac function and conduction pattern in 14 classic-
infantile patients. Eight of these 14 patients received treatment for more than 4 
years to a maximum period of 13.9 years. The results confirm that ERT significantly 
reduces the left ventricular mass and improves cardiac function, which is in line 
with a recently published study showing that effects of ERT are sustained over a 
longer period of time.42 Nevertheless, not all of our patients showed normalization 
of LVMI as was described by Prater et al who followed 11 children up to 12 years. 
Two patients reached normal values after 13 years of treatment, and an increase 
of LVMI during treatment was seen in two other patients. However, it is important 
to note that all these patients were either in a severe clinical condition with paresis 
of the arms and paralysis of the legs at the time they started to receive enzyme 
replacement therapy, were in need of ventilator support, or deteriorated during 
treatment and became ventilator dependent. 
ERT seems to be less effective in preventing rhythm disturbances. The short 
PR interval that is characteristic for Pompe disease and is also found in other 
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storage diseases such as Fabry disease, Danon disease and patients with PRKAG2 
mutations,43 remained below normal values in most of our patients until study 
end. This is in contrast to a study by Ansong et al., in which all patients showed a 
progressive increase of PR interval during treatment.44 The mechanism that causes 
the short PR interval is not completely understood; one study that correlated 
electrophysiological abnormalities to pathologic post mortem findings in the 
conduction system of patients with classic- infantile Pompe disease found marked 
glycogen infiltration, vacuolization and an increase in cell size in the Purkinje cells. 
They suggested that the short PR interval could reflect enhanced conduction 
caused by the deposition of glycogen.45 The electrophysiological finding that the 
atrium-His interval was shortened and the His-ventricular interval was normal, 
while enlarged cells filled with glycogen were found in all parts of the conduction 
system including the bundle of His, challenges this hypothesis. A result that fits 
the above described electrophysiological findings was reported by Arad et al. They 
studied a mouse model with a human PRKAG2 mutation, which leads to excessive 
glycogen accumulation in myocytes. They observed that the annulus fibrosis was 
disrupted by glycogen-filled myocytes, as a consequence allowing atrioventricular 
activation by bypassing the AV node.46,47 A non-reversible disruption of the annulus 
fibrosis would be in line with the PR interval that remained below normal values 
despite treatment as found in most of the patients presented in chapter 11. It may 
also explain the Wolff-Parkinson-White pattern that is often found in patients with 
classic-infantile Pompe disease. Nevertheless, since some of our patients and all 
patients in the study published by Ansong et al showed an increase of their PR 
interval during treatment, the hypothesis that reduction of glycogen within the 
conduction system may result in normalization of conduction speed must also be 
considered.
The fact that two of our patients showed recurrent supraventricular tachyar-
rhythmia (SVT) despite ERT should be noted. Several publications report that 
arrhythmias, including fatal arrhythmia, may occur in patients with classic-infantile 
Pompe disease, even though ERT improves cardiac size and function.44,48-51 While 
Wang et al described a correlation between arrhythmias and LVMI, Ansong et 
al. did not. In our study, both patients with recurrent SVTs were already severely 
250
Chapter 13
affected before start of treatment. Both became ventilator dependent within their 
first year of life and are currently tetraplegic. The cardiac hypertrophy reduced, but 
the heart did not regain a normal size during most of the study period. 
Hearing, cognitive functioning and facial muscle weakness
Now that patients with classic-infantile Pompe disease are treated with enzyme 
replacement therapy, they survive longer and new aspects of the disease become 
apparent. One of these clinical findings is hearing deficits. Presence of hearing 
loss was first described in 2004 in four patients included in the initial pilot study 
investigating the effects of ERT.52 Kamphoven et al. found that hearing loss was 
mainly of cochlear nature and tried to get insight into the pathogenic process by 
studying a knockout mouse model of Pompe disease. They found glycogen storage 
in the cells forming the organ of Corti: the inner and outer hair cells of the cochlea, 
the supporting cells, and the stria vascularis. In addition, glycogen storage was 
found in the spiral ganglion cells, a group of nerve cells that sends impulses from 
the organ of Corti to the brain. In our study presented in Chapter 10 we revisited the 
issue by including 11 patients with classic-infantile Pompe disease and compared 
the results with those obtained in 13 children diagnosed with non-classic forms of 
Pompe disease. We found hearing deficits in 10 of the 11 classic-infantile patients. 
In addition to the earlier described cochlear dysfunction, conductive hearing loss 
was present in 75% of all hearing tests performed. These findings were confirmed 
by other studies.38,39,53 Hearing deficits are thus a major concern for these patients. 
They are already present at birth and seem to remain rather stable over time. Early 
implementation of hearing devices and speech therapy are important to protect 
speech and language development.
Hearing deficits were only sporadically identified (n=1, conductive hearing loss) in 
children with non-classic forms of Pompe disease (Chapter 10). A study performed 
in 58 adults led to the same conclusion i.e. that standard screening for hearing loss 
is not indicated in children and adults with non-classic forms of Pompe disease.54 
The latter study found that 21% of these patients had a clinically relevant hearing 
loss according to the standards of the World Health Organization, which is in 
agreement with the prevalence of hearing loss observed in the general population. 
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Two recently published studies concluded differently. A German study performed 
in 11 adult patients reported mild hearing loss in 36% of the patients, which 
slightly exceeds the normative data of the general population.55 An Italian study 
performed in 20 adult Pompe patients found a substantial number of patients 
(53%) to have mild hearing loss.56 It should be noted that a third of these cases 
were of conductive nature indicating middle-ear pathology rather than cochlear 
dysfunction. Combining the results of these three studies 29 out of a total of 89 
patients had sensorineural hearing defects (33%). Since this percentage slightly 
exceeds the overall prevalence of hearing impairment above 25 dB hearing 
threshold level described in the general population (27.2% Norway, 26.1% Great 
Britain, 22.2% South Australia),57-59 the hearing deficits in these Pompe patients 
might not be entirely attributed to physiological aging of the auditory system. As the 
underlying metabolic defect in adults and infants with Pompe disease is the same, 
cochlear pathology may also be present in non-classic forms of Pompe disease. 
Since less than half of the patients in which we measured hearing loss actually 
reported hearing problems, we suggest performing audiological assessments on a 
regular basis in all patients with Pompe disease. 
Because widespread glycogen storage was found in the brains of untreated classic-
infantile Pompe patients and the therapeutic enzyme cannot pass the blood-brain 
barrier,60 we were interested in the neurological development of these patients. In 
order to monitor neuronal function, we performed repetitive auditory brainstem 
evoked responses in 11 treated patients (Chapter 10). We found prolongation of 
inter-peak latencies in five patients. The most frequent finding was prolongation 
between peaks III and V. This is suggestive for pathology in the central part of 
the auditory pathway. The clinical meaning of these abnormalities were recently 
explored by studying regular psychological assessments and brain imaging in the 
same group of patients as described in Chapter 10.61 The data on early development 
were in concordance with other reported cases of classic-infantile Pompe disease 
and showed a wide range of scores.39,53,62,63 However, developmental tests used in 
young children are influenced by motor skills. Hence, residual muscle weakness 
in this group of patients may have affected the test results and should therefore 
be interpreted with caution.61,62 Cognitive development at school age was reliably 
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assessed and appeared to range from normal to mildly delayed. Abnormalities in 
processing speed were found in some children, which may be explained by the 
mild white matter changes detected on brain imaging. Another study in 7 classic-
infantile patients, followed for a median period of 7 years, found IQ scores within 
the lower range of normal with no evidence of a cognitive decline over time.64 In 
the latter study they also found a relative weakness in processing speed, but brain 
imaging was not performed in this group of patients.
White matter abnormalities were also reported in two other studies.53,65 In addition, 
one of these studies found brain myelination delays, especially in a patient that did 
not respond favorably to ERT.65 Few autopsy reports have been published, none of 
which described myelination defects in classic-infantile Pompe disease. Since these 
were all untreated patients, they may have lived too short to show this defect. 
The main findings of the few autopsy studies that have been published to date 
were severe glycogen storage in the anterior horn cells of the spinal cord, the 
neurons in the brain stem, the thalamus, the cerebellum, and to a lesser extent 
the cerebral cortex.66-71 This pathologic storage may explain some of the clinical 
features that were recently described in long-term survivors of classic-infantile 
Pompe disease. For example, glycogen storage in motor neurons of the spinal 
cord may be a component contributing to residual muscle weakness;72 glycogen 
storage in neurons driving the respiratory function may contribute to respiratory 
dysfunction;73 storage in the hypothalamic para-ventricular nuclei may have added 
to the etiology of an intractable fever that was described in three Pompe patients 
before they died (personal communication and66); and the severe storage of 
glycogen in the motor nuclei of the brain stem, found by Martin et al., may lead 
to bulbar palsy with dysphagia (Chapter 9); involvement of the third cranial nerve 
nucleus may add to the ptosis and extra-ocular motility dysfunction as described in 
one of our classic-infantile patients.74
Progressive glycogen accumulation in the lower motor neurons as described 
above together with weakness of the bulbar muscles are probably responsible 
for the profound facial muscle weakness (including ptosis), speech disorders and 
dysphagia that we encountered in our classic-infantile Pompe patients (Chapter 
9) despite receiving ERT. These findings have been supported by others42,74-77 and 
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raise important clinical concerns. The effect of aspiration on pulmonary function 
is of particular concern, since respiratory insufficiency is the main cause of death 
in these patients. Poor facial expression and disordered speech can hinder a 
patients’ social interaction. A bilateral ptosis may become so severe that surgical 
intervention may be necessary. 
If we compare these findings in classic-infantile Pompe disease with our study 
in 31 children with non-classic forms of the disease (Chapter 2), ptosis was not 
encountered, and bulbar weakness was found in only one patient. Thus, it appears 
that treated patients with classic-infantile Pompe disease develop a different 
phenotype than naturally less affected children with non-classic forms of Pompe 
disease. 
3. Outcome measures 
The approach towards evaluating disease severity and effect of treatment has 
become increasingly multi-dimensional over the past years, in agreement with the 
International Classification of Functioning, Disability and Health (ICF, World health 
organization). However, a core set of standardized outcome measures has not yet 
been implemented on an international basis. A recent literature study showed that 
direct comparisons between different studies is difficult because of the different 
outcome measures used in these studies.13 The clinical studies in adults and 
children with non-classic forms of Pompe disease presented in this thesis used the 
following outcome measures: FVC in sitting and supine position as a measure of 
pulmonary function; the Medical Research Council (MRC) grading scale, hand held 
dynamometry, and quantitative muscle testing as measure of muscle strength; 
the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), the 
Rotterdam 9-item Handicap Scale (RHS) and the Pompe Pediatric Evaluation of 
Disability Inventory (Pompe PEDI) to assess the level of participation, restrictions, 
and quality of life. In the past, muscle strength tests have often been applied to 
assess muscle function, but both should be evaluated separately by valid and 
reliable assessment tools. For this purpose the Quick Motor Function Test (QMFT) 
was developed as described in Chapter 12. It is a functional motor scale specific for 
Pompe disease that appears to be sufficiently sensitive to assess disease severity 
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and to detect clinically important changes over time. The test is conveniently quick 
as it comprises a mere 16 items and can be applied by a physician in the outpatient 
clinic. However, it is not widely used as yet. In Chapter 6, the test is used for studying 
the effect of enzyme replacement therapy in adolescents over a period of three 
years’ time. Furthermore, it was used in a nationwide prospective observational 
study to evaluate the natural course in 91 adults with Pompe disease,10 and in an 
open-label therapy study in 69 adult Pompe patients.20 While the QMFT showed a 
significant improvement of muscle function during ERT, which correlated with an 
improvement of muscle strength, the test results did not reflect the group-level 
changes in muscle strength found in the natural course study over a median period 
of 1.6 years. The discrepancy is difficult to explain other than that the changes in 
muscle strength might have been too small to result in a change in muscle function. 
The test itself seems to satisfy since its responsiveness to change appeared to be 
good, as shown by a high standardized response mean of 0.81 and an area under 
the ROC curve of 0.88 (p<0.05)78 (Chapter 12). Whether the QMFT is not sensitive 
enough, indeed, to detect small changes in muscle function may be answered by 
performing a larger study. The suggestion made by van der Beek to refine this 
outcome measure by Rasch methodology seems justified.79
During our studies we encountered some difficulties while using the six minute 
walk test (6MWT) and Hand Held Dynamometry (HHD) in children. The 6MWT, a 
frequently used scale to assess motor function in neuromuscular disorders and 
one of the primary endpoints in the LOTS study, was originally developed to assess 
functional capacity in patients with moderate to severe heart or lung disease. It 
evaluates the integrated responses of all the systems involved in exercise: including 
the pulmonary and cardiovascular systems, systemic and peripheral circulation, 
blood, neuromuscular units, and muscle metabolism. It does not provide specific 
information on the neuromuscular unit, and therefore cannot be used as a measure 
of limb-girdle muscle function.80 Although the 6MWT has recently been applied in 
different chronic pediatric conditions,81 including Duchenne muscular dystrophy,82 
we (Chapter 6) and others were unable to obtain any consistency over different 
assessment days when applied to children. The test appeared to be insufficiently 
challenging for our patients. Geiger et al. also stated that a lack of motivation and 
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understanding for the need of a 6MWT may affect performance in children.83 To 
improve motivation we asked our patients to run. These results appeared to be 
more consistent, but no reference values exist for 6 minutes running, which makes 
the test difficult to use in a childhood Pompe population.
We encountered another difficulty by using Hand Held Dynamometry in our 
childhood studies. When interpreting the test results, we used published reference 
values by Beenakker et al.84 To our surprise, some patients that were diagnosed 
pre-symptomatically showed muscle strength results below normal values, while all 
other tests showed maximum scores (Chapter 2). When we compared the reference 
values to those established for adult Pompe patients, there appeared to be a large 
difference and the percentage of normal scores for strength were approximately 
10% lower using the adult reference values85 instead of those obtained for children. 
Since the study that obtained the reference values in children was performed in 
270 subjects and no clear methodological inconsistencies could be identified, we 
cannot explain these differences. In 1989 another study which contains muscle 
force values obtained in a control group of children between 3.5 and 15 years of 
age, was published by Bäckman et al.86 Reference values obtained by Bäckman et al 
were approximately 10% lower than those obtained by Beenakker et al. and seem 
more in line with those obtained for adults. Unfortunately, Bäckman et al. assessed 
muscle strength in only 10 muscle groups and did not provide reference values 
for some muscle groups that are clearly affected in Pompe patients like the neck 
flexors. To be able to reliably interpret follow-up of muscle strength in children with 
Pompe disease and other neuromuscular disorders, we encourage the construction 
of a new set of reference values for HHD. 
MAIn COnCLuSIOnS
The studies presented in this thesis illustrate that Pompe disease presents as a 
true clinical spectrum whereby childhood phenotypes bridge the classic-infantile 
and adult onset phenotypes. While some patients with a non-classic forms of 
Pompe disease present in adulthood with a slowly progressive disease course, a 
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substantial number of patients becomes wheelchair bound or respirator dependent 
already during childhood. Childhood Pompe disease presents with delayed motor 
development or limb-girdle weakness, but disproportional weakness of the neck 
flexors, unexplained fatigue or solitary elevation of transaminases should also raise 
suspicion for the disease. Children with the common c.-32-13T>G/null genotype are 
predominantly male, and patients with other mutations than the c.-32-13T>G/null 
genotype presenting during childhood generally are more severely affected. ERT 
initiated when a child is still ambulant mostly results in significant improvements 
of muscle strength and muscle function as well as in stabilization of pulmonary 
function. In patients with a more advanced stage of the disease at start of therapy, 
ERT merely stabilizes muscle strength and pulmonary function, while quality of life 
improves.
The emerging phenotype of treated patients with classic-infantile Pompe disease 
clearly differs from the phenotype of children with less progressive forms of the 
disease. Treated classic-infantile patients, as opposed to non-classic patients, 
appear prone to manifest new problems like facial muscle-weakness, speech 
disorders, dysphagia, arrhythmias, hearing loss, and distal muscle weakness. 
Additionally, although less profound than in other lysosomal storage disorders like 
the Mucopolysaccharidoses, lysosomal storage is found in the CNS, which might 
be responsible for delayed processing speed, while these abnormalities are not 
observed in children with non-classic forms of Pompe disease. 
FuTuRE PERSPECTIVES
The outcome of patients with Pompe disease has clearly improved since the 
introduction of ERT. The studies presented in this thesis demonstrate that the 
process has come a long way: patients live longer, muscle strength, cardiac 
size, pulmonary function, and quality of life has clearly improved. However, the 
studies reveal several hurdles that still need to be taken. Not all patients respond 
equally well to treatment, and patients with classic-infantile Pompe disease who 
receive ERT are prone to develop new problems. Thus, a lot of work remains 
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ahead for improving the currently available enzyme replacement therapy and 
searching for possible alternatives. Potential improvements lay in structurally 
optimizing the therapeutic enzyme so that it reaches and enters the muscle cells 
more effectively87-91 or, along a completely different line, trying to reduce the 
lysosomal glycogen accumulation by interfering with the autophagic pathway.92 
The prevention of antibody formation towards the therapeutic enzyme53,93,94 may 
enhance95,96 the efficacy of ERT in specific cases, and so may the co-administration 
of chaperones.97-100 Besides, the long-term investments in the development of gene 
therapy101,102 might finally come to fruition. 
FInAL REMARKS
In the footsteps of ‘Cardiomegalia glycogenica’, the first thesis on Pompe disease 
written by Dr. J.C. Pompe himself, the current thesis is the 13th dissertation on 
Pompe disease at the Erasmus MC University Medical Center in Rotterdam, 
The Netherlands. The studies were aimed to contribute to the ever expanding 
knowledge on Pompe disease so to improve patient care and treatment, and could 
not have been completed without the close collaboration between clinicians, basic 
scientists, patients, and patient associations. 
258
Chapter 13
REFEREnCES
1. Pompe JC. Cardiomegalia glycogenica. Nijmegen-Utrecht, University of Amsterdam; 1936.
2. Lignac GOE. Cardiomegalia glycogenica. Nederlands Tijdschrift voor Geneeskunde. 1936; 80:3747.
3. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. Oct 11 2008; 372(9646):1342-1353.
4. Hirschhorn R, Reuser AJJ. Glycogen Storage Disease Type II: acid alpha-glucosidase (acid maltase) 
deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly WS, eds. The Metabolic and Molecular Bases of 
Inherited Disease. 8 ed. NY: McGraw-Hill; 2001: 3389-3420.
5. Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; 
a review of 225 published cases. J Neurol. Aug 2005; 252(8):875-884.
6. Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity 
in children and adults with Pompe disease related to age and disease duration. Neurology. Jun 
28 2005; 64(12):2139-2141.
7. Kroos, Pomponio RJ, Hagemans ML, et al. Broad spectrum of Pompe disease in patients with the 
same c.-32-13T->G haplotype. Neurology. Jan 9 2007; 68(2):110-115.
8. Montalvo AL, Bembi B, Donnarumma M, et al. Mutation profile of the GAA gene in 40 Italian 
patients with late onset glycogen storage disease type II. Human mutation. Oct 2006; 27(10):999-
1006.
9. Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of 
infantile acid maltase deficiency. The Journal of pediatrics. 2000; 137(2):283-285.
10. van der Beek NA, de Vries JM, Hagemans ML, et al. Clinical features and predictors for disease 
natural progression in adults with Pompe disease: a nationwide prospective observational study. 
Orphanet journal of rare diseases. Nov 12 2012; 7(1):88.
11. Wens SC, van Gelder CM, Kruijshaar ME, et al. Phenotypical variation within 22 families with 
Pompe disease. Orphanet journal of rare diseases. Nov 19 2013; 8(1):182.
12. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset 
Pompe’s disease: a three-year follow-up. Annals of neurology. Apr 2004; 55(4):495-502.
13. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic 
literature review. J Neurol. Aug 28 2012.
14. van der Ploeg AT, Barohn R, Carlson L, et al. Open-label extension study following the Late-Onset 
Treatment Study (LOTS) of alglucosidase alfa. Molecular genetics and metabolism. Sep 17 2012.
15. Gungor D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe 
disease prior to treatment with enzyme replacement therapy. Orphanet journal of rare diseases. 
Jun 1 2011; 6(1):34.
16. Bembi B, Pisa FE, Confalonieri M, et al. Long-term observational, non-randomized study of 
enzyme replacement therapy in late-onset glycogenosis type II. Journal of inherited metabolic 
disease. Dec 2010; 33(6):727-735.
17. Regnery C, Kornblum C, Hanisch F, et al. 36 months observational clinical study of 38 adult Pompe 
disease patients under alglucosidase alfa enzyme replacement therapy. Journal of inherited 
metabolic disease. Jan 31 2012.
General discussion
259
13
18. Corbu A, Scaramozza A, Badiali-DeGiorgi L, et al. Satellite cell characterization from aging human 
muscle. Neurological research. Feb 2010; 32(1):63-72.
19. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and 
proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-
old men. Journal of the neurological sciences. Apr 1988; 84(2-3):275-294.
20. de Vries JM, van der Beek NA, Hop WC, et al. Effect of enzyme therapy and prognostic factors 
in 69 adults with Pompe disease: an open-label single-center study. Orphanet journal of rare 
diseases. Sep 26 2012; 7(1):73.
21. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset 
pompe disease. Muscle Nerve. Oct 21 2011.
22. Alejaldre A, Diaz-Manera J, Ravaglia S, et al. Trunk muscle involvement in late-onset Pompe 
disease: Study of thirty patients. Neuromuscular disorders. Oct 1 2012; 22 Suppl 2:S148-154.
23. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL. Later-Onset Pompe Disease: Early 
Detection and Early Treatment Initiation Enabled by Newborn Screening. The Journal of pediatrics. 
Jan 11 2011; 158(6):1023-1027 e1021
24. van der Beek NA, Soliman OI, van Capelle CI, et al. Cardiac evaluation in children and adults with 
Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities. Journal 
of the neurological sciences. Aug 29 2008.
25. Muller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and 
neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. 
Neuromuscular disorders. Oct 2007; 17(9-10):698-706.
26. Francesconi M, Auff E, Ursin C, Sluga E. [WPW syndrome combined with AV block 2 in an adult 
with glycogenosis (Type II)] WPW-Syndrom, kombiniert mit AV-Block 2 bei einer adulten Form 
einer Glykogenose Typ II. Wiener Klinische Wochenschrift. 1982; 94(15):401-404.
27. Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate use by the 
heart. Cardiovascular research. Dec 1992; 26(12):1172-1180.
28. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 
20 original cases compared with 133 cases from the literature. Pediatrics. Aug 2003; 112(2):332-
340.
29. Henning SL, Wambolt RB, Schonekess BO, Lopaschuk GD, Allard MF. Contribution of glycogen to 
aerobic myocardial glucose utilization. Circulation. Apr 15 1996; 93(8):1549-1555.
30. Goodwin GW, Arteaga JR, Taegtmeyer H. Glycogen turnover in the isolated working rat heart. J 
Biol Chem. Apr 21 1995; 270(16):9234-9240.
31. Castello A, Rodriguez-Manzaneque JC, Camps M, et al. Perinatal hypothyroidism impairs the 
normal transition of GLUT4 and GLUT1 glucose transporters from fetal to neonatal levels in heart 
and brown adipose tissue. Evidence for tissue-specific regulation of GLUT4 expression by thyroid 
hormone. The Journal of biological chemistry. Feb 25 1994; 269(8):5905-5912.
32. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression 
in fetal and failing human heart. Circulation. Dec 11 2001;104(24):2923-2931.
33. Kolwicz SC, Jr., Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, 
and survival of cardiomyocytes. Circulation research. Aug 16 2013;113(5):603-616.
34. Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in 
palmitate oxidation. Molecular and cellular biochemistry. Apr 2008; 311(1-2):215-224.
260
Chapter 13
35. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative 
metabolism and glycolysis to ATP production in hypertrophied hearts. The American journal of 
physiology. Aug 1994; 267(2 Pt 2):H742-750.
36. Barger PM, Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular 
regulatory mechanisms. The American journal of the medical sciences. Jul 1999; 318(1):36-42.
37. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-
activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. 
The Journal of biological chemistry. Nov 30 2001; 276(48):44390-44395.
38. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase 
(rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. 
Neuromuscular disorders. Jan 2005; 15(1):24-31.
39. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human 
acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of pediatrics. Jul 2006; 
149(1):89-97.
40. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. 
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000; 
356(9227):397-398.
41. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme 
therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genetics 
in medicine. 2001; 3(2):132-138.
42. Prater SN, Banugaria SG, Dearmey SM, et al. The emerging phenotype of long-term survivors with 
infantile Pompe disease. Genetics in medicine. Apr 26 2012.
43. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic 
cardiomyopathy. The New England journal of medicine. Jan 27 2005; 352(4):362-372.
44. Ansong AK, Li JS, Nozik-Grayck E, et al. Electrocardiographic response to enzyme replacement 
therapy for Pompe disease. Genetics in medicine. May 2006; 8(5):297-301.
45. Bharati S, Serratto M, DuBrow I, et al. The conduction system in Pompe’s disease. Pediatric 
Cardiology. 1982; 2(1):25-32.
46. Arad M, Moskowitz IP, Patel VV, et al. Transgenic mice overexpressing mutant PRKAG2 define the 
cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation. Jun 
10 2003; 107(22):2850-2856.
47. Patel VV, Arad M, Moskowitz IP, et al. Electrophysiologic characterization and postnatal 
development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-
Parkinson-White syndrome. Journal of the American College of Cardiology. Sep 3 2003; 42(5):942-
951.
48. Wang LY, Ross AK, Li JS, et al. Cardiac arrhythmias following anesthesia induction in infantile-
onset Pompe disease: a case series. Paediatr Anaesth. Aug 2007; 17(8):738-748.
49. Desena HC, Brumund MR, Superneau D, Snyder CS. Ventricular Fibrillation in a Patient with 
Pompe Disease: A Cautionary Tale. Congenit Heart Dis. Mar 10 2011.
50. McDowell R, Li JS, Benjamin DK, Jr., et al. Arrhythmias in patients receiving enzyme replacement 
therapy for infantile Pompe disease. Genetics in medicine. Sep 18 2008.
General discussion
261
13
51. Cook AL, Kishnani PS, Carboni MP, et al. Ambulatory electrocardiogram analysis in infants treated 
with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe 
disease. Genetics in medicine. May 2006; 8(5):313-317.
52. Kamphoven JH, de Ruiter MM, Winkel LP, et al. Hearing loss in infantile Pompe’s disease and 
determination of underlying pathology in the knockout mouse. Neurobiol Dis. Jun 2004; 16(1):14-
20.
53. Rohrbach M, Klein A, Kohli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month 
treatment outcome. Journal of inherited metabolic disease. Sep 30 2010.
54. van der Beek NA, Verschuure H, Reuser AJ, van der Ploeg AT, van Doorn PA, Poublon RM. Hearing 
in adults with Pompe disease. Journal of inherited metabolic disease. Mar 2012; 35(2):335-341.
55. Hanisch F, Rahne T, Plontke SK. Prevalence of hearing loss in patients with late-onset Pompe 
disease: Audiological and otological consequences. Int J Audiol. Dec 2013; 52(12):816-823.
56. Musumeci O, Catalano N, Barca E, et al. Auditory system involvement in late onset Pompe disease: 
A study of 20 Italian patients. Molecular genetics and metabolism. Aug 17 2012.
57. Borchgrevink HM, Tambs K, Hoffman HJ. The Nord-Trondelag Norway Audiometric Survey 1996-
98: unscreened thresholds and prevalence of hearing impairment for adults >20 years. Noise & 
health. Jul-Sep 2005; 7(28):1-15.
58. Davis AC. The prevalence of hearing impairment and reported hearing disability among adults in 
Great Britain. International journal of epidemiology. Dec 1989; 18(4):911-917.
59. Wilson DH, Walsh PG, Sanchez L, et al. The epidemiology of hearing impairment in an Australian 
adult population. International journal of epidemiology. Apr 1999; 28(2):247-252.
60. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Current 
pharmaceutical design. 2008; 14(16):1566-1580.
61. Ebbink BJ, Aarsen FK, van Gelder CM, et al. Cognitive outcome of patients with classic infantile 
Pompe disease receiving enzyme therapy. Neurology. May 8 2012; 78(19):1512-1518.
62. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of 
Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. May 2004; 
113(5):e448-457.
63. Hamdan MA, Almalik MH, Mirghani HM. Early administration of enzyme replacement therapy 
for Pompe disease: Short-term follow-up results. Journal of inherited metabolic disease. Dec 12 
2008.
64. Spiridigliozzi GA, Heller JH, Kishnani PS. Cognitive and adaptive functioning of children with 
infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. Am J 
Med Genet C Semin Med Genet. Feb 15 2012; 160(1):22-29.
65. Chien YH, Lee NC, Peng SF, Hwu WL. Brain Development in Infantile-Onset Pompe Disease Treated 
by Enzyme Replacement Therapy. Pediatric research. Jul 20 2006; 60(3):349-352.
66. Martini C, Ciana G, Benettoni A, et al. Intractable fever and cortical neuronal glycogen storage in 
glycogenosis type 2. Neurology. 2001; 57(5):906-908.
67. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment 
pathology after enzyme replacement therapy for pompe disease. Laboratory investigation; a 
journal of technical methods and pathology. Oct 30 2006; 86(12):1208-1220.
68. Martin JJ, De Barsy T, Van Hoof F, Palladini G. Pompe’s disease: an inborn lysosomal disorder with 
storage of glycogen. A study of brain and striated muscle. Acta Neuropathol. 1973; 23(3):229-244.
262
Chapter 13
69. Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s disease. Ultrastructure and 
biochemistry. J Neuropathol Exp Neurol. 1971; 30(3):412-430.
70. Mancall EL, Aponte GE, Berry RG. Pompe’s disease (diffuse glycogenosis) with neuronal storage. J 
Neuropath Exp Neurol. 1965; 24:85-96.
71. Teng YT, Su WJ, Hou JW, Huang SF. Infantile-onset glycogen storage disease type II (Pompe 
disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J. 
May 2004; 27(5):379-384.
72. Chien YH, Lee NC, Huang PH, Lee WT, Thurberg BL, Hwu WL. Early pathologic changes and 
responses to treatment in patients with later-onset Pompe disease. Pediatr Neurol. Mar 2012; 
46(3):168-171.
73. Fuller DD, Elmallah MK, Smith BK, et al. The respiratory neuromuscular system in Pompe disease. 
Respir Physiol Neurobiol. Jun 21 2013.
74. Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I. Ptosis, extraocular motility 
disorder, and myopia as features of pompe disease. Orbit. Mar 2011; 30(2):111-113.
75. Muller CW, Jones HN, O’Grady G, Su AH. Language and speech function in children with infantile 
Pompe disease. J Pediatr Neurol. 2009; (7):147-156.
76. Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS. Clinical and histologic ocular findings in pompe 
disease. J Pediatr Ophthalmol Strabismus. Jan-Feb 2010; 47(1):34-40.
77. Jones HN, Muller CW, Lin M, et al. Oropharyngeal Dysphagia in Infants and Children with Infantile 
Pompe Disease. Dysphagia. Sep 10 2009.
78. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic 
evaluation. Medical care. Jul 1990; 28(7):632-642.
79. van der Beek NAME. Clinical features, disease course, and effects of enzyme therapy in Pompe 
disease. Breda, Erasmus University Rotterdam; 2013.
80. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. American 
journal of respiratory and critical care medicine. Jul 1 2002; 166(1):111-117.
81. Bartels B, de Groot JF, Terwee CB. The six-minute walk test in chronic pediatric conditions: a 
systematic review of measurement properties. Physical therapy. Apr 2013; 93(4):529-541.
82. Kempen JC, Harlaar J, van der Kooi AJ, et al. Reliability of the walking energy cost test and the 
six-minute walk test in boys with Duchenne muscular dystrophy. Neuromuscular disorders : NMD. 
Mar 2014; 24(3):216-221.
83. Geiger R, Strasak A, Treml B, et al. Six-minute walk test in children and adolescents. The Journal 
of pediatrics. Apr 2007; 150(4):395-399, 399 e391-392.
84. Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM. Reference values of maximum 
isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. 
Neuromuscular disorders. Jul 2001; 11(5):441-446.
85. van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: reference values. Journal of 
neurology, neurosurgery, and psychiatry. Mar 1991; 54(3):244-247.
86. Backman E, Odenrick P, Henriksson KG, Ledin T. Isometric muscle force and anthropometric 
values in normal children aged between 3.5 and 15 years. Scandinavian journal of rehabilitation 
medicine. 1989; 21(2):105-114.
General discussion
263
13
87. Zhu Y, Li X, Kyazike J, et al. Conjugation of mannose 6-phosphate-containing oligosaccharides 
to acid alpha-glucosidase improves the clearance of glycogen in pompe mice. The Journal of 
biological chemistry. Nov 26 2004; 279(48):50336-50341.
88. Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered Acid alpha-Glucosidase With Improved Efficacy 
at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe 
Disease. Molecular therapy. Mar 10 2009.
89. Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid 
alpha-glucosidase enhances muscle glycogen clearance in pompe mice. The Journal of biological 
chemistry. Jan 18 2013; 288(3):1428-1438.
90. Tiels P, Baranova E, Piens K, et al. A bacterial glycosidase enables mannose-6-phosphate 
modification and improved cellular uptake of yeast-produced recombinant human lysosomal 
enzymes. Nat Biotechnol. Nov 18 2012.
91. McVie-Wylie AJ, Lee KL, Qiu H, et al. Biochemical and pharmacological characterization of 
different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe 
disease. Molecular genetics and metabolism. Aug 2008; 94(4):448-455.
92. Spampanato C, Feeney E, Li L, et al. Transcription factor EB (TFEB) is a new therapeutic target for 
Pompe disease. EMBO Mol Med. Apr 18 2013.
93. Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme 
replacement therapy in CRIM-negative infantile Pompe disease. Genetics in medicine. Jan 2012; 
14(1):135-142.
94. Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG. Desensitization of an adult patient 
with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Molecular genetics and 
metabolism. Jul 7 2009.
95. Amalfitano A, McVie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen 
storage disease type II after hepatic targeting of a modified adenovirus vector encoding human 
acid-alpha-glucosidase. Proceedings of the National Academy of Sciences of the United States of 
America. 1999; 96(16):8861-8866.
96. Fraites TJ, Jr., Schleissing MR, Shanely RA, et al. Correction of the Enzymatic and Functional 
Deficits in a Model of Pompe Disease Using Adeno-associated Virus Vectors. Molecular therapy. 
2002; 5(5 Pt 1):571-578.
97. Porto C, Ferrara MC, Meli M, et al. Pharmacological Enhancement of alpha-Glucosidase by the 
Allosteric Chaperone N-acetylcysteine. Molecular therapy. Sep 18 2012.
98. Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1-deoxynojirimycin increases 
the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Human 
mutation. Sep 4 2009.
99. Parenti G, Zuppaldi A, Gabriela Pittis M, et al. Pharmacological Enhancement of Mutated alpha-
Glucosidase Activity in Fibroblasts from Patients with Pompe Disease. Molecular therapy. Mar 
2007; 15(3):508-514.
100. Porto C, Cardone M, Fontana F, et al. The Pharmacological Chaperone N-butyldeoxynojirimycin 
Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts. Molecular therapy. Mar 
17 2009.
264
Chapter 13
101. Smith BK, Collins S, Conlon T, et al. Phase I/II trial of AAV1-GAA gene therapy to the diaphragm for 
chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene 
Ther. Apr 9 2013.
102. Falk DJ, Mah CS, Soustek MS, et al. Intrapleural Administration of AAV9 Improves Neural and 
Cardiorespiratory Function in Pompe Disease. Molecular therapy. Jun 4 2013.
14
Summary
Samenvatting
266
Chapter 14
Summary
Pompe disease is a rare metabolic disease, caused by an inherited deficiency of the 
enzyme acid α-glucosidase. This enzyme is required for the breakdown of glycogen 
in the lysosomes. Lysosomes are membrane-bound organelles that are responsible 
for the intracellular digestion of macromolecules. Partial or total deficiency of acid 
α-glucosidase leads to the accumulation of lysosomal glycogen in all cells of the 
body, but the pathological changes are most notable in skeletal muscle.
Pompe disease presents as a continuous spectrum of clinical phenotypes in which 
progressive muscle weakness is the main manifestation. Patients with the classic-
infantile form of this disease have virtually no residual enzyme activity and are 
at the severe end of the spectrum, while patients with a certain level of residual 
enzyme activity present milder phenotypes at the other end of the spectrum. 
Patients with classic-infantile Pompe disease present shortly after birth with severe 
generalized muscle weakness and a progressive hypertrophic cardiomyopathy; 
before a treatment became available, these patients usually died before the age 
of one year. Patients with less progressive phenotypes present with a slowly 
progressive proximal myopathy, eventually leading to wheelchair dependency and 
use of ventilator support. 
The first results of enzyme replacement therapy with recombinant human 
α-glucosidase were promising since most patients with the classic-infantile form 
of Pompe disease survived far beyond the first year of life. But, there is still little 
known about the long-term treatment effects in this group of patients. Much less 
is known about the natural course of disease in children with less progressive 
phenotypes and how they respond to enzyme replacement therapy. This thesis 
describes the clinical spectrum of children with Pompe disease, compares them 
with adult Pompe patients, and evaluates the effects of enzyme replacement 
therapy in these childhood Pompe patients. Furthermore, it describes the long-
term outcome of enzyme replacement therapy in patients with classic-infantile 
Pompe disease, for a maximum period of 14 years, and compares the functioning 
of these treated infants with that of children with less progressive forms of Pompe 
disease.
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Chapter 1 provides a general introduction into the field of Pompe disease by giving 
a short historical background, by describing the clinical spectrum, the pathology, 
the genetic heterogeneity, diagnostic procedures, and the current stage of enzyme 
replacement therapy. 
Part I of this thesis focuses on the clinical characteristics and natural course of 
children with slowly progressive phenotypes of Pompe disease. Chapter 2 provides 
information on the initial presentation and the clinical and genetic characteristics 
of 31 children with less progressive forms of Pompe disease. These children 
usually present with delayed motor development or limb-girdle weakness, but 
the disease should also be considered in the differential diagnosis of less familiar 
signs such as disproportional weakness of the neck flexors, unexplained fatigue, 
persistent diarrhea, and an elevation of transaminase levels. Disease presentation, 
distribution of muscle weakness, and the occurrence of specific symptoms such 
as bulbar muscle weakness or ptosis appear to be different from adult patients. 
Patients in this group with other mutations than c.-32-13T>G were more severely 
affected than those with the c.-32-13T>G mutation, in line with their more severe 
genotypes, but, the clinical course varied substantially in both groups. Children 
with a c.-32-13T>G/null genotype presenting in childhood appeared to be 
predominantly males. Chapter 3 focuses in more detail on pulmonary function in 
17 children and 75 adults with Pompe disease. Seventy-four percent of all patients, 
including 53% of the children, had some degree of respiratory dysfunction. Forty-
seven percent of the children had a decreased vital capacity in sitting position and 
59% in supine position. The youngest patient in whom a diminished pulmonary 
function was measured was seven years old. Pulmonary function was severely 
diminished in four of the childhood patients. Male patients appeared to have more 
severe pulmonary involvement than female patients. During an average follow-up 
period of 1.6 years, there were significant declines in vital capacity in upright and 
supine position. We concluded that pulmonary dysfunction in Pompe disease is 
much more common than generally thought. The presence and extent of cardiac 
involvement in children and adults with the common c.-32-13T>G genotype 
is described in Chapter 4. Sixty-eight patients were evaluated, of which 23 had 
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symptom onset before the age of 18 years. Two patients had cardiac abnormalities 
possibly related to Pompe disease. In one 8-year old patient a Wolff-Parkinson-
White pattern was found. A severely affected adult patient had a mild hypertrophic 
cardiomyopathy that did not change during enzyme replacement therapy. It was 
concluded that cardiac involvement is rare among Pompe patients with the c.-32-
13T>G/null genotype. Since all patients with cardiac abnormalities were detected 
by electrocardiography, an electrocardiogram should be performed as first level of 
screening in this group of patients.
Part II focuses on the effect of ERT in children and adults with Pompe disease 
and includes the results of eight years of treatment in two children and one adult 
with Pompe disease (Chapter 5). In two severely affected patients, ventilator 
dependent and wheelchair bound, further loss of muscle function was prevented 
and respiratory function stabilized. Both became more confident about their 
physical condition and more independent in daily life activities. A third and less 
severely affected patient that regained the ability to walk during the first three 
years of treatment, showed further improvements and caught up with healthy 
peers regarding muscle strength. None of the patients showed severe side effects 
during the enzyme infusions. The results indicate that long-term follow-up and 
timing of treatment are important topics for future studies. Chapter 6 shows the 
results of an open-label study that included five children aged 5.9 to 15.2 years 
that were treated with enzyme replacement therapy for three years. Pulmonary 
function remained stable in four patients and improved in one patient, while two 
unmatched historical cohorts of untreated patients with Pompe disease showed 
an average decline of pulmonary function of 1.6 to 5% per year. Muscle strength 
improved in all patients, and one of the patients approached the normal range. 
Muscle function as measured by the Quick Motor Function Test improved in all 
patients. No-infusion associated reactions were observed. The small number of 
patients and the fact that the study was not placebo controlled made it difficult 
to draw firm conclusions, but we found it encouraging that none of the patients 
deteriorated over a three-year period. In Chapter 7 we report the results of a 
randomized, placebo-controlled trial of alglucosidase alpha in 90 patients, older 
than 8 years of age. Over an 18-month period, treatment was associated with a 
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significant increase in walking distance in the 6-minute walk test and stabilization 
of pulmonary function compared to placebo. The greatest improvement in the 
treatment group occurred during the first 26 weeks and was maintained over the 
following 12 months. Although subgroup analyses suggested a more pronounced 
treatment effect in patients with better clinical status at baseline, this was not 
confirmed and the treatment response appeared to be consistently positive for all 
subgroups. Three of the 60 patients treated with alglucosidase alpha experienced 
anaphylactic reactions, and their treatment had to be discontinued. All patients 
developed IgG antibodies, but no consistent effect on clinical outcome was 
detected. 
Part III reports on the long-term outcome of patients with classic-infantile Pompe 
disease. Chapter 8 describes the occurrence of gingival overgrowth in one of the 
longest survivors of enzyme replacement therapy who is currently 15 years old. 
Histopathology of the gingiva showed marked glycogen accumulation in smooth 
muscle cells of the arteries but the glycogen content in fibroblasts did not exceed 
that of controls. We concluded that glycogen storage is not a direct cause of 
gingival overgrowth in this patient, rather chronic inflammation in combination 
with dryness of the gingiva. Chapter 9 shows that facial muscle weakness, 
speech disorders and dysphagia are common in patients with classic infantile 
Pompe disease treated by ERT. Eleven patients were included in the study. Age 
at final assessment ranged from 7.7 months to 12.2 years (median 4.3 years). All 
patients developed facial muscle weakness before the age of 15 months. Speech 
assessments showed that articulation was disordered with hyper nasal resonance 
and reduced speech intelligibility. More important swallowing was ineffective and 
patients appeared to be at risk for aspiration and related complications. Therefore 
early treatment by a speech therapist and regular assessments of swallowing was 
recommended. In Chapter 10 hearing was analyzed in a group of 24 children with 
Pompe disease using repetitive auditory brainstem response measurements and 
pure tone audiometry. Only 1 out of 13 children with non-classic forms of Pompe 
disease showed recurrent conductive hearing loss, while 10 out of 11 patients 
with classic-infantile Pompe disease had sensorineural hearing loss. These infants 
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also had a high prevalence of conductive hearing loss. Five patients showed 
evidence of mild retro cochlear pathology, suggestive of glycogen accumulation 
in the central nervous system. Auditory function should be carefully monitored in 
patients with classic-infantile Pompe disease and early implementation of hearing 
aids is pivotal to preserve adequate speech development. The results of almost 14 
years of treatment with alglucosidase alpha on cardiac structure and function are 
described in Chapter 11. The study shows that significant reduction of cardiac size 
and improvement of cardiac function is maintained over this period of time. This is 
an important finding as the reduction of cardiac mass is associated with decreased 
morbidity and mortality in this group of patients. Arrhythmias remain a threat to 
these patients and close cardiac follow-up is required. 
Part IV, which includes Chapter 12 reports the construction and validation of the 
quick motor function test (QMFT): a functional motor scale specifically designed 
for Pompe disease. The test comprises 16 items, which can be easily applied in 
clinical practice. The QMFT appeared to be a reliable and valid test for assessing 
motor function in children and adults with Pompe disease between 5 and 76 years 
of age. The test proved to be sufficiently sensitive to assess disease severity and to 
detect clinically important changes in motor function over time.
Finally, Chapter 13 summarizes the main findings and discusses their significance 
and clinical implications.
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Samenvatting
De ziekte van Pompe is een erfelijke stofwisselingsziekte die wordt veroorzaakt 
door een tekort aan het lysosomale enzym zure α-glucosidase. Dit enzym zorgt bij 
gezonde mensen voor de afbraak van glycogeen in het lysosoom. Een lysosoom 
is een organel waarin allerlei grote moleculen afkomstig uit het intra-cellulaire 
en het extracellulaire milieu gerecycled worden. Een tekort aan het enzym zure 
α-glucosidase leidt tot stapeling van glycogeen in het lysosoom en uiteindelijk tot 
weefselschade. Dit gebeurt in vrijwel alle lichaamscellen, maar de schade is het 
duidelijkst merkbaar in spiercellen. 
De ziekte van Pompe kan zich op alle leeftijden manifesteren. Bij patiënten met de 
klassiek-infantiele vorm van de ziekte van Pompe is er totaal geen zure α-glucosidase 
aanwezig. Dit ziektebeeld heeft een snel progressief beloop, waarbij de eerste 
symptomen al kort na de geboorte optreden. Baby’s vertonen gegeneraliseerde 
spierzwakte en hebben een ernstige hypertrofische cardiomyopathie (verdikking 
van de hartspier). Zij sterven vrijwel altijd voor het eerste levensjaar ten gevolge 
van hartfalen en ademhalingsproblemen. Bij kinderen en volwassenen met een 
gedeeltelijk tekort van zure α-glucosidase zijn vooral de skeletspieren van de 
romp, de schouder- en bekkengordel betrokken en niet het hart. Het ziektebeeld 
is minder progressief, maar de toenemende spierzwakte leidt uiteindelijk tot 
rolstoelafhankelijkheid en noodzaak tot beademing. 
Tot 2006 was de ziekte van Pompe een onbehandelbare ziekte waarvoor alleen 
ondersteunende behandeling mogelijk was. De ontwikkeling van enzymtherapie, 
waarbij het ontbrekende enzym wordt toegediend met een infuus, heeft het 
toekomstbeeld van de patiënten sterk verbeterd. Patiënten met de klassiek 
infantiele vorm van de ziekte komen niet meer voor hun eerste levensjaar te 
overlijden. De oudste patiënten met deze vorm van de ziekte zijn inmiddels 15 jaar 
oud, maar de effecten op heel lange termijn zijn nog onbekend. Ook is er behoefte 
aan meer inzicht in het natuurlijk beloop van minder ernstige vormen van de ziekte 
van Pompe en de effecten van enzymtherapie in deze groep patiënten. Daarover 
is nog nauwelijks literatuur verschenen. De onderzoeken die in dit proefschrift 
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beschreven worden hadden dan ook als doel om 1) het ziektebeeld van kinderen 
met minder progressief verlopende vormen van de ziekte te beschrijven, 2) de 
effecten van enzymtherapie in deze groep patiënten te evalueren en 3) de lange 
termijn effecten van de therapie bij patiënten met de klassiek infantiele vorm 
te onderzoeken waarbij wij deze patiënten, inmiddels bijna 14 jaar oud, hebben 
vergeleken met kinderen met minder progressieve vormen van de ziekte. 
In Hoofdstuk 1 wordt achtergrondinformatie gegeven over de ziekte van Pompe. 
Dit hoofdstuk geeft een historische achtergrond en beschrijft de pathofysiologie 
van de ziekte. Verder worden het klinische beeld beschreven, de manier waarop de 
diagnose wordt gesteld, de huidige kennis over het natuurlijk beloop en de huidige 
behandelingsmogelijkheden. 
Deel I van dit proefschrift richt zich voornamelijk op de klinische kenmerken en het 
natuurlijk beloop van de ziekte van Pompe bij kinderen met langzaam progressieve 
vormen van de ziekte. Hoofdstuk 2 beschrijft dan ook hoe de ziekte zich presenteert 
en wat de specifieke klinische en genetische kenmerken zijn van 31 kinderen, die bij 
dit onderzoek betrokken waren. Het eerste symptoom van de ziekte was meestal 
vertraagde motorische ontwikkeling of spierzwakte van de romp en bekkengordel. 
Het bleek echter dat de ziekte van Pompe ook moet worden overwogen bij de 
volgende kenmerken: een buitenproportionele spierzwakte van de flexoren van de 
nek, onbegrepen vermoeidheidsklachten, aanhoudende diarree of een verhoging 
van leverenzymen in het bloed. Een aantal symptomen van deze kinderen bleek 
te verschillen van die van aangedane volwassenen zoals de verdeling van de 
spierzwakte en het hebben van een afhangend ooglid, en zwakte van de spieren die 
gebruikt worden bij het spreken, eten en slikken. Patiënten met andere mutaties in 
het α-glucosidase gen dan de meest voorkomende c.-32-13T>G base verandering 
waren over het algemeen ernstiger aangedaan dan patiënten die deze mutatie 
wel hadden en vertoonden een snellere achteruitgang. Overigens was de klinische 
variatie binnen de groepen ook groot. In de groep aangedane kinderen met de 
veel voorkomende c.-32-13T>G mutatie hadden er opvallend veel het mannelijk 
geslacht. Hoofdstuk 3 richt zich op de longfunctie in een cohort van 17 kinderen 
en 75 volwassenen met de ziekte van Pompe. Vierenzeventig procent van de 
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patiënten en 53% van de kinderen bleek een verminderde longfunctie te hebben. 
In zittende houding was de longfunctie verminderd bij 47% van de kinderen en in 
liggende houding bij 59%. De jongste patiënt waarbij een verminderde longfunctie 
werd gevonden was 7 jaar oud. Vier kinderen hadden een ernstig verminderde 
longfunctie. Mannen bleken ernstiger te zijn aangedaan dan vrouwen. Gedurende 
de vervolgperiode van gemiddeld 1.6 jaar werd een significante achteruitgang 
gezien van longfunctie in zittende en liggende houding. Hieruit concluderen wij 
dat een verminderde longfunctie bij patiënten met de ziekte van Pompe vaker 
voorkomt dan werd verwacht. In Hoofdstuk 4 worden de bevindingen beschreven 
van cardiaal onderzoek bij kinderen en volwassenen met de veel voorkomende 
c.-32-13T>G mutatie. Achtenzestig patiënten werden geëvalueerd. Drieëntwintig 
van deze patiënten vertoonden reeds voor het 18e levensjaar symptomen van de 
ziekte van Pompe. In twee patiënten werden cardiale afwijkingen gevonden die 
kunnen passen bij de ziekte van Pompe. Een meisje van 8 jaar oud had een Wolff-
Parkinson-White (WPW) patroon op het elektrocardiogram en een volwassen man 
die reeds ernstig door de ziekte was aangedaan bleek een milde verdikking van de 
hartspier te hebben. Deze verdikking veranderde niet na start van enzymtherapie. 
Er werd geconcludeerd dat cardiale afwijkingen zelden voorkomen bij patiënten 
met de c.-32-13T>G mutatie en dat een elektrocardiogram een goede eerste 
screeningsmethode is voor het opsporen van cardiale afwijkingen in deze groep 
patiënten.
Deel II van dit proefschrift beslaat een drietal studies waarin de effecten van 
enzymtherapie bij kinderen en volwassenen met de ziekte van Pompe worden 
beschreven. Allereerst rapporteren we de resultaten van een studie waarin 
twee kinderen en één volwassene gedurende 8 jaar met enzymtherapie werden 
behandeld (Hoofdstuk 5). De therapie zorgde ervoor dat de overgebleven 
spierkracht van twee ernstig aangedane patiënten, beiden afhankelijk van een 
rolstoel en beademingsapparaat, niet verder achteruitging en dat hun longfunctie 
stabiliseerde. Hun kwaliteit van leven verbeterde en zij werden zelfstandiger 
op het gebied van ADL (algemene dagelijkse levensverrichtingen). De jongste 
patiënt was het minst ernstig aangedaan toen de therapie startte. Tijdens de 
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eerste drie jaar van behandeling heeft hij weer leren lopen en tijdens de overige 
5 jaar verbeterde zijn spierkracht verder tot normaalwaarden werden bereikt. 
Er werden geen ernstige bijwerkingen gezien tijdens de enzym infusies. Deze 
resultaten tonen aan dat lange termijn follow-up en timing van behandeling 
belangrijke aandachtspunten zijn voor vervolg onderzoek. Hoofdstuk 6 beschrijft 
de resultaten van een open-label studie betreffende 5 kinderen die tussen 5 en 15 
jaar oud waren bij start van de behandeling en gedurende 3 jaar enzymtherapie 
ontvingen. Gedurende deze periode verbeterde de longfunctie van één patiënt en 
bleef deze stabiel in de overige 4 patiënten, terwijl 2 historische niet gematchte 
cohorten van onbehandelde patiënten met de ziekte van Pompe een gemiddelde 
achteruitgang van longfunctie lieten zien van 1.6 tot 5% vitale capaciteit per jaar. 
De spierkracht verbeterde bij alle patiënten, waarbij de spierkracht van één patiënt 
bijna normaliseerde. Spierfunctie werd onderzocht middels de “Quick Motor 
Function Test” en verbeterde bij alle patiënten. Er werden geen bijwerkingen gezien 
tijdens de enzyminfusies. Het is lastig om harde conclusies te trekken gezien het 
kleine aantal patiënten en het feit dat de studie niet placebo gecontroleerd was. 
Een positieve bevinding was dat geen van de patiënten achteruitgang vertoonde 
gedurende de drie jaar behandeling. Hoofdstuk 7 beschrijft de resultaten van een 
gerandomiseerde placebogecontroleerde studie naar de effecten van alglucosidase 
alfa in 90 kinderen en volwassenen die ouder waren dan 8 jaar. Na 18 maanden 
therapie werd een significante verbetering gevonden van de afstand die patiënten 
konden afleggen in een 6 minuten looptest vergeleken met de groep die placebo 
kreeg. De duidelijkste verbetering werd in de eerste 26 weken gezien. Deze 
verbetering werd gehandhaafd gedurende de overige 12 maanden behandeling. 
Globaal genomen leek het effect van behandeling beter te zijn bij patiënten met een 
relatief goede klinische conditie bij start van enzymtherapie, maar in een subgroep 
analyse kon geen statistisch significant verschil worden aangetoond. Er traden bij 3 
van de 60 patiënten die met het enzym werden behandeld anafylactische reacties 
op waarbij 2 patiënten niet verder konden worden behandeld. Bij alle patiënten 
werden verhoogde IgG antilichamen gemeten, maar deze leken geen effect te 
hebben op de klinische uitkomst. 
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Deel III van dit proefschrift beschrijft de lange termijn effecten van de behandeling 
met enzymtherapie bij patiënten met de klassiek infantiele vorm van de ziekte van 
Pompe. In Hoofdstuk 8 beschrijven we het voorkomen van tandvleeshypertrofie 
bij één van de langst overlevende patiënten met de klassiek infantiele vorm 
van de ziekte van Pompe. Zij is inmiddels 15 jaar oud. Histopathologie van het 
tandvlees toonde glycogeen stapeling in gladde spiercellen van de vaten maar de 
hoeveelheid glycogeen in fibroblasten was vergelijkbaar met controle patiënten 
die niet de ziekte van Pompe hebben. We concludeerden dat glycogeen stapeling 
waarschijnlijk niet de directe oorzaak is van de tandvleeshypertrofie, maar dat dit 
mogelijk veroorzaakt wordt door een chronische ontsteking en uitdroging van het 
tandvlees. De resultaten gepresenteerd in Hoofdstuk 9 tonen aan dat spierzwakte 
van het gelaat, spraakproblemen en dysfagie frequent voorkomen bij patiënten 
met de klassiek infantiele vorm van de ziekte van Pompe al dan niet behandeld met 
enzymtherapie. Elf patiënten werden geïncludeerd in deze studie. De leeftijd ten 
tijde van de laatste metingen varieerde van 7.7 maanden tot 12.2 jaar (gemiddeld 
4.3 jaar). Gezichtsspierzwakte werd in alle patiënten gevonden, reeds voor de 
leeftijd van 15 maanden. Bij de evaluatie van de spraak bleek dat er sprake was van 
afwijkende articulatie met hypernasale resonantie. De slikfunctie bleek ineffectief 
te zijn wat het risico op aspiratie en gerelateerde complicaties vergroot. Er werd 
dan ook aanbevolen om vroegtijdige begeleiding door een logopedist te starten 
en frequente controles van de slikfunctie uit te voeren. In Hoofdstuk 10 wordt het 
gehoor van 24 kinderen met de ziekte van Pompe geanalyseerd met herhaaldelijke 
“auditory brainstem response” metingen en toonaudiometrie. In slechts 1 van 
de 13 kinderen met een niet klassieke vorm van de ziekte van Pompe werd bij 
herhaling conductief gehoorverlies gevonden, terwijl 10 van de 11 patiënten met 
de klassiek infantiele vorm van de ziekte een sensorineuraal gehoorverlies hadden. 
Een conductief gehoorverlies kwam ook veelvuldig voor bij deze laatste groep 
patiënten. Vijf patiënten toonden retro cochleaire pathologie, welke suggestief 
is voor glycogeen stapeling in het centrale zenuwstelsel. We concluderen dat het 
belangrijk is om in de groep patiënten met de klassiek infantiele vorm van de 
ziekte van Pompe het gehoor regelmatig te testen en tijdig gehoorapparaten aan 
te meten om adequate taal- en spraakontwikkeling te garanderen. Het effect van 
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bijna 14 jaar behandeling op het hart wordt in Hoofdstuk 11 beschreven. Deze 
studie toont aan dat de enorme afname van de hypertrophie en de verbetering van 
de hartfunctie die in het begin van behandeling bereikt werden doorzetten tijdens 
de volgende langdurige behandelperiode. Dit is een belangrijke bevinding omdat 
verbetering van de hartfunctie een significante invloed heeft op de vermindering 
van morbiditeit en mortaliteit in deze groep patiënten. Ondanks de goede effecten 
van enzymtherapie op het hart blijven hartritmestoornissen helaas voorkomen bij 
deze patiënten. Dit maakt nauwgezette cardiale controle noodzakelijk. 
Deel IV bevat Hoofdstuk 12 en rapporteert over de samenstelling en de validatie 
van de Quick Motor Function Test (QMFT): een spierfunctie test die speciaal is 
ontworpen voor de ziekte van Pompe. Deze test bestaat uit 16 items en kan door 
een arts in de kliniek worden uitgevoerd. De QMFT bleek een betrouwbare en 
valide test te zijn om spierfunctie te meten in kinderen en volwassenen met de 
ziekte van Pompe tussen 5 en 76 jaar. De test bleek voldoende sensitief te zijn 
om de ernst van de ziekte te bepalen en om klinisch relevante veranderingen van 
spierfunctie te meten.
Hoofdstuk 13 bediscussieert de belangrijkste bevindingen en bespreekt de 
klinische consequenties van de bevindingen en de implicaties.
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Appendix: Quick Motor Function Test
1. Raising the torso
Starting position: prone with arms by sides. Examiner may hold the patient’s legs.
Movement: the torso must be completely raised from the mat without using the 
arms.
 □ initiates no neck extension
 □ initiates neck extension but cannot raise head from mat
 □ raises head from mat but torso remains on mat
 □ partially raises head and torso from the mat
 □ completely lifts head and torso from the mat (approx. 45o)
2. neck flexion 
Starting position: supine position, preferably with head in midline and arms by 
sides.
Movement: raises head to 45o.
 □ initiates no neck flexion
 □ initiates neck flexion (some movement of the head that indicates neck 
flexion such as lifting or retracting the chin) but does not raise head
 □ raises head <45o
 □ raises head to 45o with difficulty 
 □ raises head to 45o or more with no difficulty 
3. Hand across midline
Starting position: supine position, preferably with head in the midline and arms by 
sides. Examiner holds hand at level of patient’s chest on L/R sides of the midline. 
Asks patient to reach towards hand. 
Movement: reaches with R/L arm and crosses the midline. 
 □ makes no attempt to reach towards the midline
 □ makes attempt to reach towards the midline
 □ reaches with R/L arm, hand does not cross the midline 
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 □ reaches with R/L arm, hand crosses the midline with difficulty (slowly, 
requiring effort)
 □ reaches with R/L arm, hand crosses the midline without difficulty 
4. Hip and knee flexion
Starting position: supine position, preferably with head in the midline, legs 
extended and arms by sides.
Movement: flexes R/L hip and knee through full range of motion.
 □ unable to initiate flexion in R/L hip and knee
 □ initiates flexion in R/L hip and knee, but does not move hip more than 10o
 □ flexes R/L hip and knee through part of full range of motion(<90o)
 □ flexes R/L hip and knee through full range of motion but with difficulty 
(slowly, with effort)
 □ without difficulty flexes R/L hip and knee through full range of motion 
5. Extending the legs 
Starting position: supine position, preferably with head in the midline, legs 
stretched and arms by sides. 
Movement: extends and raises both legs simultaneously. 
 □ does not attempt to raise legs
 □ attempts to raise legs but neither leg leaves the mat (tightens abdominal/
leg muscles), or raises 1 leg 
 □ raises legs from mat but does not extend them, or uses arms
 □ with difficulty extends both legs and lifts them from the mat (e.g. very 
briefly)
 □ extends both legs and lifts them from the mat without difficulty 
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6. Sit up
Starting position: supine position, preferably with head in the midline, legs in 
comfortable position, arms by sides or crossed over the chest. 
Movement: sit up without support. 
 □ does not attempt to sit up (or initiate neck flexion)
 □ attempts, but does not achieve sit up (even using the arms)
 □ does a sit up, but using the arms 
 □ does a sit up without using arms but with difficulty 
 □ does a sit up without using arms without difficulty (quick and controlled 
movement)
7. Extending the arms 
Starting position: comfortable sitting position (seated on a chair, not leaning on 
back of the chair), arms by sides. 
Movement: raises both arms upwards along the body (180o).
 □ does not attempt to raise arms
 □ attempts to raise arms but they do not come above shoulder level 
 □ raises both arms above shoulder level but arms do not quite reach 180o
 □ raises both arms along the body and hands touch above the head but with 
difficulty (arms are not completely stretched)
 □ raises both arms along the body and hands touch above the head without 
difficulty (arms remain extended)
8. Standing up from a chair
Starting position: seated in a chair, arms by sides not leaning on the back of the 
chair.
Movement: stands up from chair without using arms.
 □ makes no attempt to stand up from chair 
 □ attempts to stand up from chair but is not able to (even using arms)
 □ stands up from chair using arms
 □ stands up from chair without using arms but with difficulty (slowly, with 
effort, number of attempts are necessary)
 □ stands up from chair without using arms without difficulty 
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9. Standing up from half-knee
Starting position: kneeling without arm support.
Movement: stands by means of half-knee position using L/R knee without using 
arms. 
 □ makes no attempt to stand, OR: non-applicable
 □ attempts to stand up but is not able to (even using arms)
 □ stands by means of half-knee position using L/R knee and using arms
 □ stands by means of half-knee position using L/R knee without using arms 
but with difficulty 
 □ stands by means of half-knee position using L/R knee without using arms 
and without any difficulty 
10.  Squatting
Starting position: standing. 
Movement: squats without using arms.
 □ does not initiate squat, or: non-applicable
 □ initiates squat but is unable to bend legs to 90° (even using arms or a 
support)
 □ able to squat using arms or holding on
 □ able to squat without using arms, but with difficulty (quickly falls over, 
cannot easily maintain position)
 □ squats with no difficulty without using arms
11.  Standing up from a squatting position
Starting position: squatting:
Movement: stands without using arms.
 □ unable to stay in squatting position without help, OR: non-applicable
 □ attempts to get up from squatting position but is unable to stand (also not 
when using arms)  
 □ able to go from squatting to standing using arms
 □ able to go from squatting to standing without using arms but with difficulty
 □ goes from squatting to standing without using arms with no difficulty 
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12.  Picking up an object 
Starting position: standing without arm support.
Movement: able to pick up an object from the floor and stand up again without 
arm support. 
 □ makes no attempt to pick up an object from the floor, OR: non-applicable
 □ attempts to pick up an object from the floor, put does not pick up the object
 □ picks up object from the floor and stands up again using arms (uses arms for 
balance, both on the floor and on the body)
 □ able to pick up an object from the floor without arm support and stand up 
again with difficulty 
 □ able to pick up an object from the floor without arm support and stand up 
again without difficulty (fast, controlled movement)
13.  Standing on one leg
Starting position: standing without arm support 
Movement: standing without arm support, lift L/R foot up for 10 seconds (and 
remains standing on the same leg).
 □ lifts L/R foot up without arm support, OR: non-applicable
 □ stands without arm support, lift L/R foot up for <3 seconds 
 □ stands without arm support, lifts L/R foot up for 3‒9 seconds 
 □ stands without arm support, lifts L/R foot up for 10 seconds with difficulty 
 □ stands without arm support, lifts L/R foot up for 10 seconds without difficulty 
14.  Walking ten metres
Starting position: standing without arm support. 
Movement: walks forward for 10 metres without arm support. 
 □ does not attempt to walk, OR: non-applicable
 □ attempts to, but cannot walk for 10 m, even with support (hands, wall)
 □ walks 10 m but uses hands or wall for support 
 □ walks 10 m without support of hands or wall, but with abnormal gait (e.g. 
staggering)
 □ walks 10 m without difficulty 
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15.  Jumping
Starting position: standing without arm support. 
Movement: jumps forward with both feet simultaneously. 
 □ does not attempt to jump forwards, OR: non-applicable
 □ jumps forwards <10 cm with both feet simultaneously (or falls on jumping 
or landing)
 □ jumps forwards between 10 and 40 cm with both feet simultaneously 
 □ jumps forwards between 40 and 100 cm with both feet simultaneously 
 □ jumps forwards more than 100 cm with both feet simultaneously and 
without effort 
16.  Walking up steps
Starting position: standing without arm support. 
Movement: walks up 4 steps using alternating feet without arm support. 
 □ does not attempt to walk up 4 steps, OR: non-applicable
 □ walks (alternating or non-alternating feet), up 1 or more step using railing
 □ walks (alternating or non-alternating feet), up 4 steps using railing
 □ walks up 4 steps using non-alternating feet without arm support 
 □ walks up 4 steps using alternating feet without arm support 
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Dankwoord
Het duurde even maar het is klaar! Na negen jaar raak je er zo aan gewend dat er 
altijd weer tijd moet worden gevonden om aan je proefschrift te werken, dat het 
bijna onwaarschijnlijk voelt dat ik nu dit dankwoord zit te schrijven. Graag wil ik 
een aantal mensen bedanken die mij in de afgelopen jaren hebben gesteund en 
geholpen.
Allereerst wil ik alle kinderen (en hun ouders) bedanken die deelnamen aan de 
verschillende studies die in dit proefschrift zijn beschreven. Ik heb veel bewondering 
voor jullie optimisme, doorzettingsvermogen en kracht waarmee jullie omgaan 
met jullie ziekte of strijden voor een toekomst voor jullie kinderen. 
Daarnaast wil ik mijn promotor en co-promotor bedanken. Prof. dr. A.T. van der 
Ploeg, beste Ans, toen ik via een vriendin met jou kwam praten over onderzoek, 
had ik nog nooit van de ziekte van Pompe gehoord. Daar is snel verandering in 
gekomen. De jaren met jou waren altijd veelbewogen. Er lijkt geen eind te komen 
aan de stroom van projecten, patiënten en studies. Ik heb daardoor een zeer 
gevarieerde onderzoekstijd meegekregen. Niet alleen heb je mij de mogelijkheid 
gegeven me te ontwikkelen op het gebied van wetenschap, ook heb ik mij kunnen 
profileren in de kliniek met een opleidingsplek tot kinderarts als gevolg. Ik bewonder 
hoe je het Centrum voor Lysosomale en Metabole Ziekten hebt opgebouwd tot 
een nationaal en internationaal expertisecentrum en hoe je door het vuur gaat 
voor deze patiënten. Terwijl wij in “de goeie ouwe tijd “met z’n vieren de kliniek 
draaiende hielden, is het team inmiddels ruim vervijfvoudigd. Dank voor al je steun 
en vertrouwen, ik zal je nu niet meer stalken  .
Dr. A.J.J Reuser, beste Arnold, dank voor al je hulp en steun. Ongelofelijk hoe jij 
altijd mensen weet te prikkelen en uit te dagen. Nadat je mij een keer tijdens een 
thuiswerkdag opbelde en zei “zit ons Carientje met een wijntje op het terras?” (ik 
zat inderdaad even lekker in het zonnetje), was ik bang dat je me nooit serieus zou 
nemen. Toch bleef je me begeleiden en heb ik in de loop der jaren heel veel van 
je geleerd. Samen met Ans vormen jullie een bijzonder team, jullie samenwerking 
heeft uiteindelijk tot de ontwikkeling van enzymtherapie voor de ziekte van 
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Pompe geleid. Ik heb groot respect voor wat jullie in de afgelopen jaren hebben 
opgebouwd!
De leden van de kleine commissie wil ik hartelijk bedanken voor het lezen en 
beoordelen van het manuscript. Prof. dr. A.J. van der Heijden, beste Bert, hartelijk 
dank voor alle interesse en morele steun die je me de afgelopen jaren hebt gegeven. 
Prof. dr. P.A. van Doorn, beste Pieter, ik heb tijdens het schrijven van mijn eerste 
artikel veel van je geleerd. Ik vind het een voorrecht dat je je zo hebt verdiept in mijn 
proefschrift: het helder formuleren en doelgericht werken komen ook hier weer 
naar voren en zal ik niet vergeten. Prof. dr. W.A. Helbing, beste Wim, hartelijk dank 
voor je interesse in de ziekte van Pompe, mijn onderzoek en de samenwerking de 
afgelopen jaren. Het actief meedenken hoe mijn toekomst als kinderarts er verder 
uit zal zien, je hulp en adviezen stel ik erg op prijs. 
Dr. Simon Jones, thank you for participating in my committee. The past years we 
have met several times on congresses and courses and we always had interesting 
conversations considering our patients. I think we should end this afternoon with a 
good pint of beer! Prof. dr. R. Hofstra, Dr. J.J. Boelens en Dr. J.M.P. van den Hout wil 
ik hartelijk danken voor het plaatsnemen in mijn promotiecommissie. Hannerieke, 
dank voor alle morele support, tips en kinderneurologische wijsheden waarvan je 
me de afgelopen jaren hebt voorzien. Ik vind het heel bijzonder dat jij in mijn grote 
commissie zit!
Tom de Vries Lentsch, met mijn twee linker (computer) handen was ik erg blij dat jij 
de figuren voor mijn artikelen en posters hebt gemaakt. Elke keer moest het weer 
een beetje anders: 6.5 jaar therapie, dan weer 8 jaar therapie. Met geduld heb 
je ze telkens aangepast. Heel veel dank voor al je werk! Wim Hop, dank voor alle 
statistische adviezen. David Alexander, ik heb veel geleerd van je English writing 
course, fijn dat je als tekst corrector mijn laatste twee manuscripten naar leesbaar 
Engels omtovert. Dank aan alle co-auteurs, thanks to all co-authors, I appreciate 
your help, corrections and suggestions. 
Marloes Hagemans, wat moet je het zwaar hebben gehad in het kleinste kamertje 
van het Sophia Kinderziekenhuis. Terwijl jij hard zwoegend de laatste hand legde 
aan je proefschrift, zat ik, net begonnen en fulltime bezig met patiëntenzorg, naast 
je door de telefoon te tetteren om de kliniek draaiende te houden. Ik begrijp nu 
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hoe irritant dat moet zijn geweest. Ik heb veel van je geleerd. Je schrijft als de 
beste en bent mijn voorbeeld hoe je onderzoek moet opzetten, nauwkeurig en 
georganiseerd moet werken maar vooral hoe je duidelijk en heldere taal schrijft. 
Nadine, de “laatste loodjes” waren inderdaad geen verkleinwoord waard! Wat 
hebben we een leuke tijd gehad. Samen patiëntenzorg, Duitse poli’s draaien, 
congressen bezoeken, nog een dagje extra sight-seeing in o.a. Berlijn, maar 
vooral samen aan onze artikelen werken (via de email, want dat Dijkzicht is toch 
wel erg ver weg). Je hebt een prachtig proefschrift afgeleverd en volgens mij mag 
iedereen in zijn handjes knijpen met zo’n doortastende en vooral lieve neuroloog. 
Jacqueline Hardon en Rineke Nelisse, jut en jul (), uren hebben we samen op de 
“Pompe zaal” op afdeling 2 noord doorgebracht, dagen aan de planning, uren met 
een videocamera assessments filmen; maar naast het werk hebben we ook veel 
plezier gehad. Zalmsalade maken voor onze kerstborrel op de gang naar 2 noord 
waardoor de hele afdeling dagen naar zalm heeft geroken, samen op stap voor een 
training in Waxholm, bij wildvreemde mensen in auto’s stappen en nog veel meer. 
Jacq, ik heb bewondering voor je kracht en de manier waarop je je twee prachtige 
dochters hebt opgevoed, ik hoop dat we elkaar niet uit het oog verliezen. Rineke, 
wat een warm mens ben je toch, de patiënten mogen blij zijn met zo’n betrokken 
verpleegkundige. Lianne van der Giessen en Suzanne Moors, uren video materiaal 
heb ik van jullie fysiotherapeutische assessments. Het was leuk om met jullie 
samen te werken! Joke Ponsen, jarenlang heb ik bij je aangeklopt om echo’s te 
maken van de patiënten, waarden na te rekenen en nieuwe testen toe te voegen. 
Dank voor alle geduld, uitleg over echografie, en alle metingen die je keer op keer 
heb uitgevoerd. Ik probeer nog een afspraak bij je te maken voor een eerste cursus 
echografie voordat ik naar Leiden vertrek! Prof. dr. Arts, hartelijk dank voor de 
samenwerking en de leerzame momenten tijdens uw polikliniek kinderneurologie. 
Iris Plug en Michelle Kruijshaar, wat een waardevolle toevoeging zijn jullie voor 
het team. Dank voor de bijdrage aan mijn discussie. Marian Kroos, dank voor de 
jarenlange plezierige samenwerking. Marianne van Elck , je hebt waarschijnlijk 
geen idee hoe belangrijk je voor mij bent geweest. Alle afspraken, formulieren, 
gaatjes in Ans haar agenda en andere praktische zaken die altijd door jou worden 
geregeld hebben mij enorm geholpen. Dank daarvoor, voor de gezellige gesprekken 
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en het af en toe stoom afblazen. Nathalie en Djowrain, ook veel dank voor alles wat 
jullie voor mij hebben gedaan. 
Alle oude onderzoekers en dan in het bijzonder Maaike, Chris en Frans. Als 
ganggenoten hebben jullie mij, enige promotiekandidaat binnen de Metabole 
ziekten, een beetje geadopteerd. Inmiddels zijn jullie drie al lang gepromoveerd en 
verspreid over Rotterdam en Amsterdam, maar het was leuk en vooral erg gezellig! 
Alle nieuwe onderzoekers: Carin van Gelder, mijn opvolgster. Het was even slikken 
dat je eerder ging promoveren dan ik maar wat heb je een mooi boekje gemaakt. 
Ik hoop dat je het erg naar je zin hebt in Den Bosch en Nijmegen en dat we elkaar 
later als collegae weer tegen zullen komen. Marion, dank voor de gezelligheid 
en goede gesprekken (in de Fyra of auto naar A’dam), jij ook veel succes met je 
opleiding tot kinderarts in het AMC. Esther en Chris, het huidige onderzoekers duo 
voor de kinderen met de ziekte van Pompe. Heel erg leuk om de laatste maanden 
nog zo intensief met jullie samen te werken. Chris, dank voor de hulp met mijn 
overzichtsartikel, maar ook voor al je computer weetjes en opschoon trucs. Het 
is wel duidelijk dat ik niet veel van mijn opleiding Medisch Technische Informatica 
heb opgestoken. Esther, ook met jou heb ik heel prettig samen gewerkt. Met 
je organisatietalent en gestructureerde manier van werken heb je mij door 
de laatste periode heen geholpen. Daarnaast was het natuurlijk ook vooral erg 
gezellig. Jelte en Hidde vragen nog steeds wanneer je weer een keer komt eten?! 
Alle andere onderzoekers en medewerkers van het Centrum voor Lysosomale en 
Metabole Ziekten wil ik graag bedanken voor de leuke samenwerking: Deniz, Juna, 
Johanneke, Audrey, Marein, Anneke, Rachel, Wilma, George Ruijter, Jan Huijmans, 
Frans Verheijen, Kees Schoonderwoerd en Marianne Hoogeveen-Westerveld. 
Hans de Klerk, Monique Williams, Esmee Oussoren, Elles van der Louw en Marit 
Verhagen: het was erg leuk om mij tijdens de afgelopen maanden te verdiepen in 
het specialisme Stofwisselingsziekten. Ik kwam er achter dat ik er nog bizar weinig 
van wist. Helaas was de combinatie promotie afmaken en verdiepingsstage niet de 
beste combinatie om echt een goede metabole basis te leggen, toch heb ik enorm 
veel van jullie geleerd. Dank voor de leermomenten maar ook voor de gezelligheid! 
Ous, Esmeralda, Esmee, ik vind het bijzonder om jouw ontwikkeling van assistent 
kindergeneeskunde, via chef de clinique op de medium care kindergeneeskunde 
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tot kinderarts Metabole Ziekten te hebben gevolgd. Je bent een betrokken, 
consciëntieuze en bevlogen kinderarts en je gaat door het vuur voor je patiënten. 
Een mooie combinatie waar velen van ons een voorbeeld aan kunnen nemen. 
Dank voor je adviezen, humor en goede gesprekken. Ik hoop dat er nog vele zullen 
volgen. Sylvia Walet, carpool-buddy, heerlijk om even rustig wakker te worden op 
weg naar Rotterdam, maar vooral erg gezellig. Ik hoop je ook na mijn vertrek naar 
Leiden nog vaak te zien in Amsterdam/Amstelveen. 
Lieve collegae uit het Sophia Kinderziekenhuis, mede dankzij jullie heb ik een 
hele leuke opleidingstijd gehad. Het was hard werken maar gelukkig was er ook 
vaak tijd voor gezelligheid of een goed gesprek. Samen met deze promotie eindigt 
mijn opleidingstijd in het Sophia en zal ik nog enkele maanden in het LUMC mijn 
opleiding afmaken. Gek idee om na negen jaar Rotterdam het Sophia achter me 
te laten. Ik zal jullie missen! Veel sterkte met het afmaken van jullie opleiding en 
hopelijk tot ziens.
Mijn paranimfen, Linda van den Berg en Evelien Kerkhof. Linda, roomy, we hebben 
heel wat promotie-stress, kliniek frustraties maar vooral ook plezier gedeeld. 
Samen kliniek, congressen bezoeken, praatjes voorbereiden. Je humor en de goede 
gesprekken die we samen hebben gevoerd zal ik niet vergeten. Ik bewonder hoe jij 
je door je heftige periodes in het leven heen slaat. Ik ben blij dat jij naast me staat 
op deze belangrijke dag, de week erna sta ik naast jou! Evelien, we hebben elkaar in 
de eerste periode van mijn opleiding op de medium care kindergeneeskunde leren 
kennen en we zijn elkaar tijdens de opleiding steeds weer tegen gekomen, niet 
tijdens werktijden maar ook erna, onder andere tijdens de vele vergaderingen als 
arts-assistenten weekendcie. Je bent een lieve vriendin, hebt altijd een luisterend 
oor, en bij jou logeren betekent verwend worden met lekkere ontbijtjes, zelfs op 
zaterdag voor een weekenddienst! Ik ben erg blij dat je naast me staat. 
Dit dankwoord is al veel te lang, ik zal dan ook niet iedereen bij naam noemen maar 
wil de medische staf van het Sophia Kinderziekenhuis bedanken voor de jarenlange 
samenwerking en opleiding, tijdens mijn promotieonderzoek maar ook daarna. 
Dank aan mijn opleider, Prof. dr. M. de Hoog, beste Matthijs, voor alle kansen en 
begeleiding de afgelopen jaren. Graag zou ik een paar weken in de kliniek privéles 
van je krijgen, dan heb ik de kindergeneeskunde echt onder de knie, wat kun jij 
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goed onderwijs geven. Barbara Sibbles, ik wil jou graag noemen en bedanken voor 
de steun die je mij gegeven hebt de afgelopen jaren. Ik heb je leren kennen tijdens 
de klinische jaren van mijn onderzoek en later tijdens mijn opleiding tot kinderarts 
heb ik met je samen gewerkt op de Medium Care, je bent een groot voorbeeld, dank 
voor je vertrouwen. Peter de Laat, buurman op de gang naar 2 noord, wandelende 
Nelson tijdens de opleiding. Tijdens de grote visites heb ik gemerkt dat ik nog heel 
veel van je kan leren. Dank voor je support gedurende de afgelopen jaren. 
Lieve vrienden en vriendinnen, bijna niet meer verwacht maar eindelijk is het klaar. 
Dank voor jullie meeleven op alle fronten, jullie geduld, geheugensteuntjes, het 
hebben van vertrouwen in mij, maar vooral in onze vriendschap. Ik verheug me om 
meer tijd met jullie door te brengen.
Lieve schoonfamilie, dank voor het warme bad waarin ik ben terecht gekomen, jullie 
interesse, steun en de vele logeerpartijtjes tijdens mijn zwangerschap van Jelte 
toen het reizen tussen Amsterdam en Rotterdam even niet meer zo gemakkelijk 
ging. Ondanks dat het niet officieel is voel ik me een echte “Vink”!
Lieve opa en oma Brommelcamp en opa van Capelle, dank voor jullie interesse in 
mijn promotie onderzoek. Ik ben opgegroeid met jullie drie op loop-fiets afstand. 
Dat heeft voor een hele bijzondere band gezorgd. Ik ben blij dat jullie nog zo 
genieten van Jelte en Hidde en dat jullie zo gezond oud zijn geworden. Ik hoop dat 
er nog veel gezonde jaren zullen volgen. Lieve Jan-Willem en Eefje, dank voor jullie 
interesse en meeleven met mijn promotieperikelen, je bent een super-oom voor 
de jongens, we gaan snel weer met z’n allen zwemmen! 
Lieve pap en mam, dank voor de stevige basis die jullie hebben gelegd. Ik kan me 
geen warmer nest wensen. Jullie hebben me altijd gemotiveerd, ondersteund maar 
vooral geleerd om mensen te nemen zoals ze zijn en jezelf te zijn. Dank voor alles 
wat jullie voor mij, Maarten en de kinderen doen, ik vind het heel fijn dat Jelte en 
Hidde zo’n bijzondere band met jullie hebben. 
Mijn mannen: lieve Maarten, thuis komen is echt thuis komen, bij jou voel ik me 
veilig (oeps songtekst van Blöf?), ik heb je sarcastische humor inmiddels bijna 
overgenomen, je geeft me soms het duwtje in de rug en ontnuchteringscursus die 
ik nodig heb; als we oud en grijs zijn kopen we een huis aan de gracht in A’dam en 
gaan we echt al die musea bezoeken en restaurantjes uitproberen waar we nu voor 
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in Amsterdam wonen en totaal geen tijd voor hebben. Luv ya! Lieve Jelte en Hidde, 
heerlijk zo’n mannengezin; van jullie humor, energie, onuitputtelijk geklets (jullie 
vader hoopte op twee jongens die op hem leken) en vrolijkheid geniet ik elke dag 
weer. Jelt, het boekje en de uren achter de computer zijn nu eindelijk klaar, jouw 
ipad-toetsenbord waarmee je zo vaak naast me zat mee te typen kan samen met 
mijn laptop de kast in!  
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Curriculum Vitae
Carine van Capelle werd geboren op 26 augustus 1978 in Heemstede. Nadat zij in 
1996 haar diploma had gehaald aan het Stedelijk Gymnasium te Haarlem startte 
zij, nadat zij was uitgeloot voor de studie geneeskunde, met de studie medisch 
technische informatica aan de Universiteit Utrecht. Aansluitend studeerde 
zij een jaar sociale wetenschappen waarna zij in 1998 werd ingeloot voor de 
studie geneeskunde aan dezelfde universiteit. Tijdens deze studie deed zij een 
wetenschappelijke stage in het Centre for Cardiovascular Science aan de University 
of Edinburgh, Schotland. Twee van haar co-schappen heeft zij volbracht in het St. 
Elisabeth Hospitaal in Willemstad, Curaçao. Een keuze co-schap cardiologie werd 
gevolgd in het St. Antonius Ziekenhuis in Nieuwegein. Na haar artsexamen werkte 
zij eerst een jaar als arts-assistent kindergeneeskunde in het Meander Medisch 
Centrum te Amersfoort, waarna zij in 2005 startte met het promotieonderzoek dat 
heeft geleid tot dit proefschrift onder supervisie van prof. dr. A.T. van der Ploeg en 
dr. A.J. Reuser. In 2009 begon zij met de opleiding tot kinderarts in het Erasmus 
MC Sophia Kinderziekenhuis (opleider prof. dr. M. de Hoog). Tijdens het perifere 
gedeelte van haar opleiding werkte zij in het Reinier de Graaf Gasthuis te Delft 
(opleider dr. N. van der Lely). In januari 2015 zal zij haar opleiding tot kinderarts 
voltooien. Carine woont samen met Maarten Vink en zij hebben 2 zoons: Jelte en 
Hidde.
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PhD portfolio
PhD Portfolio
Year Workload
General Academic Skills and Research Skills
Classical methods for data-analysis 2006 5.7
Methodology of patient oriented research and preparation 
for subsidy application 
2006 1.0
Biomedical English writing and communication 2008 3.0
Weekly research meeting, Center for Lysosomal and 
Metabolic Diseases
2005-2009 4.0
In depth courses
Pompe disease expert days 2006-2009, Rotterdam 2006 2.0
International postgraduate course on lysosomal storage 
disorders, Nierstein, Germany
2006 2.0
Presentations and International Conferences
Selbsthilfegruppe Glycogenose Deutschland, Duderstadt, 
Germany (oral presentation)
2005 1.0 
International Symposium on Lysosomal Storage Disorders, 
Budapest, Hungary (poster presentation)
2006 1.0
International Symposium on Lysosomal Storage Disorders, 
Berlin, Germany
2006 0.3
6th International Symposium on Lysosomal Storage 
Diseases, Stockholm, Sweden
2006 0.3
First Pompe disease expert day, Rotterdam (oral 
presentation)
2006 1.0
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Year Workload
SSIEM, Annual Symposium, Hamburg, Germany (poster 
presentation)
2007 1.0
Second Pompe expert day, Rotterdam (oral presentation) 2007 1.0
7th Congres of the European Paediatric Neurology Society,  
Turkey (oral presentation)
2007 1.5
International Symposium: Steps forward in Pompe disease, 
Nice, France (oral presentation)
2007 1.0
4th Symposium on Lysosomal Storage Disorders, Vienna, 
Austria
2007 0.3
7th International Symposium of Lysosomal Storage Diseases 
Rome, Italy
2007 0.3
Najaarssymposium Vereniging Erfelijke 
Stofwisselingsziekten Nederland, Zeist (oral presentation)
2008 1.0
3rd Europaediatrics 2008, Istanbul, Turkey (oral 
presentation)
2008 1.5
5th Symposium on Lysosomal Storage Disorders, Paris, 
France
2008 0.3
World Muscle Society, Geneva, Austria (poster 
presentation)
2009 0.5
International Symposium: Steps forward in Pompe disease, 
London, United Kingdom (oral presentation)
2010 1.0          
Teaching activities
Supervising Master’s thesis 2007 0.5
